UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-K

~~(Mark~~x ~~One~~Annual Report under Section 13 or 15 (d) of The Securities Exchange Act of 1934

xFor ~~ANNUAL~~the ~~REPORT~~fiscal ~~UNDER~~year ~~SECTION~~ended 13December OR31, ~~15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934~~2016

~~For~~o ~~the~~Transition ~~fiscal~~Report ~~year~~under ~~ended~~Section ~~December~~14 ~~31,~~or ~~2015~~15 (d) of The Securities Exchange Act of 1934

¨ TRANSITION REPORT UNDER SECTION 14 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from N/A to N/A

GLUCOSE HEALTH, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-55439	90-1117742
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation or Organization)	File Number)	Identification No.)

609 SW 8^th Street, Suite 600, Bentonville, AR, 72712

(Address of Principal Executive Offices) (Zip Code)

(479) 802-3827

(Registrant'’s telephone number, including area code)

Securities registered under Section 12 (b) of the Exchange Act of 1934:

None

Securities registered under Section 12 (g) of the Exchange Act of 1934:

~~None~~Common Stock $0.001 par value per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by checkmark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such sorter period that the Registrant was required to submit and post such files. Yes x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant'’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "“accelerated filer and large accelerated filer"” in Rule 12b-2 of the Exchange Act of 1934.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Small Business Issuer	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of the last business day of the registrant'’s most recently completed second fiscal quarter.

As of June 30, ~~2015~~2016, the aggregate market value of the 2,153,232 shares of Common Stock held by non-affiliates of the Registrant was $7178,~~489~~485. Such aggregate market value was computed by reference to the closing price of the Common Stock on June 30, ~~2015~~2016 of $0.0503645 per share. For purposes of making this calculation only, the Registrant has defined affiliates as including all directors and executive officers.

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of the latest practicable date.

As of ~~April~~March 1428, ~~2016~~2017, there were 23,~~541~~312,~~982~~273 shares of the issuer's $0.001 par value common stock issued and outstanding and ~~1000~~1,000 shares of its Series A Preferred Stock issued and outstanding.

List hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g. Part I, Part II, etc.) into which the document is incorporated: (1) Any annual report to the security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933.

None.

EXPLANATORY NOTE

Unless otherwise indicated or the context otherwise requires, all references in this Annual Report on Form 10-K to "“we,"” "“us,"” "“our,"” and the "“Company"” are to Glucose Health, Inc., a Nevada corporation.

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States dollars.

The Company'’s financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States ~~Generally~~generally ~~Accepted~~accepted ~~Accounting~~accounting ~~Principles~~principles.

CAUTIONARY NOTE REGARDING FORWARD- LOOKING STATEMENTS

Some of the statements in this report are "“forward-looking statements."” These forward-looking statements involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The words "“believe,"” "“expect,"” "“anticipate,"” "“intend,"” "“plan,"” and similar expressions identify forward-looking statements. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to update and revise any forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements in this report to reflect any future or developments. However, the Private Securities Litigation Reform Act of 1995 is not available to us as a penny stock issuer and thus we may not rely on the statutory safe harbor from liability for forward-looking statements. Further, Section 27A(b)(2)(D) of the Securities Act of 1933 and Section 21E(b)(2)(D) of the Securities Exchange Act of 1934 expressly state that the safe harbor for forward looking statements does not apply to statements made in connection with any offering.

Glucose Health Inc.

Annual Report on Form 10-K

PART I
ITEM 1.	DESCRIPTION OF BUSINESS	5
ITEM 1B.	UNRESOLVED STAFF COMMENTS	9
ITEM 1A.	RISK FACTORS	10
ITEM 2.	DESCRIPTION OF PROPERTY	910
ITEM 3.	LEGAL PROCEEDINGS	910
ITEM 4.	MINE SAFETY DISCLOSURES	9
PART II
ITEM 5.	MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY SECURITIES	1011
ITEM 6.	SELECTED FINANCIAL DATA	1314
ITEM 7.	MANAGEMENT'’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	1415
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	2019
ITEM 8.	FINANCIAL STATEMENTS	~~F-1~~20
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	21
ITEM 9A.	CONTROLS AND PROCEDURES	21
ITEM 9B.	OTHER INFORMATION	22
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	23
ITEM 11.	EXECUTIVE COMPENSATION	24
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	2625
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	2726
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	27
PART IV
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	2928
SIGNATURES		3029

PART I1

Item 1. Description of Business.

Overview

Glucose Health, Inc. was incorporated under the laws of the State of Nevada on March 27, 2007. Our principal executive office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712 and our telephone number is 479-802-3827. Our corporate website is www.glucosehealthinc.com, and our product website is www.glucosehealth.com. Our CUSIP number is 379894108 and trading symbol is GLUC. We are a manufacturer of dietary supplements formulated to help maintain healthy blood sugar, triglycerides and cholesterol and digestive health, and our business focus is serving the consumer market segment of persons ~~with~~concerned about pre-diabetes and/or Type-2 diabetes. As discussed in greater detail below, our principal product is Glucose ~~HealthÒ~~Health® ("“product"”). We acquired this product in October of 2014, and we are in the early stages of manufacturing, marketing and distributing this product. WeFor ~~have~~the aperiod ~~history~~ending ofDecember ~~losses~~31, ~~and~~2016, ~~have~~we generated ~~only~~a ~~nominal~~gross ~~revenues~~profit ~~since~~before ~~our~~operating ~~inception~~expenses, a loss from operations and a net loss per share.

Corporate Information

We were incorporated under the laws of State of Nevada on March 27, 2007, as Bio-Solutions Corp.

On ~~October~~June 1730, ~~2012~~2010, ~~our~~the ~~Board~~board of ~~Directors~~directors ~~and~~approved ~~shareholders~~the ~~holding~~increase ~~a majority~~ of the ~~total~~authorized ~~issued and outstanding~~ shares of common stock, pursuant to written consents in lieu of a meeting, approved an amendment to our Articles of Incorporation to increase our authorized capital (the "amendment"). The amendment was filed with the Nevada Secretary of State on October 17, 2012, increasing our authorized capital from 9075,000,000 ~~shares of common stock,~~ to ~~200~~90,000,000. ~~shares~~In ofaddition, ~~common~~the ~~stock,~~board ~~with~~approved a ~~par~~1.20 ~~value~~for of1 $0stock split.~~001.~~

On ~~January~~October 1017, ~~2014~~2012, ~~the~~our ~~Company's~~board ~~Board~~ of ~~Directors~~directors ~~unanimously~~and ~~voted~~shareholders toholding ~~reverse~~a ~~split~~majority ~~the Company's common stock on the basis~~ of ~~one share of~~ the ~~Company's~~total ~~common~~issued ~~stock~~and ~~for each 10 shares~~ outstanding ~~while maintaining the authorized capital structure of the Company at 200,000,000~~ shares. ~~The Board resolution set the date~~ of ~~record~~common ~~for shareholder approval for January 14~~stock, ~~2014.~~pursuant Asto ~~of January 29, 2014, the Company obtained~~ written ~~consent~~consents in lieu of a meeting, ofapproved ~~the~~an ~~shareholders~~amendment to ~~authorize~~our aArticles ~~reverse split~~ of ~~the~~Incorporation ~~Company's~~to ~~common~~increase ~~stock.~~our ~~Shareholders~~authorized ~~owning~~capital ~~a total of 100,992,469 shares of the Company's common stock voted in favor of the reverse split. There were a total of 199,611,900 shares of common stock issued and outstanding as of January 14, 2014~~ (the ~~date of record~~“amendment”). The ~~number~~amendment ~~of shares of common stock voting in favor of the reverse split~~ was ~~sufficient for approval. On February 4, 2014, the Company~~ filed ~~a Certificate of Change~~ with the ~~State of~~ Nevada ~~effecting~~Secretary ~~a 1-for-10 reverse split pursuant to which every ten shares~~ of ~~the~~State ~~Company's~~on ~~common~~October ~~stock~~17, ~~were~~2012, ~~combined~~increasing ~~and~~our ~~converted~~authorized ~~into~~capital ~~one share of the Company's common stock (with all fractional shares resulting there~~ from ~~being~~90,000,000 ~~rounded up to the next whole share) with the total number of~~ shares of ~~the Company's authorized~~ common stock, ~~remaining~~to at 200,000,000 shares. ~~The effective date~~ of ~~the~~common ~~above~~stock, ~~corporate~~with ~~action~~a ~~was~~par ~~February~~value ~~26,~~of ~~2014~~$0. 001.

On ~~October~~January 3010, 2014, the Company’s board of directors ofunanimously ~~the Company~~ voted to reverse split the Company'’s common stock on the basis of one share of the Company'’s common stock for each 5010 shares outstanding while maintaining the authorized capital structure of the Company at 200,000,000 shares~~; to authorize 1,000 shares of preferred stock with "blank check" rights; and to change the Company's name from Bio-Solutions Corp~~. ~~to Glucose Health, Inc. (the "corporate action").~~ The ~~board~~Board resolution set the date of record for shareholder approval ~~of the corporate action~~ for ~~October~~January 3114, 2014 ~~and the effective date of the corporate action for November 19, 2014~~. As of ~~October~~January 3129, 2014, the Company obtained written consent in lieu of a meeting of the shareholders to authorize a reverse split of the ~~corporate~~Company’s ~~action~~common stock. Shareholders owning a total of 30100,~~596~~992,~~154~~469 shares of the Company'’s common stock voted in favor of the ~~corporate~~reverse ~~action~~split. There were a total of 60199,~~132~~611,~~271~~900 shares of common stock issued and outstanding as of ~~October~~January 3114, 2014 (the date of record). The number of shares of common stock voting in favor of the ~~corporate~~reverse ~~action~~split was sufficient for approval. On ~~November~~February 54, 2014, the Company filed a Certificate of ~~Amendment~~Change ~~to its Articles of Incorporation,~~ with the ~~Nevada~~State ~~Secretary~~ of ~~State~~Nevada effecting, asa ~~of November 19, 2014, the~~ 1-for-5010 reverse split pursuant to which every ~~fifty~~ten shares of the Company'’s common stock were combined and converted into one share of the Company'’s common stock (with all fractional shares resulting there from being rounded up to the next whole share) with the total number of shares of the Company'’s authorized common stock remaining at 200,000,000 shares~~; effecting the authorization of 1,000 shares of preferred stock with "blank check" rights; and effecting the change of the Company's name from Bio-Solutions Corp~~. toThe ~~Glucose~~effective ~~Health,~~date ~~Inc. On November 20, 2015, the board~~ of ~~directors voted to designate Series A Special Preferred Shares consisting of 1,000 shares of preferred stock with special voting rights whereby~~ the ~~holder(s)~~above ~~may~~corporate ~~exercise~~action their right to vote on all shareholder matters representing the number of votes equal to all shares of common stock then issued and outstanding, plus an additional ten thousand (10,000) shares. Additionally, the board of directors voted to extend an existing 12 month consulting contract with the Company's CEO, Murray Fleming, for an additional 12 months, through October 1, 2016, without further compensation, in exchange for the issuance to Mr. Fleming, of the 1,000 Series A Special Preferred Shares. A Certificate of Designation for the Series A Special Preferred Shares was ~~filed~~February ~~with the Nevada Secretary of State and effective on December 1~~26, 2014.

On October 30, 2014, the board of directors of the Company voted to reverse split the Company’s common stock on the basis of one share of the Company’s common stock for each 50 shares outstanding while maintaining the authorized capital structure of the Company at 200,000,000 shares; to authorize 1,000 shares of preferred stock with “blank check” rights; and to change the Company’s name from Bio-Solutions Corp. to Glucose Health, Inc. (the “corporate action”). The board resolution set the date of record for shareholder approval of the corporate action for October 31, 2014 and the effective date of the corporate action for November 19, 2014. As of October 31, 2014, the Company obtained written consent in lieu of a meeting of shareholders to authorize the corporate action. Shareholders owning a total of 30,596,154 shares of the Company’s common stock voted in favor of the corporate action. There were a total of 60,132,271 shares of common stock issued and outstanding as of October 31, 2014 (the date of record). The number of shares of common stock voting in favor of the corporate action was sufficient for approval. On November 5, 2014, the Company filed a Certificate of Amendment to its Articles of Incorporation, with the Nevada Secretary of State effecting, as of November 19, 2014, the 1-for-50 reverse split pursuant to which every fifty shares of the Company’s common stock were combined and converted into one share of the Company’s common stock (with all fractional shares being rounded up to the next whole share) with the total number of shares of the Company’s authorized common stock remaining at 200,000,000 shares; effecting the authorization of 1,000 shares of preferred stock with “blank check” rights; and effecting the change of the Company’s name from Bio-Solutions Corp. to Glucose Health, Inc. On November 20, 2015, the board of directors voted to designate Series A Special Preferred Shares consisting of 1,000 shares of preferred stock with special voting rights whereby the holder(s) may exercise their right to vote on all shareholder matters representing the number of votes equal to all shares of common stock then issued and outstanding, plus an additional ten thousand (10,000) shares. Additionally, the board of directors voted to extend an existing 12-month consulting contract with the Company’s CEO, Murray Fleming, for an additional 12 months, through October 1, 2016, without further compensation, in exchange for the issuance to Mr. Fleming, of the 1,000 Series A Special Preferred Shares. A Certificate of Designation for the Series A Special Preferred Shares was filed with the Nevada Secretary of State and effective on December 1, 2014.

~~Our~~5 ~~Business~~Table Of Contents

~~From~~We ~~inception~~qualify ~~through~~as ~~September 25, 2011, we were~~ a ~~manufacturer~~“smaller ofreporting ~~Nutra-Animal,~~company” aunder ~~pre-mix~~Rule ~~anti~~12b-~~oxidant~~2 ~~for~~of ~~chicken~~the ~~integrators~~Exchange ~~containing~~Act ~~wheat~~of ~~middlings~~1934, ~~vitamin~~which E,is ~~calcium~~defined ~~carbonate,~~as ~~silicone~~a ~~dioxyde,~~company ~~shrimp~~with ~~flour,~~a ~~sodium~~public ~~selenite~~equity ~~and~~float ~~fish~~of ~~oil.~~less Wethan ~~were~~$75 ~~also~~million. aAs ~~distributor of GreenExTM,~~ a ~~biological~~“smaller ~~larvicide~~reporting ~~produced~~company” ~~from~~we ahave ~~strain~~reduced ofdisclosure ~~Bacillus~~requirements ~~thuringiensis~~for ~~subspecies~~our ~~israelensis~~public ~~(Bti)~~filings, aincluding ~~naturally~~but ~~occurring~~not ~~bacterium~~limited ~~that~~to ~~produces~~not abeing ~~crystalline~~required ~~protein~~to ~~toxin~~comply ~~(cystal)~~with ~~toxic~~the ~~for~~auditor ~~mosquitoes,~~attestation ~~vectors~~requirements of ~~malaria.~~Section We404 ~~were~~of ~~not~~the ~~successful~~Sarbanes-Oxley ~~in these business endeavors~~Act.

OnPast September 26, 2011, we acquired the "Type2 Defense" product together with all intellectual property associated therewith. Upon the acquisition of Type2 Defense we discontinued our former operations as a manufacturer of Nutri-Animal and distributor of GreenExTM. Since we discontinued our former operations, we wrote off any inventories attributable to our former operations. Type2 Defense is a dietary supplement made from natural ingredients and formulated to support healthy glucose levels and targeted to consumers concerned about Type-2 and pre-diabetes.Business

~~The~~From ~~first~~inception ~~production~~through ~~run~~September ~~of the Company's Type2 Defense product was completed in June 2013 with the manufacture of 1764 cases. On July 8~~25, ~~2013~~2011, ~~the~~we ~~Company~~were ~~announced~~a ~~the~~manufacturer ~~product~~of ~~was~~a ~~available~~pre-mix ~~for on~~anti-~~line~~oxidant ~~sales~~for onchicken ~~Amazon.com.~~integrators Oncontaining ~~July~~wheat 9middlings, ~~2013~~vitamin E, ~~the~~calcium ~~Company~~carbonate, ~~announced~~silicone ~~the product was available for on-line sales via the www.Type2Defense.com website. Subsequently~~dioxyde, ~~the~~shrimp ~~Company encountered significant management~~flour, ~~operational~~sodium ~~and~~selenite ~~financial challenges resulting in poor product sales~~ and ~~inadequate~~fish ~~inventory control~~oil. AsWe awere ~~consequence,~~also ~~the~~a ~~Company~~distributor ~~generated~~of ~~only~~a ~~nominal~~biological ~~revenues~~larvicide inproduced ~~the~~from ~~fiscal~~a ~~year~~strain ~~ended~~of ~~December~~Bacillus ~~31,~~thuringiensis ~~2013~~subspecies ~~and~~israelensis ~~the~~(Bti). ~~Company~~We ~~elected~~were tonot ~~declare~~successful ~~the~~in ~~$200,000~~these ~~intellectual~~business ~~property for Type2 Defense, recorded as other intangible assets, as impaired at December 31, 2013~~endeavors.

On ~~April~~September 826, ~~2014~~2011, we acquired the ~~Company~~“Type2 ~~appointed~~Defense” ~~James~~product ~~Hodge~~together ~~chairman~~with ofall ~~the~~intellectual ~~Company's~~property ~~board~~associated therewith. Upon the acquisition of ~~directors~~Type2 Defense, we discontinued our former operations and wrote off all inventories attributable to our former operations. Type2 Defense is a dietary supplement made from natural ingredients formulated to support healthy glucose levels and targeted to consumers concerned about Type-2 and pre-diabetes.

The first production run of the Company’s Type2 Defense product was completed in June 2013. On ~~April~~July 8, ~~2014~~2013, inthe aCompany ~~special~~announced ~~meeting~~the ofproduct ~~the~~was ~~board~~available offor ~~directors~~on-line sales on Amazon.com. On July 9, 2013, the ~~board~~Company ~~voted~~announced inthe ~~favor~~product ofwas ~~amending~~available for on-line sales via the www.Type2Defense.com website. Subsequently, the Company's ~~bylaws~~encountered tosignificant ~~decrease~~management, ~~the~~operational ~~number~~and offinancial ~~members~~challenges ofresulting ~~the~~in ~~board~~poor ofproduct ~~directors~~sales ~~from~~and ~~three~~inadequate toinventory ~~one~~control. ~~The~~As ~~previous~~a ~~board~~consequence, ~~members~~the ~~agreed~~Company togenerated ~~resign~~only ~~from~~nominal revenues in the ~~board~~fiscal ~~and~~year ~~accept~~ended ~~other~~December ~~duties~~31, ~~for~~2013 and the Company elected to declare the $200,000 intellectual property for Type2 Defense, recorded as other intangible assets, as impaired at December 31, 2013.

On April 218, 2014, the Company appointed ~~Thomas~~James ~~Metzger~~Hodge ~~Ph.D.,~~chairman ~~Chief~~of ~~Executive~~the ~~Officer~~Company’s ~~and~~board ~~Chief~~of ~~Financial Officer~~directors. ~~In addition, Peggy Knight was appointed Chief Marketing Officer.~~

On April 8, 2014, in a special meeting of the board of directors, the board voted in favor of amending the Company’s bylaws to decrease the number of members of the board of directors from three to one. The previous board members agreed to resign from the board and accept other duties for the Company.

On April 21, 2014, the Company appointed Thomas Metzger Ph.D., Chief Executive Officer and Chief Financial Officer.

On July 22, 2014, Thomas Metzger Ph.D., Chief Executive Officer and Chief Financial Officer, resigned from the Company. James Hodge, chairman of the board of directors was appointed interim Chief Executive Officer and Chief Financial Officer.

Table Of Contents

Current Business

On October 1, 2014, Murray Fleming was appointed the Company'’s Chief Executive Officer for the 12-month period ending October 1, 2015. Additionally, on October 1, 2014, the Company entered into an Intellectual Property Purchase Agreement to purchase the "“Glucose Health Natural Blood Sugar Maintenance"” product from a company of which Mr. Fleming is the beneficial owner. Following this purchase, the Company undertook a series of steps to achieve a final product offering that would be considered efficacious as well as pleasant tasting by our target consumer market and would offer a value proposition relative to our competition in order to be considered for stocking by national and regional pharmacy retailers. To assist in achieving our final product objectives, we retained a former head of beverage product development at Nestle. We retained an attorney specializing in compliance with Food and Drug Administration (FDA) regulations, necessary, in part, to allow our product to be stocked by national pharmacy retailers. We also undertook a number of actions to establish and build our Glucose HealthÒ brand. The Company conducted a design competition related to its packaging artwork and product logo and retained an experienced product packaging graphic artist to assist with all digital and print representations of the product. The Company filed for and received trademark protection for Glucose HealthÒ with the United States Trademark and Patent Office (USPTO). While our primary sales and marketing focus is achieving sales to consumers through national and regional pharmacies, secondarily, we intend to also market the product directly to customers via our dedicated product website and through other online marketplaces.

6Following this purchase, the Company undertook a series of steps to achieve a final product offering that would be considered efficacious, as well as, pleasant tasting by our target consumer market, being persons concerned with pre-diabetes and Type-2 diabetes, and would offer a value proposition relative to our competition to be considered for stocking by national and regional pharmacy retailers. To assist in achieving our final product objectives, we retained a former head of beverage product development at Nestle. We retained an attorney specializing in compliance with Food and Drug Administration (FDA) and regulations pertaining to dietary supplements and Federal Trade Commission (FDC) regulations, necessary, in part, to enable our product to be stocked by national pharmacy retailers. We also undertook several actions to establish and build our Glucose Health® brand. The Company conducted a design competition related to its packaging artwork and product logo and retained an experienced product packaging graphic artist to assist with all digital and print representations of the product. The Company filed for and received trademark protection for Glucose Health® with the United States Trademark and Patent Office (USPTO). While our primary sales and marketing focus is achieving sales to consumers through national and regional pharmacies, secondarily, we intend to also market the product directly to customers via our dedicated product website and through other online marketplaces.

Glucose ~~HealthÒ~~Health® is a dietary supplement formulated from nine natural ingredients shown in certain clinical research such as that published by the National Institutes of Health, National Library of Medicine website (see www.glucosehealth.com/clinical-trials), to have a beneficial impact upon blood glucose, ~~insulin,~~ triglyceride and cholesterol levels. The Centers for Disease Control and Prevention (CDC) publishes a National Diabetes Statistics Report annually. The 2014 Report estimates 2 of 5 presently healthy Americans will develop Type-2 diabetes in their lifetime. We believe the CDC Report and other similar research points to a large and growing market of consumers likely concerned with pre-diabetes or Type-2 diabetes including many of whom are also likely seeking natural products like Glucose ~~HealthÒ~~Health® to proactively maintain their good health.

~~Glucose~~On ~~HealthÒ~~November is20, ~~currently~~2014, ~~packaged~~the inexisting ~~a "Value~~12-~~Size"~~month ~~container~~consulting ~~format~~contract ~~consisting~~with ofthe ~~384~~Company’s ~~grams~~CEO, ofMurray ~~product~~Fleming, ~~formula~~was ~~lasting~~extended 60an ~~days.~~additional In12 ~~addition~~months ending October 2016, ~~the~~without ~~Company~~further ~~plans~~compensation, toin ~~introduce~~exchange anfor ~~"On-~~the~~-Go"~~ ~~packaging~~issuance ~~format~~to ofMr. 30Fleming, ~~stick~~of ~~packs~~1,000 toSeries aA ~~box~~Special inPreferred ~~fiscal 2016~~Shares.

On ~~November~~December 2031, 2014, the ~~existing 12 month consulting contract with the~~ Company's ~~CEO,~~elected ~~Murray~~to ~~Fleming,~~write-off ~~was~~its ~~extended~~inventory anof ~~additional~~Type2 12Defense ~~months~~product ~~ending~~to ~~October~~-0- ~~2016,~~and ~~without~~cease ~~further~~manufacturing ~~compensation,~~and insales ~~exchange~~activities ~~for~~related ~~the issuance~~ to ~~Mr.~~the ~~Fleming, of 1,000 Series A Special Preferred Shares~~product.

On ~~December~~January 315, ~~2014~~2015, the Company ~~elected~~signed toa ~~write-off~~contract ~~its~~manufacturing ~~inventory~~agreement offor ~~Type2~~testing, ~~Defense~~compounding, ~~product~~supply toand ~~-0-~~order ~~and~~fulfillment ~~cease~~for ~~all~~the ~~manufacturing~~Glucose Health® product and ~~sales~~additionally ~~activities~~a ~~related~~purchasing agreement to distribute the product through a limited number of Northwest Arkansas pharmacies.

On January 5, 2015, the Company signed a contract manufacturing agreement for testing, compounding, supply and order fulfillment for the Glucose HealthÒ product and additionally a purchasing agreement to distribute the product in a limited number of Northwest Arkansas pharmacies.

On January 7, 2015, the Company completed its implementation of Current Good Manufacturing Practices (CGMP). The Dietary Supplement (DS) CGMP rule in 21 CFR part 111 of the FDA's regulations requires companies which manufacture, package, label, or hold a dietary supplement to establish and follow current good manufacturing practice to ensure the quality of the dietary supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.

On January 26, 2015, the Company filed an initial application for trademark protection related to its line of dietary products, with the United States Trademark and Patent Office (USPTO).

On January 29, 2015, the Company appointed of Chandrasekhar Mallangi, Ph.D., as an advisor. Dr. Mallangi earned a Ph.D. in Food Science from Oregon State University and is an advisor to multinational companies in the development of nutritional products. Dr. Mallangi is the credited inventor and co-inventor for patents ~~in the area of food nutrition,~~ awarded by the USPTO to subsidiaries of Nestle, SA of Vevey, Switzerland.

On7 ~~February~~Table ~~10,~~Of 2015, Murray Fleming, the Company's Chief Executive Officer was appointed the Company's Chief Financial Officer. Mr. Fleming replaces James Hodge the Company's interim Chief Financial Officer. Mr. Hodge will remain the Company's chairman of the board of directors.Contents

On February 2410, 2015, Murray Fleming, the Company’s ~~completed~~Chief ~~FDA~~Executive ~~facility~~Officer ~~registration,~~was aappointed ~~compliance~~the ~~procedure~~Company’s ~~for~~Chief ~~manufacturers~~Financial Officer. Mr. Fleming replaced James Hodge the Company’s interim Chief Financial Officer. Mr. Hodge continued as the Company’s Chairman of ~~dietary~~the ~~and~~board ~~nutritional~~of ~~supplements~~directors.

~~The~~On ~~Company~~February ~~completed the first production run of the product on May 26~~24, 2015, ~~and pursuant to~~ the ~~January~~Company 5,completed ~~2015~~FDA ~~purchasing~~facility ~~agreement~~registration, ~~the~~a ~~product~~compliance ~~began~~procedure ~~to be offered~~ for ~~retail~~manufacturers ~~sale through a limited number~~ of ~~Northwest~~dietary ~~Arkansas pharmacies as well as on the Company's product website www~~supplements.~~glucosehealth.com.~~

On ~~July~~May 726, 2015, the Company ~~received~~completed ~~notification~~the ~~from~~first ~~the~~production ~~United~~run ~~States~~of ~~Patent~~the product and ~~Trademark~~pursuant ~~Office~~to ~~(USPTO)~~the ~~that~~January ~~its~~5, ~~application~~2015 ~~for~~purchasing ~~trademark~~agreement, ofthe ~~"Glucose~~product ~~Health"~~began ~~was~~to ~~accepted~~be tooffered ~~the~~for ~~Supplemental~~retail ~~Register~~sale ~~(Reg.~~through ~~4,770,720)~~a ~~with~~limited ~~first~~number ~~use~~of ~~recognized~~Northwest byArkansas ~~the~~pharmacies ~~USPTO~~as well as ofon ~~February~~the 1,Company’s ~~2015~~product website www. glucosehealth.com.

On July 7, 2015, the Company received notification from the United States Patent and Trademark Office (USPTO) that its application for trademark of “Glucose Health” was accepted to the Supplemental Register (Reg. 4,770,720) with first use recognized by the USPTO as of February 1, 2015.

On January 6, 2016, the Company executed a General Merchandise Supplier Agreement ("Agreement") with Wal-Mart Stores, Inc.

On January 27, 2016, the Company notified OTC Markets, Inc. of its intention to not renew its OTCQB service. The Company filed Form 8-A12G in fiscal 2015 registering a class of securities under the 1934 Securities Exchange Act. Accordingly, the Company does not make use of the OTC Markets Disclosure and News Service and instead files its periodic and annual reports and audited financial statements with the Securities and Exchange Commission.

On February 4, 2016, the Company's Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to the board of directors of Glucose Health, Inc. ("Company"). On February 5, 2016, James Hodge resigned from the board of directors.

On March 8, 2016, the Company received a series of material purchase orders from the Customer pursuant to a General Merchandise Supplier Agreement ("Agreement") with Wal-Mart Stores, Inc., executed January 6, 2016.

On October 4, 2016, the Company executed a non-recourse receivables financing agreement with Citibank, N.A. (Citibank) whereby receivables due to the Company are assumed from Wal-Mart Stores Inc. by Citibank and paid subject to an interest premium based upon LIBOR.

As of December 31, 2016, the Company’s Glucose Health® Daily Blood Sugar Maintenance Blueberry Tea Mix (60-Day Supply) product is stocked in the "Diabetic Supplies" section of most Walmart pharmacies in all 50 states.

Government Regulation

The manufacturing, processing, formulating, packaging, labeling, distributing, selling and advertising of our products are subject to government regulation, principally by the Food and Drug Administration (hereinafter the "FDA"). In particular, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements. The FDA permits "statements of nutritional support" for dietary supplements without FDA pre-approval. Such statements may describe how particular dietary ingredients affect the structure, function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function or well-being (but may not state that a dietary supplement will diagnose, mitigate, treat, cure or prevent a disease). A company making a statement of nutritional support must possess substantiating evidence for the statement, and, for such statements that are not about the effects on the body asbecause ~~a result~~ of a dietary supplement used as a tool for its nutritive value and are not otherwise "health claims," disclose on the label that the FDA has not reviewed that statement and that the product is not intended for use for a disease. Failure to comply with applicable FDA requirements can result in various levels of regulatory actions being imposed on the Company including but not limited to action letters, product recalls and injunctions.

Table Of Contents

In addition to the FDA, the Federal Trade Commission (hereinafter the "FTC") has additional jurisdiction to regulate the labeling, promotion and advertising of dietary supplements. The FTC is authorized to use a variety of processes and remedies for enforcement, both administratively and judicially, including compulsory process, cease and desist orders, and injunctions. FTC enforcement can result in orders requiring, among other things, limits on advertising, corrective advertising, consumer redress, divestiture of assets, rescission of contracts and such other relief as may be deemed necessary. State and local authorities can also regulate advertising and labeling for dietary supplements and conventional foods. Additionally, there can be no assurance that state and local authorities will not commence other regulatory actions that could restrict the permissible scope of our product claims.

Competition

The business of developing and distributing dietary supplements is highly competitive. Our product has direct and indirect competition. We compete directly with ~~GlucernaÒ~~Glucerna® Advance, manufactured by Abbott Laboratories; Boost Glucose ~~ControlÒ~~Control®, manufactured by Nestle; and ~~EnterexÒ~~Enterex® Diabetic, manufactured by Victus, Inc. All of the companies whom are our direct competitors are substantially larger with much greater financial resources and broader name recognition. Although we are a small company, we have a competitive advantage over our larger direct competitors because they rely upon achieving their product goals principally through the benefits of high fiber content and a broad spectrum of vitamins and minerals; while our product not only has similar dietary fiber content, it is 100% soluble and therefore of greater interest to persons concerned with pre-diabetes and/or Type-2 diabetes. Instead of a broad spectrum of vitamins and minerals, Glucose ~~HealthÒ~~Health® also contains targeted plant based extracts and powders, in a proprietary formula, which have been demonstrated in certain clinical studies to have beneficial impacts on healthy levels of serum glucose, insulin, triglycerides and cholesterol. We also compete indirectly with Metamucil, manufactured by Procter and Gamble, because both Metamucil and Glucose ~~HealthÒ~~Health® have similar fiber content and are both targeted to the pre-diabetes and Type-2 diabetes consumer market. We also compete indirectly with the many individual dietary supplements marketed in pill or tablet form and ~~also~~ targeted to the pre-diabetic and Type-2 diabetic consumer market segment.

There can be no assurance that we will be able to effectively compete in such an intensely competitive environment.

Intellectual Property

Our intellectual property consists of the Glucose ~~HealthÒ~~Health® product acquired October 1, 2014 and our proprietary product formula. Glucose ~~HealthÒ~~Health® is protected by trademark protection following our successful application to the United States Patent and Trademark Office. We may consider filing patent applications with respect to our product formula and other novel aspects of our business to protect our intellectual property. Future patents, if issued, may be challenged, invalidated or circumvented. Thus, any patent awarded to us may not provide adequate protection against competitors. The patent applications we file may not result in patents being issued. Also, patents may not provide us with adequate proprietary protection or advantages against competitors with similar or competing products. As a result of potential conflicts with the proprietary rights of others, we may in the future have to prove that we are not infringing the patent rights of others or be required to obtain a license to the patent. We do not know whether such a license would be available on commercially reasonable terms, or at all.

We also rely on trade secrets and unpatentable know-how that we seek to protect, in part, by confidentiality agreements. However, it is possible that parties may breach those agreements, and we may not have adequate remedies for any breach. It is also possible that our trade secrets or unpatentable know-how will otherwise become known or be independently developed by competitors. There can be no assurance that third parties will not assert infringement or other claims against us with respect to any existing or future products, or that licenses would be available if our formulas were successfully challenged by a third party, or if it became desirable to use any third-party formulas and/or technology to enhance our products. Litigation to protect our proprietary information or to determine the validity of any third-party claims could result in significant expense to us and divert the efforts of our technical and management personnel, whether or not we are successful in such litigation.

Table Of Contents

While we have no knowledge that we are infringing the proprietary rights of any third party, there can be no assurance that such claims will not be asserted in the future with respect to our Product formula or future products. Any such assertion by a third party could require us to pay royalties, to participate in costly litigation and defend licensees in any such suit pursuant to indemnification agreements, or to refrain from selling an alleged infringing product or service.

Employees

We have no employees. We hire consultants and contract with third-party providers to support our business development. We may need to hire employees in the future to support our business development.

Item 1B1A. ~~Unresolved~~Risk ~~Staff Comments~~Factors.

~~None~~The company qualifies as a smaller reporting company and is not required to provide the information required by this Item.

Item 2. Description of Property.

Facilities

Our principal office is located at 609 SW 8th Street, Suite 600, Bentonville, AR 72712, which we rent monthly. In addition, we contract for product production, warehousing and fulfillment at facilities located at 11753 N Hwy 59, Gravette, AR 72736. We do not believe we will have difficulty in obtaining additional office or commercial space at competitive prices, if necessary. We hold no real property.

Item 3. Legal Proceedings.

~~None~~From time to time, we may be involved in litigation in the ordinary course of business. We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. To our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending which, to the knowledge of our executive officers, could have a material adverse effect on our Company.

~~Item~~10 4.Table ~~Mine~~Of ~~Safety Disclosures.~~Contents

~~Not~~PART ~~applicable~~ II

~~PART~~Market IIInformation

~~Item~~The 5Company’s Common Stock is currently quoted by OTC Markets Group, Inc. through the Pink Open Market, ~~for~~known ~~Common~~as ~~Equity~~OTC Pink, with the symbol GLUC. The high and ~~Related~~low ~~Stockholder~~closing ~~Matters~~prices of the Company’s common stock since January 1, 2015 quoted by OTC Markets Group, Inc. are set forth below. Such closing prices reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

A. Market Information

	High		Low
2015
First Quarter	$	0.1048	$	0.0375
Second Quarter	$	0.065	$	0.035
Third Quarter	$	0.061	$	0.033
Fourth Quarter	$	0.0749	$	0.031

2016
First Quarter	$	0.065	$	0.0274
Second Quarter	$	0.50	$	0.035
Third Quarter	$	0.445	$	0.09
Fourth Quarter	$	0.09	$	0.04

~~The~~Reports ~~Company's~~to ~~Common~~Security Stock is currently quoted by OTC Markets under the symbol GLUC. The high and low closing prices of the Company's common stock since January 1, 2014 are set forth below. These closing prices do not reflect retail mark-up, markdown or commissions.Holders

	High		Low
2015
First Quarter	$	0.1048	$	0.0375
Second Quarter	$	0.65	$	0.35
Third Quarter	$	0.061	$	0.033
Fourth Quarter	$	0.0749	$	0.031
2014
First Quarter	$	2.00	$	0.95
Second Quarter	$	0.95	$	0.50
Third Quarter	$	1.15	$	0.28
Fourth Quarter	$	0.47	$	0.08

The public may read and copy any materials filed with the Securities and Exchange Commission at the Security and Exchange Commission’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. The public may also obtain information on the operation of the Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Securities and Exchange Commission, which includes us. The address of that site is www.sec.gov.

~~Reports to Security~~ Holders.

~~The~~As ~~public~~of ~~may~~March ~~read~~28, ~~and~~2017, ~~copy~~we ~~any~~had ~~materials~~114 ~~filed~~shareholders ~~with~~of ~~the~~record. ~~Securities~~Shareholders ~~and~~of ~~Exchange~~record ~~Commission~~does atnot ~~the~~include ~~Security~~beneficial ~~and~~owners ~~Exchange~~of ~~Commission's~~our ~~Public~~shares ~~Reference~~held ~~Room~~in “street name” at ~~100~~brokerage Fand ~~Street,~~custodial ~~N.E.~~firms, ~~Washington, D.C. 20549. The public may also obtain information on~~ the ~~operation~~accuracy of ~~the~~which ~~Public~~cannot ~~Reference~~be ~~Room by calling the Securities and Exchange Commission at 1-800-SEC-0330~~guaranteed. ~~The~~We ~~Securities~~estimate ~~and~~our ~~Exchange~~total ~~Commission~~number ~~maintains~~of anshareholders ~~Internet~~inclusive ~~site~~of ~~that~~shareholders ~~contains~~of ~~reports,~~record ~~proxy~~ and ~~information~~beneficial ~~statements,~~owners ~~and~~of ~~other~~shares ~~information~~held ~~regarding~~in ~~issuers~~street ~~that~~name, ~~file~~to ~~electronically~~be ~~with~~approximately ~~the Securities and Exchange Commission~~1, ~~which includes us~~000. ~~The address of that site is www.sec.gov.~~

~~Holders.~~Transfer Agent

As of April 14, 2016 we had 115 shareholders of record. However, the majority of our shareholders hold their stock in "street name" at brokerage and custodial firms. We estimate our total number of shareholders to be over 700. Our transfer agent is Nevada Agency & Transfer Company located at 50 West Liberty Street, Reno, Nevada, 89501 and their phone number is (775) 322-0626.

Dividend Policy.

We have never declared or paid a cash dividend. We do not expect to pay cash dividends in the foreseeable future. We currently intend to retain our earnings, if any, for use in our business. Any dividends declared in the future will be at the discretion of our board of directors and subject to any restrictions that may be imposed by our lenders.

1011 Table Of Contents

Equity Compensation Plan

OnWe ~~March~~have 4,not ~~2013,~~established weany ~~filed~~compensation anplans ~~S-8 registration statement with the Securities and Exchange Commission registering up to 30,000,000 shares of common stock~~ under ~~our~~which ~~2013~~equity ~~Stock~~securities ~~Incentive~~are ~~Plan.~~authorized ~~During~~for ~~fiscal 2014, we issued 15,000 (split adjusted) shares pursuant to this plan~~issuance. ~~Our 2013 Stock Incentive Plan was formally rescinded by resolution of the board of directors in 2014.~~

Recent ~~sales~~Sales of ~~unregistered~~Unregistered ~~securities~~Securities

During the fiscal years ended December 31, ~~2014~~2015 and ~~December 31~~2016, ~~2015,~~ we issued a total of ~~925~~1,~~106~~142,063 and ~~973~~860,~~063~~385 shares of common stock respectively.

a) During January ~~2014~~2015, ~~William~~the ~~Gallagher~~Company issued 58,092 ~~our~~shares ~~former~~of ~~chief~~common ~~executive~~stock ~~officer~~to ~~canceled~~a ~~12,000~~corporation offor ~~his~~conversion ~~personal~~of ~~unregistered~~$250 ~~shares~~principal ofand ~~the~~$40 ~~Company's~~accrued ~~common~~interest ~~stock~~related to ~~satisfy~~ a ~~promissory note conversion request~~Note. These shares were valued at $10.75005 per share ~~or $21,000~~. b) During ~~January~~February ~~2014~~2015, athe ~~promissory~~Company ~~note~~issued ~~was~~177,072 ~~converted into unregistered~~ shares of ~~the Company's~~ common stock. ~~The~~to ~~amount~~a ~~totaled~~corporation ~~$12,849~~for ~~including~~conversion ~~interest~~of ~~was~~$750 ~~converted~~principal ~~into~~and ~~17,132~~$136 ~~unregistered~~accrued ~~shares~~interest ofrelated ~~the~~to ~~Company's~~Note. ~~common~~These ~~stock~~shares were valued at $0.75005 per share. c) During ~~March~~February ~~2014~~2015, athe ~~promissory~~Company ~~note~~issued ~~was~~70,867 ~~partially~~shares ~~converted~~of ~~into~~common ~~unregistered~~stock ~~shares~~in final settlement of a consulting agreement. These shares were valued at $0.08467. d) During March 2015, the Company's issued 162,264 shares of common stock. ~~The~~to ~~amount~~a ~~totaled~~corporation for conversion of $~~4,000~~500 ~~was~~principal ~~converted~~and ~~into~~$41 ~~16,000~~accrued ~~unregistered~~interest ~~shares~~related ofto ~~the~~a ~~Company's~~Note. ~~common~~These ~~stock~~shares were valued at $0.25005 per share. de) During ~~March~~April ~~2014~~2015, athe ~~promissory~~Company ~~note~~issued ~~was~~86,882 ~~converted into unregistered~~ shares of ~~the Company's~~ common stock. ~~The~~to ~~amount~~a ~~totaled~~corporation ~~$13,151~~for ~~including~~conversion ~~interest~~of ~~was~~$400 ~~converted~~principal ~~into~~and ~~13,171~~$40 ~~unregistered~~accrued ~~shares~~interest ofrelated ~~the~~to ~~Company's~~Note. ~~common~~These ~~stock~~shares were valued at $0.~~999~~005 per share. ef) During ~~March~~April ~~2014~~2015, the Company ~~signed~~issued an50,000 ~~agreement~~shares ~~with~~of acommon ~~firm~~stock toin ~~provide~~final ~~strategic~~settlement ~~business~~of ~~development~~a ~~activities~~consulting ~~for~~agreement. ~~the~~These ~~Company.~~shares ~~The~~were ~~firm~~valued ~~will~~at be$0.0357 ~~compensated~~per ~~with~~share. ~~7,200~~g) ~~unregistered~~During ~~shares~~May of2015, the Company's issued 100,000 shares of common stock ~~payable~~to inpursuant ~~increments~~to offinal ~~600~~settlement ~~shares~~of ~~per~~an ~~month~~outstanding ~~for~~debt. ~~twelve~~These ~~(12)~~shares ~~months~~were ~~starting~~valued onat ~~April~~$0.2278 1,per ~~2014~~share. h) During ~~2014~~June 2015, the Company issued 787,~~200~~564 ~~unregistered~~ shares of ~~the Company's~~ common stock, ~~which~~to a corporation for conversion of $400 principal and $38 accrued interest related to a Note. These shares were valued at $0.52005 per share. ori) $3During June 2015,~~732~~ the Company issued 10,000 shares of common stock pursuant to ~~fully~~a ~~satisfy~~final ~~the~~settlement ~~March~~of ~~2014~~an ~~agreement~~outstanding payable to an individual. f)These ~~During~~shares ~~April~~were ~~2014,~~valued ~~William~~at ~~Gallagher,~~$0.05 ~~our~~per ~~former~~share. ~~chief~~j) ~~executive~~During ~~officer~~September ~~was~~2015, ~~re-~~the Company issued 1288,~~000~~438 ~~unregistered~~ shares of ~~the Company's~~ common stock ~~which~~to ~~were~~a ~~canceled~~corporation infor ~~January~~conversion ~~2014~~of to$400 ~~satisfy~~principal aand ~~promissory~~$42 ~~note~~accrued ~~conversion~~interest ~~request~~pursuant to a Note. These shares were valued at $10.75005 per share ~~or $21,000~~. gk) During ~~April~~November ~~2014~~2015, ~~Thomas~~the ~~Metzger~~Company issued 89,020 ~~our~~shares ~~former~~of ~~chief~~common ~~executive~~stock ~~officer/chief~~to ~~financial~~a ~~officer~~corporation ~~was~~for ~~issued~~conversion ~~5,000~~of ~~unregistered~~$400 ~~shares~~principal ofand ~~the~~$45 ~~Company's~~accrued ~~common~~interest ~~stock~~pursuant ~~for~~to ~~compensation~~a Note. These shares were valued at $0.~~755~~04 per share ~~or $3,375~~. hl) During ~~April~~November ~~2014~~2015, ~~James~~the ~~Hodge,~~Company ~~our~~issued ~~chairman~~50,000 shares of ~~the~~common ~~board~~stock ofto ~~directors,~~an ~~was~~individual ~~issued~~for 5services rendered valued at $3,~~000~~500. ~~unregistered~~These shares ofwere valued at $0.07 per share. m) During December 2015, the Company's issued 111,864 shares of common stock to a corporation for ~~joining~~conversion ~~the~~of ~~Company's~~$500 ~~board~~principal and $59 accrued interest pursuant to a Note. These shares were valued at $0.~~755~~07 per share ~~or $3,375~~. in) During ~~April~~February ~~2014~~2016, ~~Peggy~~the ~~Knight~~Company ~~our~~issued ~~chief~~90,094 ~~marketing~~shares ~~officer~~of ~~was~~common ~~issued~~stock ~~15,000~~to ~~unregistered~~a ~~shares~~corporation for conversion of ~~the~~$400 ~~Company's~~principal ~~common~~and ~~stock~~$51 ~~for~~accrued ~~marketing~~interest ~~compensation~~pursuant to a Note. These shares were valued at $0.~~755~~005 per share ~~or $11,325~~. jo) During June ~~2014~~2016, the Company ~~signed~~issued 130,000 shares of common stock to a ~~one~~corporation ~~year~~for ~~consulting~~conversion ~~agreement~~of ~~with~~$845 anof ~~individual~~accrued interest pursuant to ~~provide~~a ~~product~~Note. ~~marketing~~These ~~and~~shares ~~performs~~were ~~duties~~valued asat ~~the~~$0.0065 ~~Company's~~per ~~spokesperson~~share. ~~The~~p) ~~consultant~~During ~~earned~~June 52016,~~000~~ ~~restricted~~the ~~shares~~Company ofissued ~~the~~81,250 ~~Company's~~shares of common stock to a corporation for conversion of $650 of accrued interest pursuant to a Note. ~~The~~These shares were valued at $0.65008 per share. orq) During August 2016, the Company issued 129,358 shares of common stock to a corporation for conversion of $31,~~250~~000 principal and $35 accrued interest pursuant to a Note. These shares were ~~issued~~valued inat ~~July~~$0.008 ~~2014~~per share. kr) During ~~July~~September ~~2014~~2016, athe ~~promissory~~Company ~~note~~issued ~~was~~121,483 ~~partially~~shares ~~converted~~of ~~into~~common ~~unregistered~~stock ~~shares~~to ofa ~~the~~corporation ~~Company's~~for ~~common~~conversion ~~stock.~~of ~~The~~$950 ~~amount~~principal ~~totaled~~and $~~4,103~~22 ~~including~~ accrued interest ~~was~~pursuant ~~converted~~to ~~into~~a ~~16,412~~Note. ~~unregistered~~These shares ofwere ~~the~~valued ~~Company's common stock~~ at $0.25008 per share. ls) During ~~July~~October ~~2014~~2016, ~~James Hodge,~~ the Company's ~~chairman~~issued of134,881 ~~the~~shares ~~board~~ of ~~directors,~~common ~~was~~stock ~~issued~~to ~~6,923~~a ~~shares~~corporation for conversion of ~~the~~$1,050 ~~Company's~~principal ~~restricted~~and ~~common~~$29 ~~stock~~accrued ~~for~~interest ~~service~~pursuant to ~~the~~a ~~Company~~Note. These shares were valued at $0.65008 per share ~~or $4,500~~. mt) During ~~July~~November ~~2014~~2016, the Company ~~signed~~issued a148,319 ~~consulting~~shares ~~agreement~~of ~~with~~common anstock ~~individual~~ to ~~provide~~a ~~website~~corporation ~~services~~ for ~~the~~conversion ~~Company.~~of ~~The~~$1,150 ~~consultant~~principal ~~was~~and ~~compensated~~$37 ~~with~~accrued ~~60,000~~interest ~~shares~~pursuant ofto ~~the~~a ~~Company's common stock~~Note. ~~The~~These shares were valued at $~~69,000 or $1~~0.15008 per share.

1112 Table Of Contents

n)All ~~During~~issuances ~~July~~referenced ~~2014,~~above ~~Thomas~~were ~~Metzger~~exempt ~~Ph.D., our former Chief Executive Officer and Chief Financial Officer resigned~~ from ~~the~~registration ~~Company~~pursuant to ~~pursue~~Section ~~other interests. Per board consent signed July 22, 2014, the 5,000 unregistered shares of the Company's common stock due to Mr. Metzger on September~~ 4~~, 2014 in accordance with his consulting agreement signed in April 2014 were issued to Mr. Metzger. The shares were valued at $4,925 or $0.985 per share. o~~(a)(2) ~~During August 2014, a promissory note was partially converted into unregistered shares~~ of the ~~Company's~~Securities ~~common~~Act ~~stock. The amount totaled $3,059 including accrued interest was converted into 12,235 unregistered shares~~ of ~~the~~1933 ~~Company's common stock at $0.25 per share. p) During September 2014, a promissory note was partially converted into unregistered shares of~~ (the ~~Company's~~“Securities ~~common stock~~Act”). The ~~amount totaled $2,529 including accrued interest was converted into 10,115 unregistered~~ shares of ~~the Company's~~ common stock athave ~~$0.25~~not ~~per~~been ~~share.~~registered q)under ~~On October 1, 2014,~~ the ~~Company~~Securities ~~entered~~Act ~~into~~or anunder ~~Intellectual~~any ~~Property~~state ~~Purchase~~securities ~~Agreement to purchase the "Glucose Health Natural Blood Sugar Maintenance" product for 300~~laws,~~000~~ ~~unregistered~~and ~~shares~~may ofnot ~~the~~be ~~Company's~~offered ~~common stock valued at $0.38 per share~~ or ~~$114,000,~~sold ~~from~~without aregistration company beneficially owned by our CEO, Murray Fleming. r) On October 1, 2014, Murray Fleming was appointed as the Company's Chief Executive Officer for the 12 month period ending October 1, 2015. Mr. Fleming was compensated with ~~300,000 unregistered shares of~~ the ~~Company's~~United ~~common~~States ~~stock~~Securities ~~valued~~and atExchange ~~$0.38~~Commission ~~per share~~ or ~~$114,000.~~an s)applicable ~~During~~exemption ~~November~~from ~~2014, a promissory note was partially converted into unregistered shares of~~ the ~~Company's~~registration ~~common stock~~requirements. The ~~amount~~investors ~~totaled~~acknowledged ~~$250~~that ~~was converted into 50,000 unregistered shares of~~ the ~~Company's~~securities ~~common~~had ~~stock~~not atbeen ~~$0.005~~registered ~~per~~under ~~share. t) During December 2014, a promissory note was partially converted into unregistered shares of~~ the ~~Company's~~Securities ~~common~~Act; ~~stock.~~they ~~The~~understood ~~amount totaled $285 including accrued interest was converted into 56,918 unregistered shares of~~ the ~~Company's~~economic ~~common~~risk ~~stock at $0.005 per share. u) During 2014, the Company issued 263 shares to satisfy rounding issues as a result~~ of ~~the~~an ~~reverse~~investment ~~stock~~in ~~splits implemented during~~ the ~~year.~~securities; v)and ~~During~~they ~~January~~had ~~2015,~~ the ~~Company~~opportunity ~~issued 58,092 shares of common stock~~ to aask ~~corporation~~questions ~~for conversion~~ of ~~$250 principal~~ and ~~$40~~receive ~~accrued~~answers ~~interest~~from ~~related~~our tomanagement aconcerning ~~Note.~~all ~~These~~matters ~~shares~~related ~~were valued at $0.005 per share. w) During February 2015, the Company issued 177,072 shares of common stock~~ to aacquisition ~~corporation for conversion~~ of ~~$750~~the ~~principal and $136 accrued interest related to Note~~securities. ~~These~~The ~~shares~~sales were ~~valued~~made atto ~~$0.005~~sophisticated ~~per~~or ~~share.~~accredited ~~x) During February 2015~~investors, ~~the~~as ~~Company~~defined ~~issued 70,867 shares of common stock~~ in ~~final~~Rule ~~settlement of~~ 501(a ~~consulting agreement~~). ~~These~~Further, ~~shares~~we ~~were~~gave ~~valued~~the atpurchasers ~~$0.08467. y) During March 2015,~~ the ~~Company~~opportunity ~~issued 162,264 shares of common stock~~ to aask ~~corporation~~questions ~~for conversion of $500 principal~~ and ~~$41~~receive ~~accrued~~answers ~~interest~~concerning ~~related to a Note. These shares were valued at $0.005 per share. z) During April 2015,~~ the ~~Company~~terms ~~issued~~and ~~86,882~~conditions ~~shares of common stock to a corporation for conversion of $400 principal~~ and ~~$40 accrued interest related~~ to ~~Note.~~obtain ~~These~~any ~~shares~~additional ~~were~~information ~~valued~~which atwe ~~$0.005~~possessed ~~per~~or ~~share.~~could ~~aa)~~acquire ~~During~~without ~~April~~unreasonable ~~2015,~~effort ~~the~~or ~~Company~~expense ~~issued~~necessary ~~50,000~~to ~~shares~~verify ~~of common stock in final settlement of a consulting agreement. These shares were valued at $0.0357 per share. bb) During May 2015,~~ the ~~Company~~accuracy ~~issued 100,000 shares~~ of ~~common~~information ~~stock to pursuant to final settlement of an outstanding debt~~furnished. ~~These~~At ~~shares were valued at $0.2278 per share. cc) During June 2015, the Company issued 87,564 shares of common stock to~~ a ~~corporation~~reasonable ~~for~~time ~~conversion~~prior ~~of $400 principal and $38 accrued interest related~~ to ~~a Note. These shares were valued at $0.005 per share. dd) During June 2015,~~ the ~~Company~~sale ~~issued~~of 10securities,~~000~~ ~~shares~~we ofadvised ~~common~~the ~~stock~~purchasers ~~pursuant to a final settlement~~ of anthe ~~outstanding~~limitations ~~payable~~on toresale anin ~~individual. These shares were valued at $0.05 per share. ee) During September 2015,~~ the ~~Company~~manner ~~issued~~contained ~~88,438~~in ~~shares~~Rule ~~of common stock to a corporation for conversion of $400 principal and $42 accrued interest pursuant to a Note. These shares were valued at $0.005 per share. ff~~502(d) ~~During November 2015, the Company issued 89,020 shares of common stock to a corporation for conversion of $400 principal and $45 accrued interest pursuant to a Note~~2. ~~These~~Neither ~~shares were valued at $0.04 per share. gg) During November 2015~~we, ~~the~~nor ~~Company~~any ~~issued~~person ~~50,000~~acting ~~shares~~on ofour ~~common stock to an individual for services rendered valued at $3~~behalf,~~500.~~ ~~These~~sold ~~shares were valued at $0.07 per share. hh) During December 2015,~~ the ~~Company~~securities ~~issued~~by ~~111,864~~any ~~shares~~form of ~~common~~general ~~stock~~solicitation toor ageneral ~~corporation for conversion of $500 principal and $59 accrued interest pursuant to a Note~~advertising. ~~These shares were valued at $0.07 per share.~~

~~All~~Recent ~~issuances~~Sales ~~referenced above were exempt from registration pursuant to Section 4(a)(2)~~ of ~~the~~Registered Securities Act of 1933. The shares of common stock have not been registered under the Securities Act or under any state securities laws and may not be offered or sold without registration with the United States Securities and Exchange Commission or an applicable exemption from the registration requirements. The investors acknowledged that the securities to be issued have not been registered under the Securities Act; they understood the economic risk of an investment in the securities; and they had the opportunity to ask questions of and receive answers from our management concerning any and all matters related to acquisition of the securities. The sales were made to sophisticated or accredited investors, as defined in Rule 501(a). Further, we gave the purchasers the opportunity to ask questions and receive answers concerning the terms and conditions and to obtain any additional information which we possessed or could acquire without unreasonable effort or expense necessary to verify the accuracy of information furnished. At a reasonable time prior to the sale of securities, we advised the purchasers of the limitations on resale in the manner contained in Rule 502(d) 2. Neither we, nor any person acting on our behalf, sold the securities by any form of general solicitation or general advertising.

12None.

Use of Proceeds of Registered Securities.

~~None~~Not applicable.

Penny Stock Regulation.

Shares of our common stock are subject to rules adopted the Securities and Exchange Commission that regulate broker-dealer practices in connection with transactions in "“penny stocks"”. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in those securities is provided by the exchange or system). These penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from these rules to deliver a standardized risk disclosure document prepared by the Securities and Exchange Commission, which contains the following:

· a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; · a description of the broker'’s or dealer'’s duties to the customer and of the rights and remedies available to the customer with respect to violation to such duties or other requirements of securities'’ laws · a brief, clear, narrative description of a dealer market, including "bid" and "ask"” prices for penny stocks and the significance of the spread between the "bid" and "ask" price; · a toll-free telephone number for inquiries on disciplinary actions; · definitions of significant terms in the disclosure document or in the conduct of trading in penny stocks; and · such other information and is in such form (including language, type, size and format), as the Securities and Exchange Commission shall require by rule or regulation.

~~Prior~~13 toTable ~~effecting~~Of ~~any transaction in penny stock, the broker-dealer also must provide the customer the following:~~Contents

·Prior ~~the~~to ~~bid~~effecting ~~and~~any ~~offer~~transaction ~~quotations~~in ~~for the~~ penny stock;, · the ~~compensation of the~~ broker-dealer ~~and~~also ~~its~~must ~~salesperson~~provide in the ~~transaction:~~customer · the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and · monthly account statements showing the market value of each penny stock held in the customer's account.following:

In· ~~addition,~~ the ~~penny~~bid ~~stock~~and ~~rules~~offer ~~require~~quotations ~~that~~for ~~prior~~the ~~to a transaction in a~~ penny stock; ~~not~~· ~~otherwise~~the ~~exempt~~compensation ~~from~~of ~~these rules,~~ the broker-dealer ~~must~~and ~~make~~its asalesperson ~~special~~in ~~written determination that~~ the ~~penny~~transaction: ~~stock~~· ~~is a suitable investment for~~ the ~~purchaser~~number ~~and receive the purchaser's written acknowledgment~~ of ~~the~~shares ~~receipt of a risk disclosure statement, a written agreement~~ to ~~transactions~~which ~~involving~~such ~~penny~~bid ~~stocks,~~ and aask ~~signed~~prices ~~and~~apply, ~~dated~~or ~~copy~~other ofcomparable ainformation ~~written~~relating ~~suitability~~to ~~statement.~~the ~~These~~depth ~~disclosure~~and ~~requirements~~liquidity ~~may have the effect~~ of ~~reducing~~ the ~~trading activity in the secondary~~ market for asuch stock; ~~that~~and ~~becomes~~· ~~subject~~monthly toaccount ~~the~~statements ~~penny~~showing ~~stock~~the ~~rules.~~market ~~Holders~~value of ~~shares~~each ofpenny ~~our common~~ stock ~~may~~held ~~have~~in ~~difficulty~~the ~~selling~~customer’s ~~those shares because our common stock is subject to penny stock rules~~account.

~~Issuer~~In ~~Purchases~~addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of ~~Equity~~the ~~Securities~~receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for a stock that becomes subject to the penny stock rules. Holders of shares of our common stock may have difficulty selling those shares because our common stock is subject to penny stock rules.

WeIssuer ~~did~~Purchases ~~not repurchase any shares~~ of ~~its~~Equity ~~common~~Securities ~~stock during the fiscal year ending December 31, 2015.~~

We did not repurchase any shares of our common stock during the fiscal year ending December 31, 2016.

Item 6. Selected Financial Data.

~~Not~~As ~~applicable~~a smaller reporting company, we are not required to provide the information required by this Item.

1314 Table Of Contents

Item 7. Management'’s Discussion and Analysis of Financial Condition and Results of Operations.

~~Cautionary~~CAUTIONARY ~~Note~~NOTE ~~Regarding~~REGARDING ~~Forward~~FORWARD ~~Looking~~LOOKING ~~Statements~~ STATMENTS

~~Plan of Operation~~Overview

OnWe ~~January~~are ~~10,~~a ~~2014,~~manufacturer ~~the Company's Board~~ of ~~Directors~~dietary ~~unanimously~~supplements ~~voted~~formulated to ~~reverse~~help ~~split~~maintain ~~the~~healthy ~~Company's~~blood ~~common stock on the basis of one share of the Company's common stock for each 10 shares outstanding while maintaining the authorized capital structure of the Company at 200~~sugar,~~000,000~~ ~~shares.~~triglycerides ~~The~~and ~~Board~~cholesterol ~~resolution~~and ~~set~~digestive ~~the~~health ~~date~~and ofour ~~record~~business ~~for~~focus ~~shareholder~~is ~~approval~~serving ~~for January 14, 2014. As of January 29, 2014,~~ the ~~Company~~consumer ~~obtained~~market ~~written~~segment ~~consent in lieu~~ of apersons ~~meeting~~concerned ofabout ~~the~~pre-diabetes ~~shareholders~~and/or toType-2 ~~authorize a reverse split of the Company's common stock~~diabetes. ~~Shareholders~~Our ~~owning~~principal aproduct ~~total~~is ofGlucose ~~100,992,469~~Health® ~~shares~~and ofwe ~~the~~are ~~Company's common stock voted~~ in ~~favor of~~ the ~~reverse~~early ~~split.~~stages ~~There were a total~~ of ~~199~~manufacturing,~~611,900~~ ~~shares~~marketing ~~of common stock issued~~ and ~~outstanding~~distributing asthis ~~of January 14, 2014 (the date of record)~~product. ~~The~~For ~~number of shares of common stock voting in favor of~~ the ~~reverse~~period ~~split~~ending ~~was~~December ~~sufficient for approval. On February 4~~31, ~~2014~~2016, ~~the~~we ~~Company~~generated ~~filed~~ a ~~Certificate~~gross ofprofit ~~Change~~before ~~with~~operating ~~the~~expenses, ~~State of Nevada effecting~~ a ~~1-for-10~~loss ~~reverse~~from ~~split~~operations ~~pursuant to which every ten shares of the Company's common stock were combined~~ and ~~converted~~a ~~into~~net ~~one~~loss ~~share~~per ~~of the Company's common stock (with all fractional shares resulting there from being rounded up to the next whole~~ share~~) with the total number of shares of the Company's authorized common stock remaining at 200,000,000 shares~~. ~~The effective date of the above corporate action was February 26, 2014.~~

On October 1, 2014, ~~Murray~~the ~~Fleming~~Company ~~was~~entered ~~appointed~~into ~~the~~an ~~Company's~~Intellectual ~~Chief~~Property ~~Executive~~Purchase ~~Officer~~Agreement ~~for~~to purchase the ~~12-month~~“Glucose ~~period~~Health ~~ending~~Natural ~~October~~Blood 1,Sugar ~~2015.~~Maintenance” Mrproduct. ~~Fleming~~The ~~was~~product ~~compensated~~concept ~~with~~is ~~300~~a dietary supplement formulated from natural ingredients shown in certain clinical research,~~000~~ ~~unregistered~~such ~~shares~~as ofthat published by the ~~Company's~~National ~~common~~Institutes ~~stock.~~of ~~Additionally~~Health, onNational ~~the~~Library ~~same~~of ~~date~~Medicine website (see www.glucosehealth.com/clinical-trials), ~~the~~to ~~Company~~have ~~entered~~a ~~into~~beneficial animpact ~~Intellectual~~upon ~~Property~~blood ~~Purchase~~glucose, ~~Agreement~~triglyceride toand ~~purchase~~cholesterol ~~the~~levels. ~~"Glucose~~The ~~Health~~Centers ~~Natural~~for ~~Blood~~Disease ~~Sugar~~Control ~~Maintenance"~~and ~~product~~Prevention ~~from~~(CDC) publishes a ~~company~~National ~~beneficially~~Diabetes ~~owned~~Statistics byReport Mrannually. ~~Fleming~~Their ~~for~~2014 ~~300,000~~Report ~~unregistered~~estimates ~~shares~~2 of ~~the~~5 ~~Company's~~presently ~~common~~healthy ~~stock.~~Americans Onwill ~~October~~develop 1,Type-2 ~~2014,~~diabetes Mrin their lifetime. ~~Fleming~~We ~~beneficially~~believe ~~owned~~this ~~600,000~~CDC ~~shares~~Report orand ~~50.1%~~other ofsimilar ~~the~~research ~~outstanding~~points ~~shares~~to a large and growing market of ~~the~~consumers ~~Company's~~likely ~~common~~concerned ~~stock~~with pre-diabetes or Type-2 diabetes, ~~which~~including ~~resulted~~many inof awhom ~~change~~are inalso ~~control~~likely ofseeking ~~the~~natural ~~Company~~products such as Glucose Health® to proactively maintain their good health.

~~Following~~After the purchase of the ~~"Glucose Health Natural Blood Sugar Maintenance"~~ product, the Company undertook a series of steps to achieve a final product offering that would be considered efficacious as well as pleasant tasting by our target consumer market, being persons concerned with pre-diabetes and Type-2 diabetes, and would offer a value proposition relative to our competition ~~in order~~ to be considered for stocking by national and regional pharmacy retailers. To assist in achieving our final product objectives, we retained a former head of beverage product development at Nestle. We retained an attorney specializing in compliance with Food and Drug Administration (FDA) and regulations pertaining to dietary supplements and Federal Trade Commission (FDC) regulations, necessary, in part, to ~~allow~~enable our product to be stocked by national pharmacy retailers. We also undertook aseveral ~~number of~~ actions to establish and build our Glucose ~~HealthÒ~~Health® brand. The Company conducted a design competition related to its packaging artwork and product logo and retained an experienced product packaging graphic artist to assist with all digital and print representations of the product. The Company filed for and received trademark protection for Glucose ~~HealthÒ~~Health® with the United States Trademark and Patent Office (USPTO). While our primary sales and marketing focus is achieving sales to consumers through national and regional pharmacies, secondarily, we intend to also market the product directly to customers via our dedicated product website and through other online marketplaces.

On15 ~~October~~Table ~~30,~~Of 2014, the board of directors of the Company voted to reverse split the Company's common stock on the basis of one share of the Company's common stock for each 50 shares outstanding while maintaining the authorized capital structure of the Company at 200,000,000 shares; to authorize 1,000 shares of preferred stock with "blank check" rights; and to change the Company's name from Bio-Solutions Corp. to Glucose Health, Inc. (the "corporate action"). The board resolution set the date of record for shareholder approval of the corporate action for October 31, 2014 and the effective date of the corporate action for November 19, 2014. As of October 31, 2014, the Company obtained written consent in lieu of a meeting of shareholders to authorize the corporate action. Shareholders owning a total of 30,596,154 shares of the Company's common stock voted in favor of the corporate action. There were a total of 60,132,271 shares of common stock issued and outstanding as of October 31, 2014 (the date of record). The number of shares of common stock voting in favor of the corporate action was sufficient for approval. On November 5, 2014, the Company filed a Certificate of Amendment to its Articles of Incorporation, with the Nevada Secretary of State effecting, as of November 19, 2014, the 1-for-50 reverse split pursuant to which every fifty shares of the Company's common stock were combined and converted into one share of the Company's common stock (with all fractional shares being rounded up to the next whole share) with the total number of shares of the Company's authorized common stock remaining at 200,000,000 shares; effecting the authorization of 1,000 shares of preferred stock with "blank check" rights; and effecting the change of the Company's name from Bio-Solutions Corp. to Glucose Health, Inc. Contents

14Recent Developments

On ~~November~~January 205, ~~2014~~2015, the ~~board~~Company ofsigned ~~directors~~a voted to designate Series A Special Preferred Shares consisting of 1,000 shares of preferred stock with special voting rights whereby the holder(s) may exercise their right to vote on all shareholder matters representing the number of votes equal to all shares of common stock then issued and outstanding, plus an additional ten thousand (10,000) shares. Additionally, the board of directors voted to extend an existing consulting contract ~~with~~manufacturing ~~the~~agreement ~~Company's CEO, Murray Fleming,~~ for ~~an additional 12 months~~testing, ~~through October 1~~compounding, ~~2016,~~supply ~~without~~and ~~further~~order ~~compensation,~~fulfillment ~~in exchange~~ for the ~~issuance~~Glucose toHealth® ~~Mr.~~product ~~Fleming,~~and ofadditionally ~~the~~a ~~1,000~~purchasing ~~Series~~agreement Ato ~~Special~~distribute ~~Preferred Shares. A Certificate of Designation for~~ the ~~Series~~product Athrough ~~Special~~a ~~Preferred~~limited ~~Shares~~number ~~was filed with the Nevada Secretary~~ of ~~State~~Northwest ~~and~~Arkansas ~~effective on December 1, 2014~~pharmacies.

On ~~December~~January 157, ~~2014~~2015, the Company ~~submitted~~completed its ~~application~~implementation toof ~~OTC~~Current ~~Markets~~Good ~~Group~~Manufacturing ~~Inc~~Practices (CGMP). ~~for~~The ~~inclusion~~Dietary inSupplement ~~the~~(DS) ~~OTCQB~~CGMP ~~tier~~rule ofin ~~quoted~~21 ~~securities.~~CFR Inpart ~~addition,~~111 of the ~~Company~~FDA's ~~new~~regulations ~~ticker~~requires ~~symbol~~companies which manufacture, ~~GLUC~~package, ~~was~~label, ~~included~~or onhold ~~the~~a ~~Financial~~dietary ~~Industry~~supplement ~~Regulatory~~to ~~Authority's~~establish ~~(FINRA)~~and ~~Daily~~follow ~~List,~~current ~~with~~good anmanufacturing ~~effective~~practice ~~date~~to ensure the quality of ~~December~~the ~~15,~~dietary ~~2014.~~supplement and to ensure that the dietary supplement is packaged and labeled as specified in the master manufacturing record.

On January 526, 2015, the Company ~~signed~~filed aan ~~contract~~initial ~~manufacturing~~application ~~agreement~~ for ~~testing,~~trademark ~~compounding,~~protection ~~supply~~related ~~and~~to ~~order~~its ~~fulfillment~~line ~~for~~of ~~the~~dietary ~~Glucose~~products, ~~HealthÒ~~with ~~product and additionally a purchasing agreement to distribute~~ the ~~product~~United inStates aTrademark ~~limited~~and ~~number~~Patent ofOffice ~~Northwest Arkansas pharmacies~~(USPTO).

On January 729, 2015, the Company ~~announced~~appointed itChandrasekhar ~~has~~Mallangi, ~~completed~~Ph.D., ~~implementation~~as ofan ~~Food~~advisor. ~~and~~Dr. ~~Drug~~Mallangi ~~Administration~~earned ~~(FDA)~~a ~~Current Good Manufacturing Practices (CGMP)~~Ph.D. ~~The Dietary Supplement (DS) CGMP rule~~ in 21Food ~~CFR~~Science ~~part~~from ~~111~~Oregon ofState ~~the~~University ~~FDA's~~and ~~regulations~~is ~~requires~~an ~~companies~~advisor ~~which manufacture, package, label, or hold a dietary supplement~~ to ~~establish~~multinational ~~and~~companies ~~follow~~in ~~current~~the ~~good~~development ~~manufacturing~~of ~~practice~~nutritional toproducts. ~~ensure~~Dr. ~~the~~Mallangi ~~quality~~is of the ~~dietary~~credited ~~supplement~~inventor and toco-inventor ~~ensure~~for ~~that~~patents ~~the~~awarded ~~dietary~~by ~~supplement~~the isUSPTO ~~packaged~~to ~~and~~subsidiaries ~~labeled~~of asNestle, ~~specified~~SA inof ~~the~~Vevey, ~~master manufacturing record~~Switzerland.

On ~~January~~February 2710, 2015, ~~the~~Murray ~~Company~~Fleming, ~~announced~~ the ~~filing~~Company’s ofChief ~~its~~Executive ~~initial~~Officer ~~application~~was ~~for~~appointed ~~trademark~~the ~~protection~~Company’s ~~related~~Chief toFinancial ~~its~~Officer. ~~Glucose~~Mr. ~~HealthÒ~~Fleming ~~line~~replaced ofJames ~~dietary~~Hodge ~~products, with~~ the ~~United States Trademark and Patent Office. If the~~ Company'’s ~~application~~interim isChief ~~successful~~Financial ~~and~~Officer. aMr. ~~trademark~~Hodge iscontinued ~~awarded~~as by the ~~USPTO, a legal presumption of the~~ Company'’s ~~ownership~~Chairman ~~nationwide~~ of ~~"Glucose Health", and~~ the ~~exclusive~~board ~~right~~of ~~to use a trademark on or in connection with all Glucose HealthÒ branded products, as set forth in the registration, will exist~~directors.

On February 1024, 2015, ~~Murray Fleming,~~ the Company's ~~Chief~~completed ~~Executive~~FDA ~~Officer~~facility ~~was~~registration, ~~appointed~~a ~~the~~compliance ~~Company's~~procedure ~~Chief~~for ~~Financial~~manufacturers ~~Officer. Mr. Fleming replaces James Hodge the Company's interim Chief Financial Officer. Mr. Hodge will remain the Company's Chairman~~ of ~~the~~dietary ~~board of directors~~supplements.

On ~~February~~May 1826, ~~OTC~~2015, ~~Markets~~the ~~Group~~Company ~~Inc.~~completed ~~issued~~the afirst ~~press~~production ~~release~~run ~~announcing~~of the ~~inclusion~~product ofand ~~Glucose~~pursuant ~~Health~~to the January 5, ~~Inc.~~2015 inpurchasing agreement, the ~~OTCQB~~product ~~venture~~began ~~marketplace~~to ~~tier,~~be ~~trading~~offered ~~under~~for retail sale through a limited number of Northwest Arkansas pharmacies as well as on the ~~symbol~~Company’s ~~GLUC~~product website www.glucosehealth.com.

On ~~February~~July 247, 2015, the Company ~~announced~~received notification from the ~~completion~~United States Patent and Trademark Office (USPTO) that its application for trademark of ~~the~~“Glucose ~~FDA's~~Health” ~~facility~~was ~~registration~~accepted ~~procedure~~to the Supplemental Register (Reg. 4,770,720) with first use recognized by the USPTO as of February 1, 2015.

On ~~May~~January 16, ~~2015~~2016, the Company ~~filed~~executed ~~Form 8-A12G registering~~ a ~~class~~General ofMerchandise ~~securities~~Supplier ~~under~~Agreement ~~the~~("Agreement") ~~Securities~~with ~~Exchange~~Wal-Mart ~~Act~~Stores, ~~of 1934 and became subject to the 1934 Act~~Inc.

~~The~~On ~~Company~~January ~~completed~~27, 2016, the ~~first~~Company ~~production~~notified ~~run~~OTC Markets, Inc. of ~~the~~its ~~product~~intention onto ~~May~~not ~~26,~~renew its OTCQB service. The Company filed Form 8-A12G in fiscal 2015 ~~and~~registering ~~pursuant~~a toclass of securities under the ~~January~~1934 5,Securities ~~2015~~Exchange ~~purchasing~~Act. ~~agreement~~Accordingly, the ~~product~~Company ~~began~~does tonot bemake ~~offered~~use ~~for~~of ~~retail~~the ~~sale~~OTC ~~through~~Markets aDisclosure ~~limited~~and ~~number~~News ofService ~~Northwest~~and ~~Arkansas~~instead ~~pharmacies~~files its periodic and ~~additionally,~~annual onreports and audited financial statements with the ~~Company's~~Securities ~~product~~and ~~website~~Exchange ~~www~~Commission.~~glucosehealth.com.~~

15On February 4, 2016, the Company's Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to the board of directors of Glucose Health, Inc. ("Company"). On February 5, 2016, James Hodge resigned from the board of directors.

~~Our~~On ~~Plan~~March 8, 2016, the Company received a series of ~~Operation~~material ~~for~~purchase orders from the ~~Next~~Customer ~~Twelve~~pursuant ~~Months~~to a General Merchandise Supplier Agreement ("Agreement") with Wal-Mart Stores, Inc., executed January 6, 2016.

~~Our~~On ~~principal~~October ~~business~~4, ~~strategy~~2016, ~~for~~ the ~~next~~Company ~~twelve~~executed ~~months~~a ~~will~~non-recourse bereceivables tofinancing ~~implement~~agreement ~~marketing~~with ~~and~~Citibank, ~~sales initiatives and earn significant revenues from our Glucose HealthÒ product~~N. ~~Our sales initiatives will be focused upon securing repeat purchase orders from national and regional pharmacy retailers for our Glucose HealthÒ Daily Blood Sugar Maintenance product~~A. ~~Our~~(Citibank) ~~marketing~~whereby ~~initiatives~~receivables ~~will~~due ~~be primarily~~ to ~~support Glucose HealthÒ channel sales through national and regional partners. We intend to begin advertising in and sponsoring, various print, digital and social media platforms, which align with~~ the ~~interest~~Company ofare ~~our~~assumed ~~customers~~from ~~in natural products including dietary supplements for pre~~Wal-~~diabetes~~Mart ~~and~~Stores ~~Type-2 diabetes~~Inc. ~~Secondarily~~by toCitibank ~~our primary sales~~ and ~~marketing~~paid ~~initiatives~~subject ~~above, we also intend~~ to ~~grow~~an ~~our~~interest ~~online~~premium ~~sales~~based ofupon ~~Glucose HealthÒ product through sales from our product website and sales through other online marketplaces~~LIBOR. We also intend to further develop our Glucose HealthÒ product in order to introduce variations of our proprietary formula and to introduce a variety of packaging options to our target consumer market segment.

AtAs of December 31, ~~2015~~2016, wethe ~~had~~Company’s ~~nominal~~Glucose ~~cash,~~Health® Daily ~~which~~Blood ~~will~~Sugar ~~not~~Maintenance beBlueberry ~~sufficient~~Tea toMix ~~satisfy~~(60-Day ~~our~~Supply) ~~working~~product ~~capital~~is ~~requirements~~stocked ~~for~~in the ~~next~~"Diabetic ~~twelve~~Supplies" ~~months.~~section ~~We cannot forecast with any degree~~ of ~~certainty~~most ~~our~~Walmart ~~anticipated~~pharmacies revenues or cash flow. Our forecasts and operations will involve risks and uncertainties, which we are unable to predict and actual results could fail. We will require additional capital to continue operations. If we cannot secure additional capital or generate significant revenues we may cease operations in ~~which~~all ~~case~~50 ~~you will lose your investment~~states.

We16 ~~intend~~Table toOf continue to source capital from the two private equity companies currently providing financing to us on a monthly basis. We cannot guarantee that such additional funding will be available on favorable terms, if at all. If adequate funds are not available, then our ability to continue or expand our operations may be significantly hindered. If adequate funds are not available, our officer, directors and principal shareholders may contribute capital to the Company in the form of debt financing or equity contributions. However, our officer, directors and principal shareholders are not committed to contribute funds to pay for our expenses.Contents

~~Even~~Our ~~assuming~~Plan ~~that we secure adequate financing, there can be no assurance that we will be profitable at any time in the future. Further, the legal and accounting costs~~ of ~~being~~Operation afor ~~public company will continue to impact our liquidity and we will need to obtain funds to pay those expenses. Other than~~ the ~~anticipated~~Next ~~increases~~Twelve in legal and accounting costs due to the reporting requirements of being a reporting company, we are not aware of any other known trends, events or uncertainties, which may affect our future liquidity.Months

Our ~~auditors~~principal ~~have~~business ~~questioned~~strategy ~~our~~for ~~ability~~the tonext ~~continue~~twelve ~~operations~~months aswill abe ~~"going~~to ~~concern."~~implement ~~While~~marketing weand ~~expect~~sales toinitiatives ~~obtain~~and earn significant revenues from ~~future~~the manufacture and distribution of our Glucose Health® product. Our sales, ininitiatives ~~the~~will ~~absence~~be offocused ~~significant~~upon ~~sales~~securing repeat purchase orders for Glucose Health® from national and ~~profits,~~regional wepharmacy retailers. Our marketing initiatives will ~~seek~~be primarily to ~~raise~~support ~~funds~~Glucose Health® channel sales through national and regional partners. We intend to ~~meet~~begin ~~our~~advertising ~~working~~in ~~capital~~and ~~needs~~sponsoring, ~~principally~~various ~~through~~print, ~~the~~digital ~~additional~~and ~~sales~~social media platforms, which align with the interest of our ~~securities.~~customers ~~However,~~in wenatural ~~cannot~~products ~~guarantee~~including ~~that~~dietary wesupplements ~~will~~related beto ~~able~~metabolic syndrome, pre-diabetes and Type-2 diabetes. Secondarily to ~~obtain~~our ~~sufficient~~primary ~~additional~~sales ~~funds~~and ~~when~~marketing ~~needed~~initiatives above, orwe ~~that~~also ~~such~~intend ~~funds,~~to ~~even~~grow ifour ~~available,~~online ~~will~~sales beof ~~obtainable~~Glucose onHealth® ~~terms~~product ~~satisfactory~~through tosales usfrom our product website and sales through other online marketplaces. AsWe aalso ~~result,~~intend to further develop our ~~auditors~~Glucose ~~believe~~Health® ~~that~~product ~~substantial~~to ~~doubt~~introduce ~~exists~~flavor ~~about~~variations of our ~~ability~~proprietary formula and to ~~continue~~introduce ~~operations~~a variety of packaging options to our target consumer market segment.

~~Liquidity~~Use ~~and~~of ~~Capital Resources.~~Estimates

AtThe ~~December~~discussion ~~31,~~and ~~2015,~~analysis of our ~~total~~financial ~~assets~~condition ~~were~~and ~~$15,407~~results ~~consisting~~ of ~~$2,055~~operations ~~cash,~~are $8based upon our financial statements,~~370~~ ~~inventory~~which ~~consisting~~have ofbeen ~~801~~prepared ~~units~~in accordance with generally accepted accounting principles in the United States. The preparation of ~~Glucose~~financial ~~HealthÒ~~statements ~~Daily~~in ~~Blood~~conformity ~~Sugar~~with ~~Maintenance~~accounting ~~product~~principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, $3liabilities,~~150~~ ~~accounts~~revenues, ~~receivable~~ and $1expenses,~~282~~ ~~prepaid~~and ~~consultant~~related ~~compensation~~disclosure of contingent assets and liabilities. ~~This~~On ~~compares~~an toongoing ~~our~~basis, ~~total~~we ~~assets~~evaluate ofour ~~$44~~estimates,~~030~~ atincluding ~~December~~those 31related to revenue recognition, ~~2014~~bad debts, ~~consisting~~investments, ofintangible $4assets,~~871~~ inand ~~cash~~income taxes. Our estimates are based on historical experience and ~~$38,859~~on invarious ~~prepaid~~other ~~consultant~~assumptions ~~compensation~~that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

AtResults ~~December 31, 2015 our current liabilities totaled $403,226 consisting~~ of $94,920 in accounts payable and accrued expenses, $6,075 for short term loans, $100,829 in related party convertible short-term loans and $201,402 in convertible short-term loans. This compares to our current liabilities at December 31, 2014 of $324,582 consisting of $154,659 in accounts payable and accrued expenses $7,747 for a short-term loan, $23,927 for a short-term loan from a related party and $138,249 in convertible short-term loans. Operations

WeThe ~~had~~following adiscussion ~~working~~should ~~capital~~be ~~deficit~~read ~~for~~in ~~2015~~conjunction ~~and~~with ~~2014~~our offinancial ~~$388,119~~statements ~~and~~included ~~$280,852,~~in ~~respectively.~~Item We8 ~~rely upon funding from two private equity firms. Unless we continue secure additional funding from these firms, or others,~~ of ~~which~~this ~~there~~annual ~~can be no assurance, we will not be able to satisfy our ongoing expenses~~report.

AtResults ~~December~~of ~~31,~~Operations ~~2015~~for ~~and~~the ~~2014,~~Year weEnded ~~had~~December no31, ~~other~~2016 ~~liabilities~~Compared ~~and~~to noYear ~~long-term~~Ended ~~commitments~~December or31, ~~contingencies.~~ 2015

16Revenues

~~Material~~We ~~Commitments~~generated revenues of $313,229 and $4,272 for the years ended December 31, 2016 and 2015, respectively. We hope to fully implement our plan of operations by December 31, 2017 and generate greater revenues, of which there is no assurance.

OnGross ~~April~~profit 8, 2014, the Company issued a $21,000 convertible note to a corporation. The loan bears interest at 8% and has a maturity date of October 8, 2014. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.0065 per share.

OnWe ~~May~~reported 8,a ~~2014,~~gross ~~the~~profit ~~Company~~of ~~issued a~~ $2119,~~000~~167 ~~convertible~~and ~~note~~$397 tofor athe ~~corporation.~~years ~~The~~ended ~~loan~~December ~~bears~~31, ~~interest~~2016 ~~at 8%~~ and ~~has~~2015, arespectively. ~~maturity~~We ~~date~~hope ofto ~~November~~fully 8,implement ~~2014.~~our Inplan ~~addition,~~of atoperations ~~any~~by ~~time~~December 31, ~~the~~2017 ~~holder~~and ~~may~~generate ~~convert~~greater ~~the~~profits, ~~note~~of ~~into~~which ~~shares~~there ofis ~~the~~no ~~Company's~~assurance, ~~common~~and ~~stock~~retain atand aninvest ~~exercise~~such ~~price~~profits ofin ~~$0.0065~~expanding ~~per~~our ~~share~~operations.

OnOperating May 28, 2014, the Company issued a $10,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of November 28, 2014. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.0065 per share.expenses

OnFor ~~June~~the 23year ended December 31, ~~2014~~2016, ~~the~~we ~~Company~~had ~~issued~~total aoperating expenses of $10105,~~000~~814, ~~convertible~~as ~~note~~compared to atotal ~~corporation.~~operating ~~The~~expenses ~~loan~~of ~~bears~~$156,570 ~~interest~~for atthe 5%year ~~and~~ended ~~has a maturity date of~~ December 2331, ~~2014~~2015. InThe ~~addition,~~decrease atof ~~any~~$50,756 ~~time~~or 32%, ~~the~~in ~~holder~~our ~~may~~operating ~~convert~~expenses between the ~~note~~two ~~into~~periods ~~shares~~is ofdue ~~the~~to ~~Company's~~continued ~~common~~further ~~stock~~reductions atin angeneral ~~exercise~~and ~~price~~administrative ofexpenses ~~$0.0065~~and ~~per~~stock ~~share~~based compensation.

OnWe ~~July~~will ~~11,~~continue ~~2014,~~to ~~the~~incur ~~Company~~significant ~~issued~~legal aand ~~$10,000~~accounting ~~convertible~~expenses ~~note~~related to amaintaining ~~corporation.~~our ~~The~~status ~~loan~~as ~~bears~~a ~~interest~~publicly-traded atcompany 5%subject ~~and~~to ~~has~~the aSecurities ~~maturity~~Exchange ~~date~~Act of ~~January 11~~1934, ~~2015.~~requiring ~~In addition, at any time,~~ the ~~holder~~filing ~~may convert the note into shares~~ of ~~the~~periodic ~~Company's~~reports ~~common~~and ~~stock~~audited atfinancial anstatements ~~exercise~~with ~~price~~the ofSecurities ~~$0.0065~~and ~~per~~Exchange ~~share~~Commission.

On17 ~~August~~Table 4,Of 2014, the Company issued an $8,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of February 4, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.0065 per share.Contents

OnNet August 4, 2014, the Company issued an $8,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of February 4, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.0065 per share.loss

OnFor ~~September~~the 3year ended December 31, ~~2014~~2016, ~~the~~we ~~Company~~had ~~issued~~ a net loss of $6410,~~000~~443 ~~convertible~~or ~~note~~$0.15 per share with $323,796 of this net loss for the period related to the recording of interest expense and amortization of debt discount, a ~~corporation~~non-cash adjustment to reconcile net loss to net cash used in operations. ~~The~~In ~~loan~~comparison, ~~bears~~for ~~interest~~the atyear 5%ended ~~and~~December ~~has~~31, 2015, we had a ~~maturity~~net ~~date~~loss of ~~March 3~~$266,064 ~~2015~~or $0.14 Inper ~~addition~~share with $120,028 atof ~~any~~this ~~time,~~net loss for the ~~holder~~period ~~may~~related ~~convert~~to the ~~note~~recording ~~into~~of ~~shares~~interest expense and amortization of debt discount, a non-cash adjustment to reconcile net loss to net cash used in operations. We expect to incur net losses for the ~~Company's~~foreseeable ~~common~~future ~~stock~~as atwe anare ~~exercise~~in ~~price~~the initial stages of ~~$0.005~~implementing ~~per~~our ~~share~~plan of operations.

OnLiquidity ~~September 3, 2014, the Company issued a $6,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5%~~ and ~~has~~Capital ~~a maturity date of March 3, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.005 per share.~~Resources

OnAt ~~October~~December 131, ~~2014~~2016, ~~the~~our ~~Company~~total ~~issued~~assets awere $433,~~625~~145 ~~convertible~~consisting ~~note~~of to$20,542 acash, ~~corporation.~~$0 ~~The~~inventory, ~~loan~~$11,724 ~~bears~~accounts ~~interest~~receivable atand 5%$639 ~~and~~prepaid ~~has~~consultant acompensation. ~~maturity~~This ~~date~~compares ofto ~~April~~our 1,total ~~2015.~~assets Inof ~~addition~~$15,407 at ~~any~~December ~~time~~31, ~~the~~2015, ~~holder~~consisting ~~may~~of ~~convert~~$2,055 ~~the~~in ~~note~~cash, ~~into~~$8,370 ~~shares~~inventory, of$3,150 ~~the~~in ~~Company's~~accounts ~~common~~receivable ~~stock~~and at$1,282 anin ~~exercise~~prepaid ~~price~~consultant ~~of $0~~compensation.~~005~~ ~~per share.~~

OnAt ~~October~~December 131, ~~2014~~2016, ~~the~~our ~~Company~~current ~~issued~~liabilities atotaled $4528,~~625~~592, ~~convertible~~consisting ~~note~~of to$138,134 ain ~~corporation~~accounts ~~owned~~payable byand ~~the~~accrued ~~Company's~~expenses, ~~CEO.~~$35,000 ~~The~~in ~~loan~~notes ~~bears~~payable, ~~interest~~related atparty, $5%,000 in notes payable, $112,157 in convertible notes payable, related party, $164,793 in convertible notes payable and ~~has~~$35,000 ain ~~maturity~~other ~~date~~notes ofpayable. ~~April~~This 1compares to our current liabilities at December 31, 2015. Inof ~~addition~~$403,226, atconsisting ~~any~~of ~~time~~$94,920 ~~the~~in ~~holder~~accounts ~~may~~payable ~~convert~~and ~~the~~accrued ~~note~~expenses, ~~into~~$6,075 ~~shares~~in ofnotes ~~the~~payable, ~~Company's~~$100,829 ~~common~~in ~~stock~~related atparty anconvertible ~~exercise~~notes ~~price~~payable ofand $~~0.005~~201,402 ~~per~~in ~~share~~convertible notes payable.

OnWe ~~October~~had ~~15,~~a ~~2014,~~working ~~the~~capital ~~Company~~deficit ~~issued~~for a2016 and 2015 of $3495,~~600~~687 ~~convertible~~and ~~note~~$388,119, respectively. We continue to arely ~~corporation~~upon funding from two private firms, one which is beneficially owned by the Company'’s CEO., ~~The~~to ~~loan~~meet ~~bears~~our ~~interest~~working atcapital 5%requirements and ~~has~~continue aour ~~maturity~~operations. ~~date~~Unless ofwe ~~April~~continue ~~15,~~secure ~~2015.~~additional Infunding ~~addition,~~from atthese ~~any time~~firms, ~~the~~or ~~holder~~others, ~~may~~of ~~convert~~which ~~the~~there ~~note~~can ~~into~~be ~~shares~~no ofassurance, ~~the~~we ~~Company's~~may ~~common~~not ~~stock~~be atable anto ~~exercise~~continue ~~price~~our ~~of $0~~operations.~~004 per share.~~

17At December 31, 2016 and 2015, we had no other liabilities and no long-term commitments or contingencies.

OnGoing ~~November~~Concern 4, 2014, the Company issued a $6,850 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of May 4, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.0025 per share.

OnOur ~~November~~independent 4registered public accounting firm has questioned our ability to continue operations as a “going concern.” While we expect to continue to grow our revenues and our gross profits from sales of Glucose Health®, ~~2014~~there is no assurance of this occurring, and in the ~~Company~~interim ~~issued~~as awe $6implement our plan of operations,~~850~~ ~~convertible~~we ~~note~~will seek to araise ~~corporation~~funds ~~owned~~to bymeet ~~the~~our ~~Company's~~working ~~CEO~~capital needs principally through sales of our securities. ~~The~~However, ~~loan~~we ~~bears~~cannot ~~interest~~guarantee atthat 5%we ~~and~~will ~~has~~be aable ~~maturity~~to ~~date~~obtain ofsufficient ~~May~~additional 4funds when needed, ~~2015.~~or Inthat ~~addition~~such funds, ateven ~~any~~if ~~time~~available, ~~the~~will ~~holder~~be ~~may~~obtainable ~~convert~~on ~~the~~terms ~~note~~satisfactory ~~into~~to ~~shares~~us. ofAs ~~the~~a ~~Company's~~result, ~~common~~our ~~stock~~independent atregistered anpublic ~~exercise~~accounting ~~price~~firm ofbelieves ~~$0.0025~~that ~~per~~substantial ~~share.~~doubt exists about our ability to continue operations.

OnMaterial November 8, 2014, the Company issued a $2,962 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of May 8, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.00475 per share. Commitments

OnNotes ~~December 1~~payable, ~~2014,~~related the Company issued a $5,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of June 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.09 per share. party:

On ~~December~~May 1, ~~2014~~2016, the Company issued a $535,000 ~~convertible~~ note to a corporation owned by the Company'’s CEO. The loan bears interest at 524% per annum and has a maturity date of ~~June~~December 131, ~~2015~~2016. ~~In addition~~$35,000 atremains ~~any~~outstanding ~~time,~~as ~~the holder may convert the note into shares~~ of ~~the~~December ~~Company's~~31, ~~common stock at an exercise price of $0~~2016.~~09 per share.~~

On ~~January~~March 711, ~~2015~~2016, the Company issued a $435,~~315~~000 ~~convertible~~ note to a corporation owned by the Company's CEO. The loan bears interest at 524% per annum and has a maturity date of July 711, ~~2015~~2016. InOn ~~addition~~July 29, ~~at any time~~2016, the ~~holder~~loan ~~may~~was ~~convert~~repaid ~~the~~in ~~note into shares of the Company's common stock at an exercise price of $0~~full.~~04 per share.~~

OnNotes January 8, 2015, the Company issued an $8,750 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of July 8, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.04 per share.payable:

On ~~January~~September 815, ~~2015~~2016, the Company issued ana $85,~~750~~000 ~~convertible~~ note to a corporation ~~owned by the Company's CEO~~. The loan bears interest at 512% ~~and~~per ~~has~~annum aand ~~maturity~~is ~~date~~payable ofon ~~July~~demand. 8$5,000 ~~2015.~~remains Inoutstanding ~~addition,~~ at ~~any~~December ~~time~~31, ~~the holder may convert the note into shares of the Company's common stock at an exercise price of $0~~2016.~~04 per share.~~

On ~~February~~May 218, ~~2015~~2016, the Company issued a $1230,~~500~~000 ~~convertible~~ note to a corporation. The loan bears interest at 524% per annum and has a maturity date of ~~August~~July 218, ~~2015~~2016. InOn ~~addition~~July 21, ~~at any time~~2016, the ~~holder~~loan ~~may~~was ~~convert~~repaid ~~the~~in ~~note into shares of the Company's common stock at an exercise price of $0~~full.~~031 per share.~~

On18 ~~February~~Table 2,Of 2015, the Company issued a $12,500 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of August 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.031 per share.Contents

OnConvertible ~~March~~notes 2payable, ~~2015,~~related the Company issued a $10,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of September 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.party:

OnThe ~~March~~Company 2,consolidated ~~2015,~~18 ~~the~~separate ~~Company~~convertible ~~issued~~promissory anotes ~~$10~~of various principal amounts and fixed conversion prices,~~000~~ ~~convertible~~all ~~note~~bearing 5% interest per annum, issued to a corporation owned by the Company'’s CEO. ~~The~~during ~~loan~~the ~~bears~~period ~~interest~~from atAugust 4, 2014 through April 1, 2016, into a single convertible promissory note of $112,157, bearing 5% ~~and~~interest ~~has~~per annum with a ~~maturity~~pro-rata ~~date~~fixed ofconversion ~~September~~price 2,of ~~2015~~$0.011, Inplus ~~addition~~$5,939 ataccrued ~~any~~interest ~~time,~~not ~~the~~subject ~~holder~~to ~~may~~additional ~~convert~~interest. ~~the~~The ~~note~~consolidation ~~into~~was ~~shares~~for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company'’s ~~common~~CEO. ~~stock~~The atcurrent annet ~~exercise~~note ~~price~~balance ofis $0112,157.~~025~~ ~~per share.~~

18Convertible notes payable:

OnThe ~~April~~Company 1consolidated 20 separate convertible promissory notes of various principal amounts and fixed conversion rates, ~~2015~~all bearing 5% interest per annum, issued to corporation during the ~~Company~~period ~~issued~~from aAugust $52,~~000~~ ~~convertible~~2013 ~~note~~through toApril 1, 2016, into a ~~corporation.~~single ~~The~~convertible ~~loan~~promissory ~~bears~~note ~~interest~~of at$169,065, bearing 5% ~~and~~interest ~~has~~per annum with a ~~maturity~~pro-rata ~~date~~fixed ofconversion ~~October~~price 1,of ~~2015~~$0.008, Inplus ~~addition~~$12,516 ataccrued ~~any~~interest ~~time,~~not ~~the~~subject ~~holder~~to ~~may~~additional ~~convert~~interest. ~~the~~The ~~note~~consolidation ~~into~~was ~~shares~~for the purposes of ~~the~~administrative ~~Company's~~simplification ~~common~~and ~~stock~~no atinducement annor ~~exercise~~benefit ~~price~~was ofgiven $0to the corporation.~~020~~ ~~per~~The ~~share~~current net note balance is $164,670.

OnOther ~~April~~notes 1, 2015, the Company issued a $5,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of October 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.020 per share.payable:

On ~~May~~December 110, ~~2015~~2013, the Company issued a ~~$5,000~~ convertible note to aan ~~corporation~~individual. The loan bears interest at 5% ~~and~~per annum, has a ~~maturity~~fixed ~~date~~conversion price of ~~November~~$0.015 1,and ~~2015.~~a Inmaturity ~~addition,~~date atof ~~any~~June ~~time~~10, ~~the~~2014. ~~holder~~$3,000 ~~may~~remains ~~convert~~outstanding ~~the note into shares of the Company's common stock~~ at anDecember ~~exercise~~31, ~~price of $0~~2016.~~025 per share.~~

On ~~May~~December 110, ~~2015~~2013, the Company issued a ~~$5,000~~ convertible note to aan ~~corporation owned by the Company's CEO~~individual. The loan bears interest at 5% ~~and~~per annum, has a ~~maturity~~fixed ~~date~~conversion price of ~~November~~$0.015 1,and ~~2015.~~a Inmaturity ~~addition,~~date atof ~~any~~June ~~time~~10, ~~the~~2014. ~~holder~~$5,000 ~~may~~remains ~~convert~~outstanding ~~the note into shares of the Company's common stock~~ at anDecember ~~exercise~~31, ~~price of $0~~2016.~~025 per share.~~

On June 111, ~~2015~~2013, the Company issued athree ~~$4,000~~ convertible ~~note~~notes to athree ~~corporation~~corporations. The ~~loan~~loans ~~bears~~bear interest at 5% ~~and~~per ~~has~~annum awith ~~maturity~~fixed ~~date~~conversion prices of ~~December 1, 2015~~$0.0065 Inand ~~addition,~~maturity atdates ~~any time, the holder may convert the note into shares~~ of ~~the~~August ~~Company's~~11, ~~common~~2013. ~~stock~~$18,377 atremains anoutstanding ~~exercise~~as ~~price~~ of ~~$0.025~~December ~~per~~31, ~~share~~2016.

On ~~June~~January 125, ~~2015~~2013, the Company issued a $412,000 ~~convertible~~ note to aan ~~corporation owned by the Company's CEO~~individual. ~~The~~$6,000 ~~loan~~remains ~~bears~~outstanding ~~interest~~ at ~~5% and has a maturity date of~~ December 131, ~~2015~~2016. ~~In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.~~

On ~~July~~April 120, ~~2015~~2012, the Company issued a ~~$9,090~~ convertible note to aan ~~corporation~~individual. The loan bears interest at 5% ~~and~~per annum, has a ~~maturity~~fixed ~~date~~conversion price of ~~December 1, 2015~~$0.009 Inand ~~addition,~~a atmaturity ~~any~~date ~~time, the holder may convert the note into shares~~ of ~~the~~October ~~Company's~~20, ~~common~~2012. ~~stock~~$2,500 atremains anoutstanding ~~exercise~~as ~~price~~ of ~~$0.025~~December ~~per~~31, ~~share~~2016.

OnAt ~~July~~December 131, ~~2015~~2016, ~~the~~accrued ~~Company~~interest ~~issued~~on ~~a $8,305 convertible note to a company owned by~~ the ~~Company's~~above ~~CEO.~~notes ~~The loan bears interest at 5%~~ and ~~has~~convertible anotes ~~maturity~~amounted ~~date~~to ~~of December 1~~$38, ~~2015~~631. ~~In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.~~

OnOff-Balance ~~December~~Sheet 10, 2015, the Company issued a $2,500 convertible note to a company owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of June 10, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.03 per share.Arrangements

~~Results~~We have no-off balance sheet contractual arrangements, as that term is defined in Item 303(a)(4) of ~~Operations~~Regulation S-K.

Results of operations for the year ended December 31, 2015 compared to year ended December 31, 2014

Revenues

We generated nominal revenues of $4,272 and $2,739 for the years ended December 31, 2015 and 2014, respectively. The Company's focus for 2016 will be the manufacturing, marketing and distribution of our Glucose HealthÒ Daily Blood Sugar Maintenance dietary supplement product. We hope to generate substantial revenues, continue our operations and fully implement our business plan by December 31, 2016.

Gross Profit (Loss)

We reported a gross profit (loss) of $397 and ($20,726) for the years ended December 31, 2015 and 2014, respectively. Included in the gross loss was an impairment to inventory of $20,829 for the year ended December 31, 2014. Until the Company generates significant revenues, our revenue will continue to be nominal.

Operating Expenses

For the year ended December 31, 2015, we had total operating expenses of $156,570, as compared to total operating expenses of $524,490 for the year ended December 31, 2014. The substantial decrease of $367,920 or 70.1%, in our operating expenses between the two periods is primarily due to an approximate $501,000 decrease in professional fees incurred in 2015 and a decrease of approximately $23,490 for other general and administrative expenses compared to 2014. We expect we will continue to incur significant legal and accounting expenses related to being a public company.

Net Loss

For the year ended December 31, 2015, we had a net loss of $266,064 or $0.14 per share. In comparison, for the year ended December 31, 2014, we had a net loss of $669,409 or $0.99 per share. We expect to continue to incur net losses for the foreseeable future and until we generate significant revenues.

Off-Balance Sheet Arrangements.

We have no off-balance sheet arrangements.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

~~Not~~As ~~applicable~~a smaller reporting company, we are not required to provide the information required by this Item.

2019 Table Of Contents

Item 8. Financial Statements.

The financial statements required by Item 8 are presented in the following order:

GLUCOSE HEALTH INC.

INDEX TO FINANCIAL STATEMENTS

Financial Statements:
Report of Independent Registered Public Accounting Firm			F-1
Report of Independent Registered Public Accounting Firms			F-2
Balance Sheets as of December 31, 2016 and 2015			F-2
Balance Sheets as of December 31, 2015 and 2014			F-3
Statements of Operations for the Years Ended December 31, 2016 and 2015			F-3
Statements of Operations for the Years Ended December 31, 2015 and 2014			F-4
Statements of Changes in Stockholders’ Equity (Deficit) for the Years Ended December 31, 2016 and 2015			F-4
Statements of Changes in Stockholders' Equity (Deficit) for the Years Ended December 31, 2015 and 2014			F-5
Statements of Cash Flows For the Years Ended December 31, 2016 and 2015			F-5
Statements of Cash Flows For the Years Ended December 31, 2015 and 2014			F-6
Notes to Financial Statements			F-6
Notes to Financial Statements			F-7

~~F-1~~20

~~REPORT~~Report OFof ~~INDEPENDENT~~Independent ~~REGISTERED~~Registered ~~PUBLIC~~Public ~~ACCOUNTING~~Accounting ~~FIRM~~Firm

To the Directors of

Glucose Health Inc.

We have audited the accompanying balance sheets of Glucose Health, Inc. (the "Company") as of December 31, ~~2015~~2016 and ~~2014~~2015, and the related statements of operations, changes in stockholders' deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company'’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company'’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company'’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Glucose Health Inc. as of December 31, ~~2015~~2016 and ~~2014~~2015, and the results of its ~~statements of~~ operations, ~~changes~~its ~~in stockholders' deficit,~~ and cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in ~~Note~~the 1Notes to the financial statements, the Company is in process of executing its ~~business~~ plan ~~and~~of ~~expansion~~operations. The Company has ~~not~~ generated ~~significant~~net ~~revenue~~losses tosince ~~this~~inception ~~point, however, has been successful in raising funds in their private placement. The lack of profitable operations~~ and the need to continue to raise funds ~~raise~~raises substantial doubt about the Company'’s ability to continue as a going concern. ~~Management's plans in this regard are described in Note 1.~~ The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Anton & Chia, LLP

Newport Beach, California

~~April~~March 1428, ~~2016~~ 2017

F-21 Table Of Contents

GLUCOSE HEALTH, INC. ~~BALANCE SHEETS~~

	DECEMBER 31, 2015			DECEMBER 31, 2014
ASSETS
CURRENT ASSETS
Cash	$	2,055		$	4,871
Accounts receivable		3,150			-
Inventory		8,370			-
Due from affiliate		250			-
Prepaid expenses		1,282			38,859
Total current assets		15,107			43,730
Other Asset
Intellectual assets, net of accumulated amortization of $0 and $0, respectively		300			300
TOTAL ASSETS	$	15,407		$	44,030
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	94,920		$	154,659
Notes payable		6,075			7,747
Convertible notes payable, related parties		100,829			23,927
Convertible notes payable		201,402			138,249
Total current liabilities		403,226			324,582
TOTAL LIABILITIES		403,226			324,582
COMMITMENT AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $ no par value, 1,000 shares authorized, 1,000 shares issued and outstanding as of December 31, 2015 and December 31, 2014		113,200			113,200
Common stock, $0.001 par value, 200,000,000 shares authorized, 2,451,888 and 1,309,825 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively (1)		2,452			1,310
Additional paid in capital		5,386,001			5,228,346
Stock subscription		23,000			23,000
Accumulated other comprehensive loss		(75,278	)		(75,278	)
Accumulated deficit		(5,837,194	)		(5,571,130	)
Total stockholders' deficit		(387,819	)		(280,552	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	15,407		$	44,030

BALANCE SHEETS

_______________

	December 31,
	2016			2015
ASSETS
CURRENT ASSETS
Cash	$	20,542		$	2,055
Accounts receivable		11,724			3,150
Inventory		-			8,370
Due from affiliate		-			250
Prepaid expenses		639			1,282
Total current assets		32,905			15,107

Other Asset
Intellectual assets, net of accumulated amortization of $60 and $0, respectively		240			300

TOTAL ASSETS	$	33,145		$	15,407

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	138,134		$	94,920
Accrued interest		38,631			-
Notes payable, related party		35,000			-
Notes payable		5,000			6,075
Convertible notes payable, related party		112,157			100,829
Convertible notes payable		164,670			201,402
Other notes payable		35,000			-
Total current liabilities		528,592			403,226

TOTAL LIABILITIES		528,592			403,226

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIT
Preferred stock, no par value, 1,000 shares authorized, 1,000 shares issued and outstanding as of December 31, 2016 and 2015		113,200			113,200
Common stock, $0.001 par value, 200,000,000 shares authorized, 3,312,273 and 2,451,888 shares issued and outstanding as of December 31, 2016 and 2015, respectively		3,312			2,452
Additional paid in capital		5,687,956			5,386,001
Stock subscription		23,000			23,000
Accumulated other comprehensive loss		(75,278	)		(75,278	)
Accumulated deficit		(6,247,637	)		(5,837,194	)
Total stockholders' deficit		(495,447	)		(387,819	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	33,145		$	15,407

~~(1)~~ The ~~common~~accompanying ~~stock~~notes ~~shares~~are ~~authorized,~~an ~~issued~~integral ~~and~~part ~~outstanding~~of ~~have~~these ~~been~~financial ~~adjusted to reflect a 10 to 1 reverse split, which was effective in February 2014 and 50 to 1 reverse split, which was effective in November 2014~~statements.

~~The~~F-2 ~~accompanying~~Table ~~notes~~Of ~~are an integral part of these financial statements.~~Contents

~~F-3~~GLUCOSE HEALTH INC.

~~GLUCOSE HEALTH, INC.~~ STATEMENTS OF OPERATIONS

	FOR THE YEAR			FOR THE YEAR
	YEAR ENDED DECEMBER 31,
	ENDED			ENDED
	2016			2015
	DECEMBER 31, 2015			DECEMBER 31, 2014
REVENUE	$	313,229		$	4,272
REVENUE	$	4,272		$	2,739
COST OF REVENUES
Cost of revenues		3294,~~875~~062			23,~~636~~875
Inventory impairment		-			20,829
GROSS PROFIT		19,167			397
Total Cost of Revenues		3,875			23,465
GROSS PROFIT/(LOSS)		397			(20,726	)
OPERATING EXPENSES
Professional fees/stock based compensation		41,702			504,192
Professional fees		52,101			8,927
Research and development		48			4,000
Stock based compensation		1,875			32,775
General and administrative		114,868			16,298
Research and development		-			48
Total Operating Expenses		156,570			524,490
General and administrative		51,838			114,820
LOSS FROM OPERATIONS		(156,173	)		(545,216	)
Total Operating Expenses		105,814			156,570
LOSS FROM OPERATIONS		(86,647	)		(156,173	)
OTHER INCOME (EXPENSE)
Interest income (expense)		(~~120~~323,~~028~~796	)		(~~109~~120,~~631~~028	)
Loss on conversion of debt		~~(10,436~~-	)		(1410,~~562~~436	)
Gain on forgiveness of accounts payable		~~20,573~~-			-20,573
Total other expense		(~~109~~323,~~891~~796	)		(~~124~~109,~~193~~891	)
LOSS BEFORE INCOME TAXES		(~~266~~410,~~064~~443	)		(~~669~~266,~~409~~064	)
PROVISION FOR (BENEFIT FROM) INCOME TAXES		-			-
NET LOSS	$	(~~266~~410,~~064~~443	)	$	(~~669~~266,~~409~~064	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED (2)		1,956,371			675,155
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC AND DILUTED		2,793,759			1,956,371
NET LOSS PER SHARE - BASIC AND DILUTED	$	(0.1415	)	$	(0.9914	)

~~(2)~~ The ~~common~~accompanying ~~stock~~notes ~~shares~~are ~~authorized,~~an ~~issued~~integral ~~and~~part ~~outstanding~~of ~~have~~these ~~been~~financial ~~adjusted to reflect a 10 to 1 reverse split, which was effective in February 2014 and 50 to 1 reverse split, which was effective in November 2014~~statements.

~~The~~F-3 ~~accompanying~~Table ~~notes~~Of ~~are an integral part of these financial statements.~~Contents

F-4

GLUCOSE HEALTH, INC.
STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

																Accumulated
									Additional		Stock					Other
	Preferred Stock				Common Stock				Paid-In		To Be		Accumulated			Comprehensive
	Shares		Amount		Shares		Amount		Capital		Issued		Deficit			Loss			Total
Balance - December 31, 2014 (3)		1,000	$	113,200		1,309,825	$	1,310	$	5,228,346	$	23,000	$	(5,571,130	)	$	(75,278	)	$	(280,552	)

Common stock issued in satisfaction of debt						58,092		58		232										290
Common stock issued in satisfaction of debt						58,750		59		235										294
Common stock issued in satisfaction of debt						59,078		59		236										295
Common stock issued in satisfaction of debt						59,244		59		237										296
Common stock issued in satisfaction of debt						54,018		54		216										270
Common stock issued as compensation						70,867		71		5,929										6,000
Common stock issued in satisfaction of debt						108,246		108		433										541
Common stock issued in satisfaction of debt						100,000		100		1,687										1,787
Common stock issued in satisfaction of debt						86,882		87		348										435
Common stock issued in satisfaction of debt						87,564		88		350										438
Common stock issued for sevices						10,000		10		490										500
Common stock issued for sevices						50,000		50		22,725										22,775
Common stock issued in satisfaction of debt						88,438		88		354										442
Common stock issued in satisfaction of debt						89,020		89		3,472										3,561
Common stock issued for sevices						50,000		50		3,450										3,500
Common stock issued in satisfaction of debt						111,864		112		7,719										7,831
Net loss for the year														(266,064	)		-			(266,064	)
Discounts on shares issued for notes payable										109,541										109,541

Balance - December 31, 2015 (3)		1,000		113,200		2,451,888		2,452		5,386,001		23,000		(5,837,194	)		(75,278	)		(387,819	)

Common stock issued in satisfaction of debt						754,135		754		4,814										5,568
Common stock issued for accrued interest						81,250		81		569										650
Common stock issued for services						25,000		25		1,850										1,875
Net loss														(410,443	)		-			(410,443	)
Discount on shares issued for notes payable										294,722										294,722

Balance - December 31, 2016 (3)		1,000		113,200		3,312,273		3,312		5,687,956		23,000		(6,247,637	)		(75,278	)		(495,447	)

~~GLUCOSE HEALTH, INC. STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY~~_______

	Preferred Stock				Common Stock				AdditionalPaid-In			Stock To Be			Deferred			Accumulated			Accumulated OtherComprehensive
	Shares		Amount		Shares		Amount		Capital			Issued			Compensation			Deficit			Loss			Total
Balance - December 31, 2013 (3)		-	$	-		377,456	$	377	$	4,761,836		$	34,400		$	(17,372	)	$	(4,901,721	)	$	(75,278	)	$	(197,758	)
Preferred shares issued for compensation under
employment agreement		1,000		113,200						-															113,200
Common shares issued for compensation under
employment agreement						300,000		300		113,700															114,000
Common shares issued for services						124,124		124		115,038															115,162
Common shares issued for liability for stock to be issued						16,000		16		14,384															14,400
Common shares issued for settlement						-
of notes payable						191,983		192		54,596															54,788
Common shares issued for Glucose Health Natural
Blood Sugar Maintenance product acquisition						300,000		300		-															300
Options issued for service						-		-		51,850															51,850
Discounts on shares issued for notes payable										116,943															116,943
Stock to be issued													(11,400	)											(11,400	)
Amortization of deferred compensation																17,372									17,372
Factional shares issued						263		1		(1	)					-									-
Net loss for the year																			(669,409	)		-			(669,409	)
Balance - December 31, 2014 (3)		1,000	$	113,200		1,309,825	$	1,310	$	5,228,346		$	23,000		$	-		$	(5,571,130	)	$	(75,278	)	$	(280,552	)
Common stock issued in satisfaction of debt						58,092		58		232															290
Common stock issued in satisfaction of debt						58,750		59		235															294
Common stock issued in satisfaction of debt						59,078		59		236															295
Common stock issued in satisfaction of debt						59,244		59		237															296
Common stock issued in satisfaction of debt						54,018		54		216															270
Common stock issued as compensation						70,867		71		5,929															6,000
Common stock issued in satisfaction of debt						108,246		108		433															541
Common stock issued in satisfaction of debt						100,000		100		1,687															1,787
Common stock issued in satisfaction of debt						86,882		87		348															435
Common stock issued in satisfaction of debt						87,564		88		350															438
Common stock issued for sevices						10,000		10		490															500
Common stock issued for sevices						50,000		50		22,725															22,775
Common stock issued in satisfaction of debt						88,438		88		354															442
Common stock issued in satisfaction of debt						89,020		89		3,472															3,561
Common stock issued for sevices						50,000		50		3,450															3,500
Common stock issued in satisfaction of debt						111,864		112		7,719															7,831
Net loss for the year																			(266,064	)		-			(266,064	)
Discounts on shares issued for notes payable										109,541															109,541
Balance - December 31, 2015 (3)		1,000		113,200		2,451,888		2,452		5,386,001			23,000			-			(5,837,194	)		(75,278	)		(387,819	)

(3)	The common stock shares authorized, issued and outstanding have been adjusted to reflect a 10 to 1 reverse split, which was effective in February 2014 and 50 to 1 reverse split, which was effective in November 2014

~~_______________~~The accompanying notes are an integral part of these financial statements

~~(3)~~F-4 ~~The~~Table ~~common~~Of stock shares authorized, issued and outstanding have been adjusted to reflect a 10 to 1 reverse split, which was effective in February 2014 and 50 to 1 reverse split, which was effective in November 2014Contents

The accompanying notes are an integral part of these financial statements.

GLUCOSE HEALTH, INC.
STATEMENTS OF CASH FLOWS


	FOR THE YEARS ENDED DECEMBER 31,
	2016			2015
OPERATING ACTIVITIES:
Net loss	$	(410,443	)	$	(266,064	)

Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services		1,875			32,775
Amortization of note discount		239,927			43,076
Amortization of intangible asset		60			-
Beneficial conversion feature of notes payable		-			109,541
Change in assets and liabilities
Increase in accounts receivable		(8,574	)		(4,572	)
Decrease (increase) in inventory		8,370			(8,370	)
(Increase) decrease in prepaid expenses and other current assets		643			37,577
Increase (decrease) in accounts payable and accrued expenses		128,879			(59,739	)
Total adjustments		371,180			150,288
Net cash used in operating activities		(39,263	)		(115,776	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in due from affilliate		250			(250	)
Net cash used in investing activities		250			(250	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes and loans payable		128,500			113,210
Payments on notes and loans payable		(71,000	)		-
Net cash provided by financing activities		57,500			113,210

NET INCREASE (DECREASE) IN CASH		18,487			(2,816	)

CASH - BEGINNING OF YEAR		2,055			4,871

CASH - END OF YEAR	$	20,542		$	2,055

NON-CASH OPERATING AND INVESTING ACTIVITIES:
Beneficial conversion feature	$	294,722		$	109,541
Conversion of notes payable and accrued interest to common stock	$	6,155		$	4,100
Conversion of liability to common stock	$	-		$	4,315

~~F-5~~The accompanying notes are an integral part of these financial statements

~~GLUCOSE~~F-5 ~~HEALTH,~~Table ~~INC.~~Of ~~STATEMENTS OF CASH FLOWS~~Contents

	FOR THE YEAR			FOR THE YEAR
	ENDED			ENDED
	DECEMBER 31, 2015			DECEMBER 31, 2014
OPERATING ACTIVITIES:
Net loss	$	(266,064	)	$	(669,409	)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory write down		-			14,402
Common stock issued for services		32,775			372,725
Amortization of note discount		43,076			100,098
Gain on forgiveness of accounts payable		-			-
(Gain) loss on conversion of debt		-			14,562
Beneficial conversion feature of notes payable		109,541			-
Change in assets and liabilities
Increase in accounts receivable		(4,572	)		-
(Increase) decrease in inventory		(8,370	)		10,477
Decrease in prepaid expenses and other current assets		37,577			-
Increase (decrease) in accounts payable and accrued expenses		(59,739	)		21,793
Total adjustments		150,288			534,057
Net cash used in operating activities		(115,776	)		(135,352	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in due from affilliate		(250	)		-
Net cash used in investing activities		(250	)		-
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes and loans payable		113,210			139,512
Net cash provided by financing activities		113,210			139,512
NET INCREASE IN CASH		(2,816	)		4,160
CASH - BEGINNING OF PERIOD		4,871			711
CASH - END OF PERIOD	$	2,055		$	4,871
NONCASH OPERATING AND INVESTING ACTIVITIES:
Beneficial conversion feature	$	109,541		$	-
Conversion of notes payable and accrued interest to common stock	$	4,100		$	54,788
Cancellation for 600,000 shares of common stock to settle liabilities	$	-		$	21,000
Conversion of liability to common stock	$	4,315		$	-

GLUCOSE HEALTH INC.

~~The~~NOTES ~~accompanying~~TO ~~notes~~FINANCIAL ~~are an integral part of these financial statements.~~STATEMENTS

~~F-6~~DECEMBER 31, 2015 AND 20143

~~GLUCOSE~~NOTE ~~HEALTH~~1 ~~INC.~~- ORGANIZATION AND BASIS OF PRESENTATION

~~NOTES~~We TOwere ~~FINANCIAL~~incorporated ~~STATEMENTS~~under the laws of State of Nevada on March 27, 2007, as Bio-Solutions Corp. Our current authorized common shares are 200,000,000 and 1,000 preferred voting shares. As of December 31, 2016, 3,312,273 of the Company’s common stock and 1,000 shares of the Company’s preferred stock were issued and outstanding. On October 30, 2014, we changed our name to Glucose Health, Inc. Our business is the manufacturing and distribution of Glucose Health® Daily Blood Sugar Maintenance. Glucose Health® is a dietary supplement in the form of a sweet tea mix formulated from nine natural ingredients shown in certain clinical research such as that published by the National Institutes of Health, National Library of Medicine website (see www.glucosehealth.com/clinical-trials), to have a beneficial impact upon blood glucose, triglyceride and cholesterol levels and regular digestive health. As of December 31, 2016, the Company’s Glucose Health® Daily Blood Sugar Maintenance Blueberry Tea Mix (60-Day Supply) product is stocked in the "Diabetic Supplies" section of most Walmart pharmacies in all 50 states.

~~DECEMBER~~Going ~~31, 2015 AND 20143~~Concern

~~NOTE~~These 1financial -statements ~~ORGANIZATION~~have ~~AND~~been ~~BASIS~~prepared OFon ~~PRESENTATION~~a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

OnThe ~~March~~Company 27had a working capital deficiency of $495,687 ~~2007~~and an accumulated deficit of $6,247,637 ~~Glucose~~as ~~Health~~of December 31, ~~Inc~~2016. ~~(f/k/~~The continuation of the Company as a ~~Bio-Solutions~~going ~~Corp~~concern is dependent upon the ability of the Company to obtain additional financing to continue operations.) ("The Company") ~~was~~estimates ~~incorporated~~it will need $120,000 in additional capital to continue operations through the ~~State~~end of ~~Nevada~~2017. This additional capital may not be obtained on terms favorable to the Company, if at all. If the capital needed to continue operations cannot be obtained outside of the Company, the Company’s officers/director may need to contribute capital to sustain operations. The Company’s officers/director are not required to contribute capital. These factors raise substantial doubt regarding the ability of the Company to continue as a going concern.

AtNOTE ~~inception,~~2 ~~the Company was a manufacturer of Nutra~~-~~Animal,~~ aSUMMARY ~~pre-mix~~OF ~~anti-oxidant~~SIGNIFICANT ~~for~~ACCOUNTING chicken integrators. The Company was also the distributor of GreenEx™, a biological larvicide produced from a naturally occurring bacterium that produces a crystalline protein toxin, toxic for mosquitoes, vectors of malaria.POLICIES

OnUse ~~June 30, 2010, the board~~ of directors approved the increase of the authorized shares of common stock from 75,000,000 to 90,000,000. In addition, the board approved a 1.20 for 1 stock split. All shares have been reflected retroactively in accordance with SAB Topic 14C.Estimates

OnThe ~~September~~preparation 26of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amounts of assets, ~~2011~~liabilities, ~~the~~revenues, ~~Company~~and ~~entered~~expenses, ~~into~~and related disclosure of contingent assets and liabilities. On an ~~acquisition~~ongoing ~~agreement~~basis, ~~for~~we ~~Type2~~evaluate ~~Defense~~our estimates, aincluding ~~natural~~those ~~dietary~~related ~~supplement~~to ~~for~~revenue ~~the~~recognition, ~~Type-2~~bad ~~diabetes~~debts, investments, intangible assets, and ~~pre-diabetes~~income ~~market~~taxes. ~~category~~Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the ~~Company's~~circumstances. ~~previous~~Actual ~~operations~~results ~~were~~may ~~discontinued~~differ from these estimates.

~~During~~Comprehensive ~~October~~Income ~~2012, the board of directors increased the number of common shares authorized from 90,000,000 to 200,000,000 shares.~~(Loss)

OnThe ~~February 4, 2014, the~~ Company ~~filed~~adopted aASC ~~Certificate~~220-10, of“Reporting ~~Change~~Comprehensive ~~with~~Income.” ~~the~~ASC ~~State of Nevada effecting a 1~~220-~~for-~~10 ~~reverse~~requires ~~split pursuant to which every ten shares of~~ the ~~Company's~~reporting ~~common stock were combined and converted into one share~~ of ~~the~~comprehensive ~~Company's~~income ~~common~~in ~~stock~~addition ~~(with~~to ~~all~~net ~~fractional~~income ~~shares resulting there~~ from ~~being~~operations. ~~rounded~~Comprehensive upincome tois ~~the~~a ~~next~~more ~~whole~~inclusive ~~share)~~financial ~~with~~reporting ~~the~~methodology ~~total~~that ~~number~~includes ofdisclosure ~~shares~~ of ~~the~~information ~~Company's~~that ~~authorized~~historically ~~common~~has ~~stock~~not ~~remaining~~been atrecognized ~~200,000,000~~in ~~shares.~~the ~~The~~calculation ~~effective date~~ of ~~the~~net ~~above corporate action was February 26, 2014~~income.

OnF-6 ~~April~~Table 8,Of ~~2014, in a special meeting of the board of directors, the board voted in favor of amending the Company's bylaws to decrease the number of members of the board of directors from three to one.~~ Contents

OnCash ~~October~~Flow 1, 2014, Murray Fleming was appointed as the Company's Chief Executive Officer for the 12-month period ending October 1, 2015 and the Company entered into an Intellectual Property Purchase Agreement to purchase the "Glucose Health Natural Blood Sugar Maintenance" product from a company beneficially owned by Mr. Fleming.Reporting

AsThe Company follows ASC 230, Statement of ~~October~~Cash 1Flows, ~~2014~~for cash flow reporting, ~~Mr.~~classifies ~~Fleming~~cash ~~beneficially~~receipts ~~owned~~and ~~600~~payments according to whether they stem from operating,~~000~~ ~~shares~~investing, or ~~50.1%~~financing ofactivities ~~the~~and ~~outstanding~~provides ~~shares~~definitions of each category, and uses the ~~Company's~~indirect ~~common~~or ~~stock~~reconciliation method (“indirect method”) as defined by ASC 230, ~~which~~Statement ~~resulted~~of inCash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) ~~change~~all indeferrals ~~control~~of past operating cash receipts and payments and all accruals of ~~the~~expected ~~Company.~~future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

OnCash November 5, 2014, the Company filed a Certificate of Amendment to its Articles of Incorporation, with the Nevada Secretary of State effecting, as of November 19, 2014, a 1-for-50 reverse split pursuant to which every fifty shares of the Company's common stock were combined and ~~converted~~Cash into one share of the Company's common stock (with all fractional shares being rounded up to the next whole share) with the total number of shares of the Company's authorized common stock remaining at 200,000,000 shares; effecting the authorization of 1,000 shares of preferred stock with "blank check" rights; and effecting the change of the Company's name from Bio-Solutions Corp. to Glucose Health, Inc. On November 20, 2015, the board of directors voted to designate Series A Special Preferred Shares consisting of 1000 shares of preferred stock with special voting rights whereby the holder(s) may exercise their right to vote on all shareholder matters representing the number of votes equal to all shares of common stock then issued and outstanding, plus an additional ten thousand (10,000) shares. Additionally, the board of directors voted to extend an existing consulting contract with the Company's CEO, Murray Fleming, for an additional 12 months, through October 1, 2016, without further compensation, in exchange for the issuance to Mr. Fleming, of the 1000 Series A Special Preferred Shares. A Certificate of Designation for the Series A Special Preferred Shares was filed with the Nevada Secretary of State and effective on December 1, 2014. Equivalents

FThe Company considers all highly liquid debt instruments and other short-7term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of December 31, 2016 and 2015.

OnThe ~~December 15, 2014, the~~ Company ~~submitted~~maintains its ~~application~~cash tobalances ~~OTC~~at ~~Markets~~one ~~Group~~financial ~~Inc.~~institution ~~for~~that ~~inclusion~~is ininsured ~~the~~by ~~OTCQB tier of quoted securities. In addition,~~ the ~~Company's~~Federal ~~new~~Deposit ~~ticker~~Insurance ~~symbol, GLUC, was included on the Financial Industry Regulatory Authority's (FINRA) Daily List with an effective date of December 15, 2014~~Corporation.

OnAccounts ~~February 10, 2015, Murray Fleming, the Company's Chief Executive Officer was appointed the Company's Chief Financial Officer.~~ Receivable

~~Going~~Accounts ~~Concern~~receivable consists of invoiced and unpaid product sales. The Company records an allowance for doubtful accounts to allow for any amounts that may not be recoverable, which is based on an analysis of the Company’s prior collection experience, customer credit worthiness, and current economic trends. During the years ended December 31, 2016 and 2015, we recorded no allowances for doubtful accounts based upon management’s review of accounts receivable.

~~The~~On October 4, 2016, the Company ~~had~~executed a ~~working~~non-recourse ~~capital~~receivables ~~deficiency~~financing ofagreement ~~$388,119~~with ~~and~~Citibank anwhereby ~~accumulated~~receivables ~~deficit~~due ofto ~~$5,837,194~~the asCompany ofare ~~December~~assumed ~~31,~~from ~~2015.~~Wal-Mart ~~The~~Stores ~~Company's~~Inc. ~~continuation~~by asCitibank aand ~~going~~paid ~~concern~~to isthe ~~dependent~~Company onin ~~its~~a ~~ability~~shorter toperiod ~~generate~~than ~~sufficient~~otherwise ~~cash~~provided ~~flows~~for ~~from~~in ~~operations~~accordance towith ~~meet~~the ~~its~~Company’s ~~obligations~~Supplier ~~and/or~~Agreement ~~obtain~~with ~~additional~~Wal-Mart ~~financing~~Stores ~~from~~Inc., ~~its~~subject ~~members~~to ora ~~other~~fixed ~~sources,~~interest aspremium ~~may~~based beupon ~~required~~LIBOR.

~~These~~Prepaid financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has not generated significant revenues, has generated losses totaling $5,837,194 since inception and needs to raise additional funds to carry out its business plan. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, and the ability of the Company to obtain necessary equity financing to continue operations. The Company has had very little operating history to date. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. These factors raise substantial doubt regarding the ability of the Company to continue as a going concern.Expenses

The Company ~~estimates~~considers itall ~~will~~items ~~need~~incurred afor ~~total~~future ofservices ~~$120,000 in capital~~ to ~~continue~~be ~~operations~~prepaid ~~through~~expenses. ~~the~~As ~~end~~ of ~~2016.~~December ~~Besides~~31, ~~generating~~2016, ~~revenues~~and ~~from current operations~~2015, the Company ~~may~~had ~~need~~prepaid toexpenses ~~raise~~of ~~additional~~$639 ~~capital~~and to$1,282, ~~expand~~respectively, ~~operations~~comprised toof the ~~point~~issuance ~~at which the Company can achieve profitability. The terms~~ of ~~equity~~unregistered ~~that~~shares ~~may be raised may not be on terms acceptable by the Company. If adequate funds cannot be raised outside~~ of the Company~~, the Company'~~’s ~~officer~~common ~~and~~stock ~~directors may need~~ to ~~contribute funds to sustain operations~~consultants.

~~NOTE~~Recoverability 2of Long-Lived ~~SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~Assets

~~Use~~The Company reviews its long-lived assets on a periodic basis, namely intellectual property, whenever events and changes in circumstances have occurred which may indicate a possible impairment. The assessment for potential impairment will be based primarily on the Company’s ability to recover the carrying value of ~~Estimates~~its long-lived assets from expected future cash flows from its operations on an undiscounted basis. If such assets are determined to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fixed assets to be disposed of by sale will be carried at the lower of the then current carrying value or fair value less estimated costs to sell.

The ~~preparation~~Company evaluates the carrying value of ~~financial~~goodwill ~~statements~~during inthe ~~conformity~~fourth ~~with~~quarter ~~accounting~~of ~~principles~~each ~~generally~~year ~~accepted~~and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating whether goodwill is impaired, the ~~United~~Company ~~States~~compares the fair value of ~~America~~the ~~requires~~reporting ~~management~~unit to ~~make~~which ~~estimates~~the ~~and~~goodwill ~~assumptions~~is ~~that~~assigned ~~affect~~to the ~~reported~~reporting ~~amounts~~unit’s carrying amount, including goodwill. The fair value of ~~assets~~the ~~and~~reporting ~~liabilities~~unit ~~and~~is ~~disclosures~~estimated using a combination of ~~contingent~~the ~~assets~~income, or discounted cash flows, approach and ~~liabilities~~the atmarket approach, which utilizes comparable companies’ data. If the ~~date~~carrying amount of a reporting unit exceeds its fair value, then the ~~financial~~amount ~~statements~~of ~~and~~the impairment loss must be measured. The impairment loss would be calculated by comparing the ~~reported~~implied ~~amounts~~fair value of ~~revenue~~reporting ~~and~~unit ~~expenses~~goodwill ~~during~~to its carrying amount. In calculating the implied fair value of reporting ~~period.~~unit ~~Actual~~goodwill, ~~results~~the ~~could~~fair ~~differ~~value ~~from~~of ~~those~~the ~~estimates~~reporting unit is allocated to all the other assets and liabilities of that unit based on their fair values. The ~~Company~~excess ~~provides~~of ~~estimates~~the ~~for~~fair ~~its~~value ~~common~~of ~~stock~~a ~~valuations,~~reporting ~~inventory~~unit ~~reserves,~~over the amount assigned to its other assets and ~~valuation~~liabilities, ~~allowances~~is ~~for~~the ~~deferred~~implied ~~taxes~~fair value of goodwill.

~~Comprehensive~~F-7 ~~Income~~Table ~~(Loss)~~Of Contents

~~The~~We ~~Company~~make ~~adopted~~critical ~~ASC~~assumptions ~~220-10~~and estimates in completing impairment assessments of goodwill and other intangible assets. Our cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, ~~"Reporting~~economic ~~Comprehensive~~conditions, ~~Income~~market competition, inflation and discount rates." ~~ASC~~A ~~220-~~10% ~~requires~~decrease in the estimated discounted cash flows for the reporting units tested would result in impairment that is not material to our results of ~~comprehensive~~operations. ~~income~~A 1.0 percentage point increase in ~~addition~~the discount rate used would also result in impairment that is not material to ~~net~~our ~~income~~results ~~from~~of operations.

~~Comprehensive~~We ~~income~~amortize isthe acost ~~more~~of ~~inclusive~~other ~~financial~~intangible ~~reporting~~assets ~~methodology~~over ~~that~~their ~~includes~~estimated ~~disclosure~~useful oflives, ~~information~~which ~~that~~range ~~historically~~up ~~has~~to ~~not~~ten ~~been~~years, ~~recognized~~unless such lives are deemed indefinite. Intangible assets with indefinite lives are tested in the ~~calculation~~third quarter of ~~net~~each ~~income~~fiscal year for impairment, or more often if indicators warrant.

~~The~~During ~~Company previously operated in Canada and certain accounts of~~ the ~~Company~~years ~~were~~ended ~~reflected~~December ~~in currencies other than the U.S. dollar. Effective January 1~~31, ~~2013,~~2016 ~~the Company changed its functional currency from the Canadian dollar to the US dollar~~ and ~~combined the accounting records into a single set of books based on the currency translation rate at January 1~~2015, ~~2013.~~we ~~Prior to January 1, 2013, the Company~~ recorded ~~translation~~no ~~adjustments~~impairment ascharges ~~accumulated~~related ~~other~~to ~~comprehensive income (loss). Gains and losses from foreign currency transactions were included in~~ other ~~income~~intangible ~~(expense) in the results of operations~~assets.

~~F-8~~Fair Value of Financial Instruments

~~Cash~~The ~~Flow~~carrying ~~Reporting~~amount reported in the balance sheets for cash, accounts payable, accrued expenses, and short-term notes approximate fair value because of the immediate or short-term maturity of these financial instruments. The Company does not utilize derivative instruments.

~~The~~ASC ~~Company~~820, ~~follows~~Fair ~~ASC~~Value ~~230~~Measurements and Disclosures, ~~Statement~~defines offair ~~Cash~~value ~~Flows,~~as ~~for~~the ~~cash~~exchange ~~flows~~price ~~reporting,~~that ~~classifies~~would ~~cash~~be ~~receipts~~received ~~and~~for ~~payments~~an ~~according~~asset or paid to ~~whether~~transfer ~~they~~a ~~stem~~liability ~~from~~(an ~~operating,~~exit ~~investing,~~price) in the principal or ~~financing~~most ~~activities~~advantageous ~~and~~market ~~provides~~for ~~definitions~~the ofasset ~~each~~or ~~category,~~liability ~~and~~in ~~uses~~an orderly transaction between market participants on the ~~indirect~~measurement ordate. ~~reconciliation~~ASC ~~method~~820 ~~("Indirect~~also ~~method")~~establishes asa ~~defined~~fair byvalue ~~ASC~~hierarchy ~~230,~~that ~~Statement~~distinguishes ofbetween ~~Cash~~(1) market ~~Flows,~~participant toassumptions ~~report~~developed ~~net~~based ~~cash~~on ~~flow~~market ~~from~~data ~~operating~~obtained ~~activities~~from byindependent ~~adjusting~~sources ~~net~~(observable ~~income~~inputs) toand ~~reconcile~~(2) an itentity’s toown ~~net~~assumptions ~~cash~~about ~~flow~~market ~~from~~participant ~~operating~~assumptions ~~activities~~developed bybased ~~removing~~on the ~~effects~~best ofinformation available in the circumstances (aunobservable inputs). ~~all~~The ~~deferrals~~fair value hierarchy consists of ~~past~~three ~~operating~~broad ~~cash~~levels, ~~receipts~~which ~~and~~gives ~~payments~~the ~~and~~highest ~~all~~priority ~~accruals~~to ofunadjusted ~~expected~~quoted ~~future~~prices ~~operating~~in ~~cash~~active ~~receipts~~markets ~~and~~for ~~payments~~identical ~~and~~assets or liabilities (bLevel 1) ~~all~~and ~~items~~the ~~that~~lowest ~~are~~priority ~~included~~to inunobservable ~~net~~inputs ~~income~~(Level ~~that~~3). doThe ~~not~~three ~~affect~~levels ~~operating~~of ~~cash~~the ~~receipts~~fair ~~and~~value ~~payments.~~hierarchy are described below:

Cash and Cash Equivalents

Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities
Level 2	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3	Inputs that are both significant to the fair value measurement and unobservable.

~~The~~Fair ~~Company~~value ~~considers~~estimates ~~all~~discussed ~~highly~~herein ~~liquid~~are ~~debt~~based ~~instruments~~upon certain market assumptions and ~~other~~pertinent ~~short-term~~information ~~investments~~available ~~with~~to ~~maturity~~management as of ~~three~~December ~~months~~31, or2016. ~~less,~~The ~~when~~respective ~~purchased,~~carrying tovalue beof ~~cash~~certain ~~equivalents.~~on-balance-sheet ~~There~~financial ~~were~~instruments noapproximated ~~cash~~their ~~equivalents~~fair asvalues ofdue ~~December~~to ~~31,~~the ~~2015~~short-term ~~and~~nature ~~2014~~of these instruments.

~~The~~Beneficial ~~Company~~Conversion ~~maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.~~Features

~~Prepaid~~ASC ~~Expenses~~470-20 applies to convertible securities with beneficial conversion features that must be settled in stock and to those that give the issuer a choice in settling the obligation in either stock or cash. ASC 470-20 requires that the beneficial conversion feature should be valued at the commitment date as the difference between the conversion price and the fair market value of the common stock into which the security is convertible, multiplied by the number of shares into which the security is convertible. This amount is recorded as a debt discount and amortized over the life of the debt. ASC 470-20 further limits this amount to the proceeds allocated to the convertible instrument.

~~The~~F-8 ~~Company~~Table ~~considers~~Of all items incurred for future services to be prepaid expenses. As of December 31, 2015 and 2014, the Company had prepaid expenses of $1,282 and $38,859, respectively, comprised of a prepaid subscription and the issuance of unregistered shares of the Company's common stock to consultants, respectively.Contents

~~Recoverability~~Income ~~of Long-Lived Assets~~Taxes

The Company ~~reviews~~accounts ~~its~~for ~~long-lived~~income ~~assets~~taxes onutilizing athe ~~periodic~~liability ~~basis,~~method ~~namely~~of ~~intellectual property, whenever events and changes in circumstances have occurred which may indicate a possible impairment~~accounting. ~~The~~Under ~~assessment~~the ~~for~~liability ~~potential~~method, ~~impairment~~deferred ~~will~~taxes beare determined based ~~primarily~~ on ~~the~~differences ~~Company's~~between ~~ability~~financial tostatement ~~recover~~and ~~the~~tax ~~carrying~~bases ~~value~~ of ~~its long-lived~~ assets ~~from~~and ~~expected~~liabilities ~~future~~at ~~cash~~enacted ~~flows~~tax ~~from~~rates ~~its~~in ~~operations~~effect onin anyears ~~undiscounted~~in ~~basis.~~which Ifdifferences ~~such assets~~ are ~~determined~~expected to bereverse. ~~impaired,~~Valuation ~~the~~allowances ~~impairment~~are ~~recognized~~established, iswhen ~~the~~necessary, ~~amount~~to byreduce ~~which~~deferred ~~the~~tax ~~carrying value of the~~ assets ~~exceeds~~to ~~the~~amounts ~~fair~~that ~~value~~are ofexpected ~~the assets. Fixed assets~~ to be ~~disposed of by sale will be carried at the lower of the then current carrying value or fair value less estimated costs to sell~~realized.

The Company ~~evaluates~~follows ~~the~~ASC ~~carrying~~740-10, ~~value~~“Accounting offor ~~goodwill~~Uncertainty ~~during~~in ~~the~~Income ~~fourth~~Taxes” ~~quarter~~(“ASC of740-10”). ~~each~~This ~~year~~interpretation ~~and~~requires ~~between~~recognition ~~annual~~and ~~evaluations~~measurement ifof ~~events~~uncertain ~~occur~~income ortax ~~circumstances~~positions ~~change~~using ~~that~~a ~~would~~ “more -likely -than -not” ~~reduce~~approach. ~~the~~The ~~fair~~Company ~~value~~has ofadopted ~~the~~ASC ~~reporting~~740-10 ~~unit~~for ~~below its carrying amount. Such circumstances could include~~2016, ~~but~~and ~~are~~evaluates ~~not~~its ~~limited~~tax topositions ~~(1)~~on aan ~~significant~~annual ~~adverse~~basis, ~~change~~and inas ~~legal~~of ~~factors~~December ~~or in business climate~~31, ~~(2) unanticipated competition~~2016, orno ~~(3)~~additional anaccrual ~~adverse~~for ~~action~~income ortaxes ~~assessment~~is ~~by a regulator~~necessary. The ~~When~~Company’s ~~evaluating~~policy ~~whether goodwill~~ is ~~impaired,~~to ~~the~~recognize ~~Company~~both ~~compares~~interest ~~the~~and ~~fair~~penalties ~~value~~related ~~of the reporting unit~~ to ~~which~~unrecognized ~~the~~tax ~~goodwill~~benefits isexpected ~~assigned~~ to ~~the~~result ~~reporting~~in ~~unit's~~payment ~~carrying amount, including goodwill. The fair value~~ of ~~the~~cash ~~reporting~~within ~~unit~~one isyear ~~estimated~~are ~~using~~classified aas ~~combination~~accrued ~~of the income~~liabilities, orwhile ~~discounted~~those ~~cash~~expected ~~flows,~~beyond ~~approach~~one ~~and~~year ~~the~~are ~~market~~classified ~~approach,~~as ~~which~~other ~~utilizes comparable companies' data~~liabilities. IfThe ~~the~~Company ~~carrying~~has ~~amount~~not ofrecorded aany ~~reporting~~interest ~~unit~~or ~~exceeds~~penalties since its ~~fair value, then the amount of the impairment loss must be measured~~inception. The ~~impairment~~Company ~~loss~~is ~~would~~required ~~be calculated by comparing the implied fair value of reporting unit goodwill~~ to ~~its~~file ~~carrying~~income ~~amount.~~tax Inreturns ~~calculating~~in the ~~implied~~U.S. ~~fair~~federal ~~value~~tax ofjurisdiction ~~reporting~~and ~~unit~~in ~~goodwill,~~various ~~the~~state ~~fair~~tax ~~value~~jurisdictions ofand ~~the~~tax ~~reporting~~years ~~unit~~2013, is2014 ~~allocated~~and to2015 ~~all~~remain ofopen ~~the~~for ~~other~~examination ~~assets~~by federal and/or ~~liabilities~~state oftax ~~that unit based on their fair values~~jurisdictions. The ~~excess~~Company ofis ~~the~~currently ~~fair~~not ~~value~~under ofexamination aby ~~reporting~~any ~~unit over the amount assigned to its~~ other ~~assets~~tax ~~and~~jurisdictions ~~liabilities,~~for isany ~~the~~tax ~~implied fair value of goodwill~~year.

~~F-9~~Revenue Recognition

WeIn ~~make~~accordance ~~critical~~with ~~assumptions~~Securities and ~~estimates~~Exchange inCommission ~~completing~~Staff ~~impairment~~Accounting ~~assessments~~Bulletin of(SAB) ~~goodwill and other intangible assets~~No. ~~Our~~104, Revenue ~~cash~~Recognition, ~~flow~~(codified ~~projections~~in ~~look~~ASC ~~several~~605) ~~years into~~ the ~~future~~Company ~~and~~recognizes ~~include~~revenue ~~assumptions~~when on(i) ~~variables~~persuasive ~~such~~evidence asof ~~future~~a ~~sales~~customer ~~and~~or ~~operating~~distributor ~~margin~~arrangement ~~growth~~exists ~~rates,~~or ~~economic~~acceptance ~~conditions~~occurs, ~~market~~(ii) ~~competition~~a retailer, ~~inflation~~distributor ~~and~~or ~~discount~~wholesaler ~~rates.~~receives ~~A 10% decrease in~~ the ~~estimated~~goods, ~~discounted~~(iii) ~~cash flows for~~ the ~~reporting~~price ~~units tested would result in impairment that~~ is ~~not~~fixed ~~material~~or todeterminable, ~~our~~and ~~results~~(iv) collectability of ~~operations. A 1.0 percentage point increase in~~ the ~~discount~~sales ~~rate~~revenues ~~used would also result in impairment that~~ is ~~not~~reasonably ~~material to our results of operations~~assured.

WeCustomer amortize the cost of other intangible assets over their estimated useful lives, which range up to ten years, unless such lives are deemed indefinite. Intangible assets with indefinite lives are tested in the third quarter of each fiscal year for impairment, or more often if indicators warrant. Concentration

~~During~~The ~~the~~Company ~~years~~generates ~~ended~~most ~~December~~of ~~31,~~its ~~2015~~revenues ~~and~~from ~~2014~~sales to a single customer, weWal-Mart ~~recorded~~Stores, noInc. ~~impairment~~which ~~charges~~accounted ~~related~~for toapproximately ~~other~~99% ~~intangible~~of ~~assets~~total revenues in 2016.

~~Fair~~Share ~~Value~~Based ~~of Financial Instruments~~Compensation

The ~~carrying~~Company ~~amount~~accounts ~~reported~~for share-based compensation in accordance with the ~~balance~~fair ~~sheets~~value ~~for~~recognition ~~cash,~~provisions ~~accounts~~of ~~payable,~~the ~~accrued~~Financial ~~expenses,~~Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and ~~short-term~~No. ~~notes~~505. ~~approximate~~The Company issues restricted stock to employees for their services. Cost for these transactions are measured at the fair value ~~because~~of the equity instruments issued at the date of grant. These shares are considered fully vested and the ~~immediate~~fair market value is recognized as expense in the period granted. The Company also issues restricted stock to consultants for various services. Costs for these transactions are measured at the fair value of the consideration received or ~~short-term~~the ~~maturity~~fair value of ~~these~~the ~~financial~~equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment only if there is sufficient disincentive to ensure performance or (ii) the date at which the counterparty's performance is complete. The Company ~~does~~recognized ~~not~~consulting ~~utilize~~expenses ~~derivative~~and ~~instruments~~a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

~~ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability~~ (~~an exit price~~Loss) inPer ~~the~~Share principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of ~~three~~Common broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:Stock

Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities
Level 2	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3	Inputs that are both significant to the fair value measurement and unobservable.

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. Except as noted below, the Company has not issued any options or warrants to date. At December 31, 2016, the total shares issuable upon conversion of convertible notes payable would be approximately 38,182,050 shares of the Company’s common stock.

~~Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2015. The respective carrying value of certain on~~F-~~balance-sheet~~9 ~~financial~~Table ~~instruments~~Of ~~approximated their fair values due to the short-term nature of these instruments.~~Contents

~~Beneficial Conversion Features~~Inventory

~~ASC~~Inventory ~~470-20~~is ~~applies~~stated toat ~~convertible securities with beneficial conversion features that must be settled in stock and to those that give~~ the ~~issuer~~lower aof ~~choice~~cost in(FIFO: ~~settling the obligation~~ first-in, ~~either~~first-out) ~~stock~~ or ~~cash.~~market, ~~ASC~~and ~~470-20~~includes ~~requires~~finished ~~that~~goods. ~~the~~The ~~beneficial~~cost ~~conversion~~of ~~feature~~finished ~~should~~goods beincludes ~~valued at~~ the ~~commitment~~cost ~~date as the difference between the conversion price and the fair market value~~ of ~~the~~packaging ~~common stock into which the security is convertible~~supplies, ~~multiplied~~direct byand ~~the~~indirect ~~number~~labor ofand ~~shares~~other ~~into~~indirect ~~which~~manufacturing ~~the security is convertible~~costs. ~~This~~As ~~amount~~of isDecember ~~recorded~~31, as2016, ~~a debt discount~~ and ~~amortized~~2015, ~~over~~ the ~~life~~Company ofhad ~~the~~inventory ~~debt.~~of ~~ASC~~$0 ~~470-20~~and ~~further~~$8,730, ~~limits~~respectively, ~~this~~with ~~amount~~no toallowance ~~the~~for ~~proceeds allocated to the convertible instrument~~obsolescence.

~~F-10~~Recently Issued Accounting Standards Not Yet Adopted

~~Income~~In ~~Taxes~~May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This guidance is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This guidance can be adopted either retrospectively to each prior reporting period presented, or retrospectively with a cumulative-effect adjustment recognized as of the date of adoption. The original effective date of this guidance for public entities was for annual reporting periods beginning after December 15, 2016. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606), to defer the effective date of this guidance by one year, to the annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. A reporting entity may choose to early adopt the guidance as of the original effective date. We do not anticipate early adoption, and are currently evaluating the impact on our financial statements upon the adoption of this guidance.

~~The~~NOTE ~~Company~~3 ~~accounts~~- ~~for~~STOCKHOLDERS’ income taxes utilizing the liability method of accounting. Under the liability method, deferred taxes are determined based on differences between financial statement and tax bases of assets and liabilities at enacted tax rates in effect in years in which differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are expected to be realized.DEFICIT

~~The~~Our ~~Company~~current ~~follows~~authorized ~~ASC~~common ~~740-10,~~shares ~~"Accounting~~are for Uncertainty in Income Taxes" ("ASC 740-10"). This interpretation requires recognition and measurement of uncertain income tax positions using a "more-likely-than-not" approach. ASC 740-10 is effective for fiscal years beginning after December 15200, ~~2006. Management has adopted ASC 740-10 for 2007~~000,000 and ~~they evaluate their tax positions on an annual basis~~1,000 ~~and~~preferred ~~have~~voting ~~determined~~shares. ~~that~~As as of December 31, ~~2015~~2016, no3,312,273 ~~additional~~of ~~accrual~~the ~~for income taxes is necessary. The~~ Company'’s ~~policy~~common isstock ~~to recognize both interest~~ and ~~penalties~~1,000 ~~related~~shares ~~to unrecognized tax benefits expected to result in payment~~ of ~~cash~~the ~~within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The~~ Company’s ~~has~~preferred ~~not~~stock ~~recorded~~were ~~any~~issued ~~interest or penalties since its inception. The Company is required to file income tax returns in the U.S. federal tax jurisdiction~~ and ~~in various state tax jurisdictions~~outstanding. ~~The tax years for 2009 to 2014 remain open for examination by federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax year.~~

~~Revenue~~Issuances ~~Recognition~~pursuant to conversions

~~The~~During ~~Company~~January ~~currently~~2015, ~~has~~the ~~nominal~~Company ~~revenues.~~issued ~~Once~~58,092 ~~the~~shares ~~Company~~of ~~generates~~common ~~significant~~stock ~~revenues~~to ~~from~~a ~~the~~corporation ~~sales~~for conversion of ~~our~~$250 ~~products~~principal and $40 accrued interest related to a Note. These shares were valued at $0.005 per share, the ~~following~~conversion ~~criteria~~price ~~for~~as ~~revenue~~stated ~~recognition~~in ~~will~~the ~~be utilized:~~Note.

1)During ~~Persuasive~~February ~~evidence~~2015, ofthe anCompany ~~arrangement~~issued ~~exists;~~177,072 2)shares ~~delivery~~of ~~has~~common ~~occurred~~stock orto ~~services~~a ~~have~~corporation ~~been~~for ~~rendered;~~conversion 3)of ~~the~~$886 ~~seller's~~in ~~price~~principal and accrued interest related to ~~the~~a ~~buyer~~Note. isThese ~~fixed~~shares orwere ~~determinable~~valued at $0.005 per share, ~~and~~the 4)conversion ~~collectability~~price isas ~~reasonably~~stated ~~assured~~in the Note.

~~Share~~During ~~Based~~March ~~Compensation~~2015, the Company issued 162,264 shares of common stock to a corporation for conversion of $541 in principal and accrued interest related to a Note. These shares were valued at $0.005 per share, the conversion price as stated in the Note.

~~The~~During ~~Company~~April ~~accounts~~2015, ~~for share-based compensation in accordance with~~ the ~~fair~~Company ~~value~~issued ~~recognition~~86,882 ~~provisions~~shares of ~~the~~common ~~Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. The Company issues restricted~~ stock to ~~employees~~a ~~for~~corporation ~~their services. Cost~~ for ~~these~~conversion ~~transactions are measured at the fair value~~ of ~~the~~$400 ~~equity~~principal ~~instruments~~and ~~issued~~$40 ataccrued ~~the~~interest ~~date~~related ofto ~~grant~~Note. These shares ~~are~~were ~~considered~~valued ~~fully~~at ~~vested and the fair market value is recognized as expense in the period granted~~$0.005 ~~The~~per Company also issues restricted stock to consultants for various services. Cost for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issuedshare, ~~whichever is more reliably measurable. The value of~~ the ~~common~~conversion ~~stock~~price isas ~~measured~~stated at the earlier of (i) the date at which a firm commitment only if there is sufficient disincentive to ensure performance or (ii) the date at which the counterparty's performance is complete. The Company recognized consulting expenses and a corresponding increase to additional paid-in~~-capital~~ ~~related to stock issued for services. For agreements requiring future services,~~ the ~~consulting expense is to be recognized ratably over the requisite service period~~Note.

~~F-11~~During June 2015, the Company issued 87,564 shares of common stock to a corporation for conversion of $400 principal and $38 accrued interest related to a Note. These shares were valued at $0.005 per share, the conversion price as stated in the Note.

~~(Loss)~~During ~~Per~~September ~~Share~~2015, the Company issued 88,438 shares of ~~Common~~common ~~Stock~~stock to a corporation for conversion of $400 principal and $42 accrued interest related to a Note. These shares were valued at $0.005 per share, the conversion price as stated in the Note.

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be antiF-~~dilutive~~10 ~~for~~Table ~~periods~~Of presented. Except as noted below, the Company has not issued any options or warrants to date. At December 31, 2015, the total shares issuable upon conversion of convertible notes payable would be approximately 2,327,352 shares of the Company's common stock.Contents

~~Inventory~~During November 2015, the Company issued 89,020 shares of common stock to a corporation for conversion of $400 principal and $45 accrued interest related to a Note. These shares were valued at $0.004 per share, the conversion price stated in the Note.

~~Inventory~~During isDecember ~~stated~~2015, at the ~~lower~~Company ofissued ~~cost (FIFO: first-in~~111,864 ~~first-out)~~shares orof ~~market,~~common ~~and~~stock ~~includes~~to ~~finished~~a ~~goods.~~corporation ~~The~~for ~~cost~~conversion of ~~finished~~$500 ~~goods~~principal ~~includes the cost of packaging supplies, direct~~ and ~~indirect~~$59 ~~labor~~accrued ~~and~~interest ~~other~~related ~~indirect~~to ~~manufacturing~~a ~~costs~~Note. AsThese ofshares ~~December~~were ~~31,~~valued ~~2015~~at ~~and 2014, the Company had inventory of~~ $~~8,370~~0.07 ~~and~~per $0share, ~~respectively,~~the ~~with~~conversion noprice ~~allowance~~stated ~~for~~in ~~obsolescence~~the Note.

~~Recent~~During February ~~Issued~~2016, ~~Accounting~~the ~~Standards~~Company issued 90,094 unregistered shares of common stock to a corporation for conversion of $400 principal and $51 accrued interest related to a Note. These unregistered shares were valued at $0.005 per share, the fixed conversion price stated in the Note.

~~There~~During June ~~were~~2016, ~~updates~~the ~~recently~~Company issued 130,000 ~~most~~unregistered shares of ~~which~~common ~~represented~~stock ~~technical corrections~~ to ~~the~~a ~~accounting~~corporation ~~literature~~for orconversion ~~application~~of to$845 ~~specific~~of ~~industries~~accrued ~~and~~interest ~~are~~related ~~not~~to ~~expected~~a toNote. ~~have~~These aunregistered ~~material~~shares ~~impact~~were onvalued ~~the~~at ~~Company's~~$0.0065 ~~financial~~per ~~position~~share, ~~results~~the offixed ~~operations~~conversion orprice ~~cash~~stated ~~flows~~in the Note.

~~NOTE~~During June 32016, -the ~~STOCKHOLDERS'~~Company ~~DEFICIT~~issued 81,250 unregistered shares of common stock to a corporation for conversion of $650 accrued interest related to a Note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the Note.

~~The~~During August ~~Company~~2016, ~~was~~the ~~established~~Company ~~with~~issued ~~one~~129,358 ~~class~~unregistered shares of ~~stock,~~ common stock –to ~~75,000,000 shares authorized at~~ a ~~par~~corporation ~~value~~for conversion of $~~0.001. On June 30~~1,000 ~~2010,~~principal ~~the~~and ~~authorized~~$35 ~~shares~~accrued ~~were~~interest ~~increased~~related to ~~90,000,000~~a Note. InThese ~~October~~unregistered ~~2012,~~shares ~~the~~were ~~Company~~valued ~~increased~~at ~~the authorized common shares to 200,000,000~~$0.008 Inper ~~November 2014~~share, the ~~Company~~conversion ~~established~~price astated ~~second~~in ~~class~~the ~~of stock – 1,000 shares of preferred stock with no par value~~Note.

AsDuring September ~~of December 31~~2016, ~~2015~~the ~~and~~Company ~~2014,~~issued 2121,~~451,888~~483 ~~and~~unregistered ~~1,309,825~~ shares of ~~the Company's~~ common stock ~~and~~to ~~1,000~~a ~~and~~corporation ~~1,000~~for ~~shares~~conversion of ~~the~~$950 ~~Company's~~principal ~~preferred~~and ~~stock~~$22 accrued interest related to a Note. These unregistered shares were ~~issued~~valued ~~and~~at ~~outstanding~~$0.008 per share, ~~respectively~~the fixed conversion price stated in the Note.

~~Issuances~~During October ~~pursuant~~2016, the Company issued 134,881 unregistered shares of common stock to ~~Conversions~~a corporation for conversion of $1,050 principal and $29 accrued interest related to a Note. These unregistered shares were valued at $0.008 per share, the fixed conversion price stated in the Note.

During November ~~January 2014~~2016, ~~a promissory note was converted into unregistered shares of~~ the Company's ~~common~~issued ~~stock. The amount totaled $12~~148,~~849~~319 ~~including interest was converted into 17,132~~ unregistered shares of ~~the Company's~~ common stock atto ~~$0.75~~a ~~per~~corporation ~~share,~~for ~~the~~ conversion ~~price~~of ~~as stated in the convertible promissory note. On January 6~~$1,150 ~~2014,~~principal ~~the~~and ~~Company agreed to modify the terms of this~~ $~~12,500~~37 ~~convertible~~accrued ~~promissory~~interest ~~notes~~related ~~dated~~to ~~May~~a ~~27, 2013~~Note. ~~The~~These ~~conversion~~unregistered ~~rate~~shares ~~was~~were ~~reduced~~valued ~~from~~at $~~5.00 per share to $~~0.75008 per share., ~~The~~the ~~Company~~fixed ~~recognized~~conversion aprice ~~loss~~stated onin ~~extinguishment of $14,562 resulting from~~ the ~~debt modification~~Note.

~~During~~Issuances ~~March~~pursuant ~~2014,~~to a promissory note was partially converted into unregistered shares of the Company's common stock. The amount totaled $4,000 was converted into 16,000 unregistered shares of the Company's common stock at $0.25 per share, the conversion price as stated in the convertible promissory note. agreements

~~F-12~~During February 2015, the Company issued 70,867 unregistered shares of the Company’s common stock as compensation to the Company’s chairman of the board. The shares were valued at $0.08467 per share or $6,000.

During ~~March~~April ~~2014~~2015, athe ~~promissory~~Company ~~note~~issued ~~was~~50,000 ~~converted into~~ unregistered shares of the Company'’s common stock. ~~The~~in ~~amount~~final ~~totaled~~settlement ~~$13,151~~of ~~including~~a ~~interest~~consulting ~~was~~agreement. ~~converted~~The ~~into 13,171 unregistered~~ shares ofwere ~~the~~valued ~~Company's common stock~~ at $~~0.999 per share~~1, ~~the conversion price as stated in the convertible promissory note~~787.

During ~~January~~May 2015, the Company issued 58100,~~092~~000 unregistered shares of the Company’s common stock toin afinal ~~corporation~~settlement ~~for conversion~~ of ~~$250~~an ~~principal~~outstanding ~~and $40 accrued interest related to a Note~~debt. ~~These~~The shares were valued at $~~0.005 per share~~22, ~~the conversion price as stated in the Note~~775.

During ~~February~~June 2015, the Company issued ~~177~~10,~~072~~000 unregistered shares of the Company’s common stock toas acompensation ~~corporation for conversion of $886 in principal and accrued interest related~~ to a ~~Note~~consultant. ~~These~~The shares were valued at $0500.~~005 per share, the conversion price as stated in the Note.~~

During ~~March~~November 2015, the Company’s issued ~~162~~50,~~264~~000 unregistered shares of the Company’s common stock toas acompensation ~~corporation for conversion of $541 in principal and accrued interest related~~ to a ~~Note~~consultant. These shares were valued at $0.~~005~~07 per share, ~~the~~or ~~conversion price as stated in the Note~~$3,500.

During ~~April~~July ~~2015~~2016, the Company issued 8625,~~882~~000 unregistered shares of the Company’s common stock toas ~~a corporation for conversion of $400 principal and $40 accrued interest related to Note~~compensation. ~~These~~The shares were valued at $~~0.005 per share~~1, ~~the conversion price as stated in the Note~~875.

~~During~~F-11 ~~June~~Table ~~2015,~~Of the Company issued 87,564 shares of common stock to a corporation for conversion of $400 principal and $38 accrued interest related to a Note. These shares were valued at $0.005 per share, the conversion price as stated in the Note.Contents

~~During~~NOTE ~~September~~4 ~~2015,~~- ~~the~~NOTES Company issued 88,438 shares of common stock to a corporation for conversion of $400 principal and $42 accrued interest related to a Note. These shares were valued at $0.005 per share, the conversion price as stated in the Note.PAYABLE

~~During~~Notes ~~November 2015~~payable, ~~the Company issued 89,020 shares of common stock to a corporation for conversion of $400 principal and $45 accrued interest~~ related ~~to a Note. These shares were valued at $0.004 per share, the conversion price stated in the Note.~~party:

~~During~~On ~~December~~May ~~2015~~1, 2016, the Company issued ~~111~~a $35,~~864~~000 ~~shares~~note ~~of common stock~~ to a corporation ~~for~~owned ~~conversion~~by ofthe ~~$500~~Company’s ~~principal~~CEO. ~~and~~The ~~$59~~loan ~~accrued~~bears interest ~~related~~at to24% aper ~~Note.~~annum ~~These~~and ~~shares~~has ~~were~~a ~~valued~~maturity atdate ~~$0.07~~of ~~per~~December ~~share~~31, ~~the~~2016. ~~conversion~~$35,000 ~~price~~remains ~~stated~~outstanding inas ~~the~~of ~~Note~~December 31, 2016.

~~Issuances~~On ~~pursuant~~March 11, 2016, the Company issued a $35,000 note to ~~Agreements~~a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of July 11, 2016. On July 29, 2016, the loan was repaid in full.

~~During~~Notes March 2014, the Company signed an agreement with a firm to provide strategic business development activities for the Company. The firm will be compensated with 7,200 unregistered shares of the Company's common stock payable in increments of 600 shares per month for twelve (12) months starting on April 1, 2014. During 2014, the Company issued 7,200 unregistered shares of the Company's common stock, which were valued at $0.52 per share or $3,732 to fully satisfy the March 2014 agreement. Compensation was calculated at the fair market value of the shares at the date earned. :

~~F-13~~On September 15, 2016, the Company issued a $5,000 note to a corporation. The loan bears interest at 12% per annum and is payable on demand. $5,000 remains outstanding at December 31, 2016.

On ~~June~~May 2718, ~~2014~~2016, the Company ~~signed~~issued a ~~one-year consulting agreement with an individual to provide product marketing~~$30, ~~endorsement and spokesperson services for the Company. The agreement began on May 10, 2014 and expires on May 10, 2015. The consultant will be compensated with 5,~~000 ~~shares~~note ofto ~~the~~a ~~Company's common stock~~corporation. ~~These shares were issued in July 2014.~~ The ~~shares~~loan ~~were~~bears ~~valued~~interest at ~~$0.65~~24% per ~~share~~annum orand ~~$3,250.~~has ~~Compensation~~a ~~was~~maturity ~~calculated~~date ~~at the fair market value~~ of ~~the~~July ~~shares at the date earned. In addition~~18, ~~the consultant may purchase 50,000 shares of the Company's common stock at an exercise price of $0~~2016.~~025~~ ~~per~~On ~~share~~July ~~each quarter ending May 10~~21, ~~2015 (an aggregate of 200~~2016,~~000~~ ~~shares). Options were valued using~~ the ~~Black~~loan ~~Scholes~~was ~~Method,~~repaid ~~resulting~~ in ~~a value of $103,700 of which $51,850 and $51,850 have vested and expense recognized in year 2015 and 2014, respectively~~full. ~~The weighted average assumptions made in calculating the fair values of options granted during the years ended December 31, 2015 and 2014 are as follows:~~

	Years Ended December 31,
	2015		2014
Expected volatility		–		197.1	%
Expected dividend yield		–		–
Risk-free interest rate		–		0.86	%
Expected term (in years)		–		3.0

Convertible notes payable, related party

~~During~~The ~~February~~Company ~~2015~~consolidated 18 separate convertible promissory notes of various principal amounts and fixed conversion prices, ~~the~~all ~~Company~~bearing ~~issued~~5% 70interest per annum,~~867~~ ~~unregistered~~issued ~~shares~~to ofa corporation owned by the Company'’s ~~common~~CEO ~~stock~~during asthe ~~compensation~~period tofrom ~~the~~August ~~Company's~~4, ~~chairman~~2014 through April 1, 2016, into a single convertible promissory note of ~~the~~$112,157, ~~board.~~bearing ~~The~~5% ~~shares~~interest ~~were~~per ~~valued~~annum atwith a pro-rata fixed conversion price of $0.~~08467~~011, ~~per~~plus ~~share~~$5,939 oraccrued interest not subject to additional interest. The consolidation was for the purposes of administrative simplification and no inducement nor benefit was given to the corporation owned by the Company’s CEO. The current net note balance is $6112,~~000~~157.

~~During~~Convertible ~~April~~notes ~~2015, the Company issued 50,000 unregistered shares of the Company's common stock in final settlement of a consulting agreement. The shares were valued at $1,787.~~payable:

~~During~~The ~~May~~Company ~~2015~~consolidated 20 separate convertible promissory notes of various principal amounts and fixed conversion prices, ~~the~~all ~~Company~~bearing 5% interest per annum, issued ~~100~~to corporation during the period from August 2,~~000~~ ~~unregistered~~2013 ~~shares~~through April 1, 2016, into a single convertible promissory note of ~~the~~$169,065, ~~Company's~~bearing ~~common~~5% ~~stock~~interest inper ~~final~~annum ~~settlement~~with a pro-rata fixed conversion price of an$0.008, ~~outstanding~~plus ~~debt~~$12,516 accrued interest not subject to additional interest. The ~~shares~~consolidation ~~were~~was ~~valued~~for atthe purposes of administrative simplification and no inducement nor benefit was given to the corporation. The current net note balance is $22164,~~775~~670.

~~During~~On ~~June~~December ~~2015~~10, 2013, the Company issued ~~10,000~~a ~~unregistered~~convertible ~~shares~~note ofto ~~the~~an ~~Company's~~individual. ~~common~~The ~~stock~~loan asbears ~~compensation~~interest toat 5% per annum, has a ~~consultant~~fixed conversion price of $0.015 ~~The~~and ~~shares~~a ~~were~~maturity ~~valued~~date atof June 10, 2014. $~~500~~3,000 remains outstanding at December 31, 2016.

~~During~~Other ~~November~~notes ~~2015, the Company's issued 50,000 unregistered shares of the Company's common stock as compensation to a consultant. These shares were valued at $0.07 per share or $3,500.~~payable:

~~NOTE~~On 4December –10, ~~NOTES~~2013, ~~PAYABLE~~the Company issued a convertible note to an individual. The loan bears interest at 5% per annum, has a fixed conversion price of $0.015 and a maturity date of June 10, 2014. $5,000 remains outstanding at December 31, 2016.

On ~~April~~June 2011, ~~2012~~2013, the Company issued athree ~~$2,500~~ convertible ~~note~~notes to athree ~~corporation~~corporations. The ~~loan~~loans ~~bears~~bear interest at 5% ~~and~~per ~~has~~annum awith ~~maturity~~fixed ~~date~~conversion ofprices ~~October 20, 2012. In addition, at any time, the holder may convert the note into shares~~ of ~~the Company's common stock at an exercise price of~~ $0.~~009~~0065 per share. After the due date, the interest rate on the convertible note increased to 15%. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and ~~the~~maturity ~~fair~~dates ~~market value~~ of ~~the~~August ~~Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $2~~11,~~083,~~ ~~and was recorded as debt discount~~2013. ~~The debt discount was amortized through the term of the note. The unpaid balance including accrued interest was~~ $318,~~391~~377 ~~and~~remains ~~$3,016~~outstanding at December 31, ~~2014 and December 31, 2013, respectively~~2016. ~~The Company is not compliant with the repayment terms of the note.~~

~~F-14~~On January 25, 2013, the Company issued a $12,000 note to an individual. $6,000 remains outstanding at December 31, 2016.

On ~~May~~April 1020, 2012, the Company issued a ~~$2,600~~ convertible note to ~~William~~an ~~Gallagher, the Company's former CEO~~individual. The loan bears interest at 5% ~~and~~per annum, has a ~~maturity~~fixed ~~date~~conversion ~~of November 10, 2012. In addition, at any time, William Gallagher may convert the note into shares of the Company's common stock at an exercise~~ price of $0.009 per share. After the due date, the interest rate on the convertible note increases to 15%. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and ~~the~~a ~~fair~~maturity ~~market value of the Company's common stock into on the~~ date of ~~issuance.~~October ~~The fair value of the conversion option in connection with the note on the date of issuance aggregated $1~~20,~~733,~~ ~~and was recorded as debt discount~~2012. ~~The debt discount was amortized through the term of the note. During June and July 2013~~$2,500 ~~the~~remains ~~Company~~outstanding ~~paid~~at ~~the~~December ~~principal and interest balance of $2~~31,~~909~~ ~~to William Gallagher~~2016.

OnAt ~~May~~December 2731, ~~2013~~2016, ~~the~~accrued ~~Company issued a $12,500 convertible note to a corporation. The loan bears~~ interest at 5% and has a maturity date of November 27, 2013. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $2.50 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on ~~the~~all ~~date~~notes ~~of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $12,500,~~ and ~~was recorded as debt discount. The debt discount was amortized through the term of the note. On January 6, 2014, the Company agreed to modify the terms of this $12,500~~ convertible ~~promissory~~ notes ~~dated~~amounted ~~May 27, 2013. The conversion rate was reduced from $2.50 per share~~ to $~~0.75 per share. During January 2014~~38, ~~$12,849 including interest was converted into 17,132 unregistered shares of the Company's common stock at $0~~631.~~75 per share to fully satisfy the promissory note. The unpaid balance including accrued interest was $12,865 at December 31, 2013.~~

OnF-12 ~~June~~Table ~~11,~~Of 2013, the Company issued a $6,500 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of August 11, 2013. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $2,500, and was recorded as debt discount. The debt discount was amortized through the term of the note. The unpaid balance including accrued interest was $7,001 and $6,676 at December 31, 2014 and December 31, 2013, respectively. The Company is not compliant with the repayment terms of the note.Contents

OnNOTE ~~June 11, 2013, the Company issued a $6,222 convertible note to a corporation. The loan bears interest at~~ 5% ~~and~~- ~~has~~PROVISION aFOR ~~maturity~~INCOME date of August 11, 2013. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $2,393, and was recorded as debt discount. The debt discount was amortized through the term of the note. The unpaid balance including accrued interest was $6,702 and $6,391 at December 31, 2014 and December 31, 2013, respectively. The Company is not compliant with the repayment terms of the note.TAX

OnDeferred ~~April~~income 8,taxes ~~2014,~~are ~~the~~determined ~~Company~~using ~~issued~~the aliability ~~$21,000~~method ~~convertible~~for ~~note to a corporation. The loan bears interest at 8% and has a maturity date of October 8, 2014. On March 12, 2015,~~ the ~~repayment~~temporary ~~term~~differences ~~were~~between ~~extended to December 31, 2015. In addition, at any time,~~ the ~~holder~~financial ~~may~~reporting ~~convert~~basis ~~the~~and ~~note~~income ~~into~~tax ~~shares~~basis of the Company'’s ~~common~~assets ~~stock~~and atliabilities. anDeferred ~~exercise~~income ~~price~~taxes ofare ~~$.0065~~measured ~~per~~based ~~share.~~on ~~The Company calculated~~ the ~~fair~~tax ~~value~~rates ofexpected ~~the~~to ~~beneficial~~be ~~conversion~~in ~~feature~~effect aswhen the ~~difference~~temporary ~~between~~differences ~~the~~are ~~conversion~~included ~~price~~in ~~and~~ the ~~fair market value of the~~ Company'’s ~~common~~tax ~~stock into on the date of issuance~~return. ~~The~~Deferred ~~fair~~tax ~~value~~assets ofand ~~the~~liabilities ~~conversion~~are ~~option~~recognized inbased ~~connection with the note~~ on ~~the~~anticipated ~~date~~future oftax ~~issuance~~consequences ~~aggregated~~attributable ~~$21,000,~~to ~~and~~differences ~~was~~between ~~recorded~~financial asstatement ~~debt~~carrying ~~discount.~~amounts ~~The debt discount is amortized through the term~~ of ~~the~~assets ~~note.~~and ~~The~~liabilities ~~unpaid~~and ~~balance~~their ~~including~~respective ~~accrued~~tax ~~interest was $22,496 at December 31, 2014~~bases.

~~F-15~~The income tax provision (benefit) consists of the following:

On May 8, 2014, the Company issued a $21,000 convertible note to a corporation. The loan bears interest at 8% and has a maturity date of November 8, 2014. On March 12, 2015, the repayment term were extended to December 31, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $14,538, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance including accrued interest was $22,365 at December 31, 2014.

	December 31,
	2016			2015
Federal
Current	$	-		$	-
Deferred		(2,060,384	)		(1,926,274	)

State and local
Current		–			–
Deferred		–			–
		(2,060,384	)		(1,926,274	)
Change in valuation allowance		2,060,384			1,926,274
Income tax provision (benefit)	$	-		$	-

OnAt ~~June~~December 2331, ~~2014~~2016 and 2015, the Company ~~issued~~had a ~~$10,000~~net ~~convertible~~operating ~~note~~loss to(“NOL’s”) acarry ~~corporation.~~forward ~~The~~in ~~loan~~the ~~bears~~amount ~~interest at 5% and has a maturity date~~ of ~~December 23~~$6,243,587 ~~2014.~~and ~~On March 12~~$5, ~~2015~~837, ~~the repayment term were extended to December 31~~194, ~~2015. In addition~~respectively, atavailable ~~any~~to ~~time,~~offset ~~the~~future ~~holder~~taxable ~~may~~income. ~~convert~~The ~~the note into shares of the~~ Company's ~~common~~established ~~stock~~valuation atallowances anequal ~~exercise~~to ~~price of $.0065 per share. The Company calculated~~ the ~~fair~~full ~~value~~amount of the ~~beneficial~~deferred ~~conversion~~tax ~~feature~~assets asdue ~~the~~to ~~difference between~~ the ~~conversion~~uncertainty ~~price~~of ~~and~~ the ~~fair~~utilization ~~market value~~ of the ~~Company's~~operating ~~common~~losses ~~stock~~in ~~into~~future ~~on the date of issuance~~periods. The ~~fair~~Company ~~value~~has ofnot ~~the~~filed ~~conversion~~its ~~option~~federal intax ~~connection~~returns ~~with~~from ~~the~~inception ~~note~~through onfiscal ~~the~~2013 ~~date~~and ~~of issuance aggregated $10~~therefore,~~000,~~ ~~and~~the ~~was~~NOL’s ~~recorded~~will asnot ~~debt~~be ~~discount.~~available ~~The~~to ~~debt~~offset ~~discount~~future istaxable ~~amortized~~income ~~through~~until the ~~term~~outstanding oftax ~~the~~returns ~~note.~~are ~~The~~filed ~~individual~~with ~~contributed~~the ~~$5,000~~respective infederal ~~June~~tax ~~2014 and $5,000 in July 2014~~authorities. ~~The unpaid balance was $10,250 at December 31, 2014.~~

OnA ~~July~~reconciliation ~~11,~~of ~~2014,~~ the Company’s ~~issued~~effective atax ~~$10,000~~rate ~~convertible~~as ~~note to~~ a ~~corporation.~~percentage ~~The~~of ~~loan~~income ~~bears~~before ~~interest~~taxes ~~at 5%~~ and ~~has~~federal astatutory ~~maturity~~rate ~~date~~for ~~of January 11, 2015. On March 12, 2015,~~ the ~~repayment~~periods ~~term~~ended ~~were extended to~~ December 31, ~~2015.~~2016 In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and ~~the~~2015 fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $10,000, and was recorded as debt discount. The debt discount is ~~amortized~~summarized ~~through the term of the note~~below. ~~The unpaid balance was $10,229 at December 31, 2014.~~

On August 4, 2014, the Company issued an $8,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of February 4, 2015. On March 12, 2015, the repayment term were extended to December 31, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $8,000, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $8,167 at December 31, 2014.

	2016			2015
Federal statutory rate		(34.0	)%		(34.0	)%
State income taxes, net of federal benefits		0.0			0.0
Valuation allowance		34.0			34.0

OnF-13 ~~August~~Table 4,Of 2014, the Company issued an $8,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of February 4, 2015. On March 12, 2015, the repayment term were extended to December 31, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0065 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $8,000, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $8,167 at December 31, 2014. Contents

FNOTE 6 -16 INTELLECTUAL PROPERTY

On ~~September~~October 31, 2014, the Company ~~issued~~entered ainto ~~$6,000~~an ~~convertible~~Intellectual ~~note~~Property toPurchase aAgreement ~~corporation~~to ~~owned~~purchase by the ~~Company's~~“Glucose ~~CEO.~~Health ~~The~~Natural ~~loan~~Blood ~~bears~~Sugar ~~interest~~Maintenance” atproduct 5%for ~~and~~the ~~has~~purchase aprice ~~maturity date~~ of ~~March 3~~300,000 ~~2015.~~unregistered Onshares ~~March~~of ~~12, 2015,~~ the ~~repayment~~Company’s ~~term~~common ~~were~~stock ~~extended~~from toa ~~December~~company ~~31,~~beneficially ~~2015.~~owned Inby ~~addition,~~the atCompany’s ~~any time~~CEO, ~~the~~Murray ~~holder~~Fleming. ~~may~~The ~~convert the note into~~ shares ofwere ~~the~~recorded ~~Company's common stock~~ at antheir ~~exercise~~par ~~price~~value of $0.~~005~~001 per share. ~~The~~or ~~Company~~$300, ~~calculated~~valued ~~the~~at ~~fair value of~~ the ~~beneficial~~nominal ~~conversion~~historical ~~feature~~cost asof the ~~difference~~related ~~between~~party ~~the~~seller. ~~conversion~~All ~~price~~assets ~~and~~other ~~the~~than ~~fair market value of~~ the ~~Company's~~intellectual ~~common~~property ~~stock~~had ~~into~~a ~~on the date of issuance. The~~ fair value of ~~the~~$0, ~~conversion option in connection~~ with the ~~note~~intellectual onproperty ~~the~~valued ~~date~~at ~~of issuance aggregated~~ $~~6,000,~~240 ~~and~~net ~~was recorded as debt discount. The debt discount is amortized through the term~~ of ~~the note. The unpaid balance was~~ $~~6,100~~60 atof ~~December~~accumulated ~~31, 2014~~amortization.

OnNOTE ~~September~~7 3,- 2014, the Company issued a $6,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of March 3, 2015. On March 12, 2015, the repayment term were extended to December 31, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.005 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $6,000, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $6,100 at December 31, 2014. COMMITMENTS/CONTINGENCIES

OnFrom ~~October~~time ~~1, 2014, the Company issued a $4,625 convertible note~~ to ~~a corporation. The loan bears interest at 5% and has a maturity date of April 1, 2015. In addition, at any~~ time, ~~the~~we ~~holder~~ may ~~convert~~be ~~the~~involved ~~note~~in ~~into~~litigation ~~shares~~in of the ~~Company's~~ordinary ~~common~~course ~~stock at an exercise price~~ of $business.~~005~~ ~~per~~We ~~share.~~are ~~The~~currently ~~Company~~not ~~calculated~~involved ~~the~~in ~~fair~~any ~~value~~litigation ofthat ~~the~~we ~~beneficial~~believe ~~conversion~~could ~~feature~~have asa ~~the~~material ~~difference~~adverse ~~between~~effect ~~the conversion price and the fair market value of the Company's common stock into~~ on ~~the~~our ~~date~~financial ofcondition ~~issuance.~~or ~~The~~results ~~fair value~~ of ~~the conversion option in connection with the note on the date of issuance aggregated $2,405, and was recorded as debt discount~~operations. ~~The debt discount is amortized through the term of the note. The unpaid balance was $4,683 at December 31, 2014.~~

OnOperating October 1, 2014, the Company issued a $4,625 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of April 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.005 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $2,405, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $4,683 at December 31, 2014.Agreements

On ~~October~~January 158, ~~2014~~2016, ~~the~~we ~~Company~~signed ~~issued~~ a ~~$3,600~~Supplier ~~convertible~~Agreement note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of April 15, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.004 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with ~~the~~Wal-Mart ~~note~~Stores ~~on the date of issuance aggregated $0, and no debt discount was recorded~~Inc. ~~The debt discount is amortized through the term~~ of ~~the~~Bentonville ~~note~~AR. ~~The unpaid balance was $3,638 at December 31, 2014.~~

On ~~November~~January 425, ~~2014~~2016, ~~the~~we ~~Company~~signed ~~issued~~ a ~~$6,850~~Contract ~~convertible~~Manufacturing ~~note~~Agreement to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of May 4, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0025 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with ~~the~~Natural ~~note~~Solution onLabs ~~the date~~ of ~~issuance aggregated $4~~Gravette,~~110,~~ ~~and was recorded as debt discount~~AR. ~~The debt discount is amortized through the term of the note. The unpaid balance was $6,907 at December 31, 2014.~~

~~F-17~~On February 3, 2016, we signed a Product Liability Insurance Agreement with Western Heritage Insurance.

On ~~November~~April 412, ~~2014~~2016, ~~the~~we ~~Company~~signed ~~issued~~ a ~~$6,850~~Warehousing/Logistics ~~convertible~~agreement note to a corporation. The loan bears interest at 5% and has a maturity date of May 4, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.0025 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with ~~the~~RR/NWA ~~note~~Logistics ~~on the date~~ of ~~issuance aggregated $4~~Rogers,~~110,~~ ~~and was recorded as debt discount~~AR. ~~The debt discount is amortized through the term of the note. The unpaid balance was $6,907 at December 31, 2014.~~

OnNOTE ~~November~~ 8, ~~2014,~~- ~~the~~SUBSEQUENT Company issued a $2,962 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of May 8, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.00475 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $2,837, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $2,981 at December 31, 2014.EVENTS

~~On December 1, 2014, the Company issued a $5,000 convertible note to a corporation~~None. The loan bears interest at 5% and has a maturity date of June 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.09 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $5,000, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $5,021 at December 31, 2014.

OnF-14 ~~December~~Table 1,Of 2014, the Company issued a $5,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of June 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $.09 per share. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock into on the date of issuance. The fair value of the conversion option in connection with the note on the date of issuance aggregated $5,000, and was recorded as debt discount. The debt discount is amortized through the term of the note. The unpaid balance was $5,021 at December 31, 2014.Contents

On January 7, 2015, the Company issued a $4,315 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of July 7, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.04 per share.

On January 8, 2015, the Company issued an $8,750 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of July 8, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.04 per share.

On January 8, 2015, the Company issued an $8,750 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of July 8, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.04 per share.

On February 2, 2015, the Company issued a $12,500 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of August 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.031 per share.

F-18

On February 2, 2015, the Company issued a $12,500 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of August 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.031 per share.

On March 2, 2015, the Company issued a $10,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of September 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On March 2, 2015, the Company issued a $10,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of September 2, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On April 1, 2015, the Company issued a $5,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of October 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.020 per share.

On April 1, 2015, the Company issued a $5,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of October 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.020 per share.

On May 1, 2015, the Company issued a $5,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of November 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On May 1, 2015, the Company issued a $5,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of November 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On June 1, 2015, the Company issued a $4,000 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of December 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On June 1, 2015, the Company issued a $4,000 convertible note to a corporation owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of December 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On July 1, 2015, the Company issued a $9,090 convertible note to a corporation. The loan bears interest at 5% and has a maturity date of December 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On July 1, 2015, the Company issued a $8,305 convertible note to a company owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of December 1, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.025 per share.

On December 10, 2015, the Company issued a $2,500 convertible note to a company owned by the Company's CEO. The loan bears interest at 5% and has a maturity date of June 10, 2015. In addition, at any time, the holder may convert the note into shares of the Company's common stock at an exercise price of $0.03 per share.

F-19

NOTE 5 - PROVISION FOR INCOME TAXES

Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company's assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company's tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.

The income tax provision (benefit) consists of the following:

	December 31,
	2015			2014
Federal
Current	$	-		$	-
Deferred		(1,926,274	)		(1,894,184	)
State and local
Current		–			–
Deferred		–			–
		(1,926,274	)		(1,894,184	)
Change in valuation allowance		1,926,274			1,894,184
Income tax provision (benefit)	$	-		$	-

At December 31, 2015 and 2014, the Company had a net operating loss ("NOL's") carry forward in the amount of $5,837,194 and $5,571,130, respectively, available to offset future taxable income. The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods. The Company has not filed its federal tax returns since inception and therefore, the NOL's will not be available to offset future taxable income until the tax returns are filed with the respective federal tax authorities.

A reconciliation of the Company's effective tax rate as a percentage of income before taxes and federal statutory rate for the periods ended December 31, 2015 and 2014 is summarized below.

	2015			2014
Federal statutory rate		(34.0	)%		(34.0	)%
State income taxes, net of federal benefits		0.0			0.0
Valuation allowance		34.0			34.0

F-20

NOTE 6 - INTELLECTUAL PROPERTY

On September 26, 2011, the Company acquired all the assets and intellectual property rights of Type2 Defense, a natural dietary supplement. The acquisition of Type2 Defense was paid for by the issuance of 40,000 shares of the Company's common stock. The shares were valued at $200,000 or $5.00 per share based on the closing price of the Company's common stock on September 26, 2011. The agreement also included the issuance of 20,000 shares of the Company's common stock upon achieving certain operational milestones and an additional 20,000 shares of Company's common stock upon reaching 1,500 customers. On November 4, 2011, an advance of 1,200 shares of the Company's common stock related to the reaching of the 1,500 customers milestone in the original agreement was approved by the board of directors. The shares were valued at $5.50 per share or $6,600. The issuance of 20,000 shares of the Company's common stock upon reaching 1,500 customers, was reduced by the advance to 1,200 shares. During June 2013, the Company achieved the operational milestones as specified in the September 26, 2011 Type2 Defense acquisition agreement. On June 18, 2013, the Company issued 20,000 shares to the Company's former CEO for the Type2 Defense product meeting the operational milestones. The shares were valued at $7.50 per share or $150,000 and included as stock based compensation in the statement of operation in 2011. In addition, on June 18, 2013, an advance of 10,000 shares of the Company's common stock related to reaching of 1,500 customers' milestone in the original agreement was approved by the board of directors and issued to William Gallagher, the Company's former CEO. The shares were valued at $7.50 per share or $75,000 and included as stock based compensation in the accompanying statement of operation in 2013.

Since the Company has not been able to generate substantial revenues from the Type2 Defense product since June 2013 and has produced only nominal sales of the product in 2014, the Company elected to write-off the $200,000 intellectual property for Type2 Defense as impaired. In addition, as the Company elected to terminate development of the Type2 Defense product in October 2014, the Company wrote down its inventory to -0- as of December 31, 2014 and no further shares will be issued or compensation paid under the aforementioned agreement with the Company's former CEO.

On October 1, 2014, the Company entered into an Intellectual Property Purchase Agreement to purchase the "Glucose Health Natural Blood Sugar Maintenance" product for the purchase price of 300,000 unregistered shares of the Company's common stock from a company beneficially owned by the Company's CEO, Murray Fleming. The shares were recorded at their par value of $0.001 per share or $300, valued at the nominal historical cost of the related party seller.

All assets other than the intellectual property had a fair value of $0, with the intellectual property valued at $300.

NOTE 7 - SUBSEQUENT EVENTS

On January 27, 2016 the Company notified OTC Markets, Inc. of its intention to not renew its OTCQB service. The Company filed Form 8-A12G in fiscal 2015 registering a class of securities under the 1934 Securities Exchange Act. Accordingly, the Company does not make use of the OTC Markets Disclosure and News Service and instead files its periodic and annual reports and audited financial statements with the Securities and Exchange Commission.

On February 4, 2016, the Company's Chief Executive Officer and Chief Financial Officer, Murray Fleming, was appointed to the Board of Directors of Glucose Health, Inc. ("Company"). On February 5, 2016, James Hodge resigned from the Board of Directors.

On January 6, 2016, Glucose Health, Inc. ("Company") executed a General Merchandise Supplier Agreement ("Agreement") with Wal-mart Stores, Inc. ("Customer") of Bentonville, Arkansas. On March 8, 2016, the Company received a series of material purchase orders from the Customer pursuant to this Agreement for delivery of its Glucose HealthÒ product - a natural dietary supplement formulated for persons concerned about pre-diabetes and Type-2 diabetes. The Company expects Glucose HealthÒ to be stocked and available for purchase by consumers in the "Diabetes Supplies" section of many of the Customer's pharmacy locations across the United States by early May, 2016.

F-21

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of ~~disclosure~~Disclosure ~~controls~~Controls and ~~procedures.~~Procedures

WeOur ~~maintain~~management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in ~~the~~our reports ~~that we file or submit~~ under the Securities Exchange Act of 1934 is ~~(i)~~ recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and ~~(ii)~~that ~~accumulated~~such ~~and~~information ~~communicated~~is toaccumulated by our ~~principal~~management, ~~executive~~including ~~and~~our ~~principal~~Chief ~~financial~~Executive ~~officers~~Officer/Chief Financial Officer, to allow timely decisions regarding required disclosure. ~~Based~~in ~~upon~~accordance ~~their~~with ~~evaluation~~the definition of ~~those~~“disclosure controls and procedures” ~~performed~~in asRule 15d-15(e) under the Exchange Act of ~~December~~1934. ~~31,~~In ~~2015,~~designing and evaluating the ~~date~~disclosure ofcontrols ~~this~~and ~~report~~procedures, ~~our~~management ~~Chief~~recognized ~~Executive~~that ~~Officer~~any controls and ~~Chief~~procedures, ~~Financial~~no ~~Officer~~matter ~~concluded~~how ~~that~~well ~~our~~designed ~~disclosure~~and ~~controls~~operated, can provide only reasonable assurance of achieving the desired control objectives, and ~~procedures~~management ~~were~~necessarily ~~not~~was ~~effective~~required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

~~Management's~~At ~~annual~~the ~~report~~end onof ~~internal~~the ~~control~~period ~~over~~covered ~~financial~~by ~~reporting~~this Form 10-K, we conducted an evaluation, with the participation of our Chief Executive Officer/Chief Financial Officer. of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon the foregoing, our Chief Executive Officer/Chief Financial Officer concluded that, as of December 31, 2016, the disclosure controls and procedures of our Company were not effective to ensure that the information required to be disclosed in our Exchange Act of 1934 reports was recorded, processed, summarized and reported on a timely basis.

The Company's ~~management~~ is ~~responsible~~undertaking ~~for~~to ~~establishing~~improve ~~and~~its ~~maintaining adequate~~ internal control over financial reporting. ~~Internal~~and ~~control~~improve ~~over~~its ~~financial~~disclosure ~~reporting~~controls isand aprocedures. ~~set~~As of ~~processes~~June ~~designed by~~30, ~~or under the supervision of~~2016, awe ~~company's~~had ~~principal~~identified ~~executive~~the ~~and~~following ~~interim~~material ~~principal~~weaknesses ~~financial~~which ~~officers,~~still toexist ~~provide~~through ~~reasonable assurance regarding~~ the ~~reliability~~date of ~~financial~~this ~~reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that~~report:

·We ~~pertain~~did tonot ~~the~~maintain ~~maintenance~~effective ofcontrols ~~records~~over ~~that in reasonable detail accurately and fairly reflect~~ the ~~Company's~~disclosure ~~transactions~~control ~~and~~environment. ~~dispositions~~Specifically, of the ~~Company's~~board ~~assets;~~does ·not ~~provide~~currently ~~reasonable~~have ~~assurance~~a ~~that~~director ~~The~~who ~~Company's~~qualifies ~~transactions are recorded~~ as ~~necessary~~an toaudit ~~permit~~committee ~~preparation~~financial ofexpert ~~the~~as ~~Company's~~defined ~~financial statements~~ in ~~accordance~~Item ~~with~~407(d)(5)(ii) ~~generally~~of ~~accepted~~Regulation ~~accounting~~S-K. ~~principles~~Additionally, ~~and~~controls ~~that~~related ~~receipts~~to ~~and~~the ~~expenditures~~segregation of ~~the~~certain ~~Company~~duties ~~are~~have ~~being~~not ~~made~~been ~~only~~developed inand ~~accordance~~therefore ~~with authorizations of~~ the Company's ~~management~~has ~~and~~not ~~directors;~~been ~~and~~able ·to ~~provide~~adhere ~~reasonable~~to ~~assurance~~them. ~~regarding~~For ~~prevention~~these ~~or timely detection of unauthorized acquisition~~reasons, ~~use~~management orhas ~~disposition~~determined ~~of the Company's assets~~ that ~~could~~these ~~have~~circumstances constitute a material ~~effect on the financial statements~~weakness.

Table Of Contents

Management's Annual Report on Internal Control Over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a set of processes designed by, or under the supervision of, a company’s principal executive and interim principal financial officers, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

	·	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the Company’s transactions and dispositions of the Company’s assets;
	·	provide reasonable assurance that the Company’s transactions are recorded as necessary to permit preparation of the Company’s financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company’s management and directors; and
	·	provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

21Under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer/Chief Financial Officer, the Company assessed the effectiveness of the Company’s internal control over financial reporting based on criteria established in “Internal Control-Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), as of December 31, 2016.

~~Under~~A ~~the~~material ~~supervision~~weakness ~~and~~is ~~with~~a ~~the~~control ~~participation of the Company's management~~deficiency, ~~including~~or ~~the~~combination ~~Company's~~of ~~Chief~~control ~~Executive~~deficiencies, ~~Officer~~that ~~and~~results ~~Interim~~in ~~Chief~~more ~~Financial~~than ~~Officer,~~a ~~the~~remote ~~Company~~likelihood ~~conducted~~that ana ~~assessment~~material ofmisstatement ~~the effectiveness~~ of ~~the~~annual ~~Company's~~or ~~internal~~interim ~~control over~~ financial ~~reporting~~statements ~~based~~will onnot ~~criteria~~be ~~established~~prevented inor ~~"Internal~~detected. ~~Control-Integrated~~In ~~Framework"~~connection ~~issued~~with by the ~~Committee~~assessment ofdescribed ~~Sponsoring~~above, ~~Organizations~~management ofidentified the ~~Treadway~~following ~~Commission~~control ~~(COSO),~~deficiency asthat ofrepresents material weaknesses at December 31, ~~2015.~~2016:

A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of annual or interim financial statements will not be prevented or detected. In connection with the assessment described above, management identified the following control deficiency that represents material weaknesses at December 31, 2015:

Due to the limited number of Company personnel, a lack of segregation of duties and responsibilities with respect to our cash and control over the disbursements related thereto. An essential part of internal control is for certain procedures to be properly segregated and the results of their performance are adequately reviewed. This is normally accomplished by assigning duties so that no one person handles a transaction from beginning to end and incompatible duties between functions are not handled by the same person.

As a result of this material weakness described above, management has concluded that, as of December 31, ~~2015~~2016, the Company'’s internal control over financial reporting was not effective based on the criteria in "“Internal Control-Integrated Framework"” issued by COSO. The Company intends to augment the Company'’s internal controls procedures and expand the Company'’s accounting staff. The Company intends to initiate measures to remediate and refine the Company'’s internal controls to address this identified material weakness as the Company grows and obtains a stronger cash position that would justify additional expenditures.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act of 1934) during our most recently completed quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

None.

22 Table Of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

As of the date of this Annual Report, the following table sets forth information regarding our executive officers and directors:

Name		Age		Position
Murray Fleming		5354		Chief Executive Officer, Chief Financial Officer, Sole Director

~~Murray Fleming.~~ On October 1, 2014, Murray Fleming was appointed the Company'’s Chief Executive Officer for the 24-month period ending October 1, 2016. On February 10, 2015, Mr. Fleming was appointed the Company'’s Chief Financial Officer. From 2006 to the present date, Mr. Fleming has been ~~the~~a ~~managing~~principal ~~director~~ of BTB Management, a ~~privately~~related ~~held~~party ~~investment~~and ~~company~~investor in Glucose Health, Inc. Mr. Fleming earned a Bachelor of Arts degree with ~~formal~~ concentrations in Economics & Environmental Studies from the University of Victoria in May of 1986. In addition to serving as ~~Chief~~director ~~Executive~~and ~~Officer~~officer of Glucose Health Inc., Mr. Fleming is a director of Nacel Energy Corporation ~~and serves as interim CEO, CFO and director of Vaporbrands International, Inc~~.

All directors hold office until the completion of their term of office, which is not longer than one year, or until their successors have been elected. All officers are appointed annually by the board of directors and serve at the discretion of the board. Currently, no compensation is paid to Directors.

There are no family relationships between any of our officers or directors. There are no orders, judgments, or decrees of any governmental agency or administrator, or of any court of competent jurisdiction, revoking or suspending for cause any license, permit or other authority to engage in the securities business or in the sale of a particular security or temporarily or permanently restraining any of our officers or directors from engaging in or continuing any conduct, practice or employment in connection with the purchase or sale of securities, or convicting such person of any felony or misdemeanor involving a security, or any aspect of the securities business or of theft or of any felony. Nor are any of the officers or directors of any corporation or entity affiliated with us so enjoined.

Code of Ethics. We do not currently have a Code of Ethics that applies to all employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We plan to adopt a Code of Ethics.

~~Nominating~~We ~~Committee.~~do ~~Our~~not ~~entire~~currently ~~board of directors participates in consideration of director nominees. The board will consider candidates who~~ have ~~experience as~~ a ~~board~~Code ~~member or senior officer~~ of aEthics ~~company~~that orapplies ~~who~~to ~~are~~all ~~generally recognized in a relevant field as a well-regarded practitioner~~employees, ~~faculty~~including ~~member~~our orprincipal ~~senior~~executive ~~government~~ officer~~. The board will also evaluate whether the candidates' skills and experience are complementary to the existing board's skills and experience as well as the board's need for operational~~, ~~management,~~principal financial, ~~international~~officer, ~~technological~~principal oraccounting ~~other~~officer ~~expertise.~~or ~~The~~controller, ~~board~~or ~~will~~persons ~~interview~~performing ~~candidates~~similar ~~that~~functions. ~~meet~~We ~~the~~plan ~~criteria~~to ~~and~~adopt ~~then~~a ~~select~~Code ~~nominees~~of ~~that Board believes best suit our needs~~Ethics.

~~The~~Nominating board will consider qualified candidates suggested by stockholders for director nominations. Stockholders can suggest qualified candidates for director nominations by writing to our board of directors at 609 SW 8th Street, 6th Floor, Bentonville, AR 72712. Submissions that are received that meet the criteria described above will be forwarded to the Board for further review and consideration. The Board will not evaluate candidates proposed by stockholders any differently than other candidates. Committee

23Our entire board of directors participates in consideration of director nominees. The board will consider candidates who have experience as a board member or senior officer of a company or who are generally recognized in a relevant field as a well-regarded practitioner, faculty member or senior government officer. The board will also evaluate whether the candidates' skills and experience are complementary to the existing board's skills and experience as well as the board's need for operational, management, financial, international, technological or other expertise. The board will interview candidates that meet the criteria and then select nominees that Board believes best suit our needs.

~~Audit~~The ~~Committee Financial Expert. Our~~ board ofwill ~~directors~~consider ~~does~~qualified ~~not~~candidates ~~have~~suggested anby ~~"audit~~stockholders ~~committee~~for ~~financial~~director ~~expert,"~~nominations. ~~within~~Stockholders ~~the~~can ~~meaning~~suggest ofqualified ~~such~~candidates ~~phrase~~for ~~under~~director ~~applicable~~nominations ~~regulations~~by ofwriting ~~the~~to ~~Securities~~our ~~and Exchange Commission, serving on its audit committee. The~~ board of directors ~~believes~~at ~~that~~609 ~~all~~SW ~~members~~8th ~~of its audit committee are financially literate and experienced in business matters~~Street, ~~and~~6th ~~that one or more members of the audit committee are capable of (I) understanding generally accepted accounting principles ("GAAP") and financial statements~~Floor, ~~(ii) assessing the general application of GAAP principles in connection with our accounting for estimates~~Bentonville, ~~accruals~~AR ~~and~~72712. ~~reserves,~~Submissions ~~(iii)~~that ~~analyzing and evaluating our financial statements, (iv) understanding our internal controls and procedures for financial reporting; and (v) understanding audit committee functions, all of which~~ are ~~attributes~~received ofthat anmeet ~~audit committee financial expert. However,~~ the ~~board~~criteria ofdescribed ~~directors~~above ~~believes~~will ~~that~~be ~~there~~forwarded isto ~~not any audit committee members who have obtained these attributes through~~ the ~~experience~~Board ~~specified in the SEC's definition of "audit committee financial expert." Further, like many small companies, it is difficult~~ for ~~the~~further ~~Company~~review ~~to attract~~ and ~~retain board members who qualify as "audit committee financial experts," as competition for these individuals is significant~~consideration. The ~~board~~Board ~~believes~~will ~~that its current audit committee is able to fulfill its role under SEC regulations despite~~ not ~~having~~evaluate acandidates ~~designated~~proposed ~~"audit~~by ~~committee~~stockholders ~~financial~~any ~~expert."~~differently Wethan ~~believe~~other ~~the cost related to retaining a financial expert at this time is prohibitive. Further, because of our start-up operations, we believe the services of a financial expert are not warranted.~~candidates

~~Audit~~23 ~~Committee.~~Table ~~Presently,~~Of the board of directors acts as the audit committee. The board of directors does not have an audit committee financial expert. The board of directors has not yet recruited an audit committee financial expert to join the board of directors because we have only recently commenced a significant level of financial operations.Contents

~~Item~~Audit ~~11.~~Committee ~~Executive~~Financial ~~Compensation~~Expert

~~Summary~~Our ~~Compensation~~board ~~Table~~of directors does not have an “audit committee financial expert,” within the meaning of such phrase under applicable regulations of the Securities and Exchange Commission, serving on its audit committee. The board of directors believes that all members of its audit committee are financially literate and experienced in business matters, and that one or more members of the audit committee are capable of (I) understanding generally accepted accounting principles and financial statements, (ii) assessing the general application of generally accepted accounting principles in connection with our accounting for estimates, accruals and reserves, (iii) analyzing and evaluating our financial statements, (iv) understanding our internal controls and procedures for financial reporting; and (v) understanding audit committee functions, all of which are attributes of an audit committee financial expert. However, the board of directors believes that there are not any audit committee members who have obtained these attributes through the experience specified in the Securities and Exchange Commission’s definition of “audit committee financial expert.” Further, like many small companies, it is difficult for the Company to attract and retain board members who qualify as “audit committee financial experts,” as competition for these individuals is significant. The board believes that its current audit committee can fulfill its role under Securities and Exchange Commission regulations despite not having a designated “audit committee financial expert.” We believe the cost related to retaining a financial expert at this time is prohibitive. Further, because of our start-up operations, we believe the services of a financial expert are not warranted.

~~The~~Audit table set forth below summarizes the annual and long-term compensation for services in all capacities to us payable to our chief executive officer, our other executive officers and our directors for years ended December 31, 2015 and 2014.Committee

Annual Compensation

Long Term Compensation

Awards

Name and Principal Position

Year

Salary

Bonus

Other AnnualCompensation

RestrictedStockAwards

Securities Underlying Options/SARs

PayoutsLTIPPayouts

All Other Compensation

Total Compensation

($)

(#)

($)

Murray Fleming,

2015

None

none

Chief Executive Officer,Chief Financial Officer

2014

None

227,300

(1)

227,300

James Hodge,

2014

6,000

None

11,275

(2)

17,275

Chairman of the board of directors

Thomas E. Metzger Ph.D.,

2014

None

8,700

(3)

8,700

former Chief Executive Officer,Chief Financial Officer, director (a)

William J. Gallagher,

2014

12,000

None

12,000

former Chief Executive Officer,Chief Financial Officer, director (b)

Presently, the board of directors acts as the audit committee and does not have an audit committee financial expert. The board of directors has not yet recruited an audit committee financial expert to join the board of directors because we have only recently commenced a significant level of financial operations.

~~______________~~Item 11. Executive Compensation.

~~(1)~~Summary ~~Value~~Compensation of 300,000 unregistered shares issued in October 2014 at $0.38 per share or $114,000 and 1,000 shares of unregistered shares preferred stock issued in November 2014 at $113.30 per share or $113,300, in accordance to Mr. Fleming's 24 month management consulting agreement dated September 30, 2014 and revised on November 28, 2014.Table

(2)	Value of 11,923 unregistered shares issued in April and July 2014 at $0.694 per share or $8,275 and 17,295 unregistered shares earned but not issued at $0.173 per share or $3,000, in accordance to Mr. Hodge's 12 month management consulting agreement dated April 4, 2014.
(3)	Value of 10,000 unregistered shares issued in April and July 2014 at $0.87 per share or $8,700, in accordance to Mr. Metzger's 12 month management consulting agreement dated April 4, 2014.
	(a)	Mr. Metzger resigned July 22, 2014.
	(b)	Mr. Gallagher resigned April 8, 2014.

The table set forth below summarizes the annual and long-term compensation for services in all capacities to us payable to our chief executive officer, our other executive officers and our directors for years ended December 31, 2015 and 2015.

Annual Compensation

Long Term Compensation

Awards

Name and Principal Position

Year

Salary

($)

Bonus

($)

Other Annual

Compensation

($)

Restricted

Stock

Awards

($)

Securities Underlying Options/SARs

(#)

Payouts

LTIP

Payouts

($)

All Other Compensation

Total Compensation

Murray Fleming,

2016

None

Chief Executive Officer,

Chief Financial Officer.

2015

None

~~Outstanding~~24 ~~Equity~~Table ~~Awards.~~Of Contents

AsOutstanding ofEquity ~~December 31, 2015, the following named executive officers had the following unexercised options, stock that has not vested, and equity incentive plan awards:~~Awards

	Option Awards										Stock Awards
Name	Number of Securities Underlying Unexercised Options# Exercisable		# Un-exercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Options		Option Exercise Price		Option Expiration Date		Number of Shares or Units of Stock Not Vested		Market Value of Shares or Units Not Vested		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights Not Vested		Value of Unearned Shares, Units or Other Rights Not Vested
Murray Fleming, Chief Executive OfficerChief Financial Officer		0		0		0		0		0		0		0		0		0
James Hodge, Chairman of the board of directors, interim Chief Financial Officer		0		0		0		0		0		0		0		0		0
Thomas E. Metzger PHD,former Chief Executive officer, Chief Financial Officer, director		0		0		0		0		0		0		0		0		0
William J. Gallagher former Chief Executive Officer, Chief Financial Officer, director		0		0		0		0		0		0		0		0		0

As of December 31, 2016, the following named executive officers had the following unexercised options, stock that has not vested, and equity incentive plan awards:

Option Awards

Stock Awards

Name

Number of Securities Underlying Unexercised Options

# Exercisable

# Un-exercisable

Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Options

Option Exercise Price

Option Expiration Date

Number of Shares or Units of Stock Not Vested

Market Value of Shares or Units Not Vested

Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights Not Vested

Value of Unearned Shares, Units or Other Rights Not Vested

Murray Fleming,

Chief Executive Officer,

Chief Financial Officer.

Stock Options/SAR Grants.

There are no arrangements for stock options or stock appreciation rights or similar benefits for directors or executive officers.

Long-Term Incentive Plans.

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers.

Director Compensation.

Currently, no compensation is paid to ~~Directors~~directors.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth certain information regarding the beneficial ownership of our common stock as of December 31, ~~2015~~2016, by each person or entity known by us to be the beneficial owner of more than 5% of the outstanding shares of common stock, ~~each of~~ our ~~directors~~director(s) and named executive officer(s), and all of our ~~directors~~director(s) and executive officer(s) as a group.

Title of Class	Name of Beneficial Owner	Amount and Nature ~~ofBeneficial~~of Beneficial Owner	Percent of Class
	Officers and Directors
Common Stock	Murray Fleming, CEO, CFO, ~~sole~~ director.	600,000 shares	4218.71%*
Common Stock	~~James~~All ~~Hodge,~~director(s) ~~former~~and director*named executive officer(s) as a group.	49600,~~219~~000 shares	318.51%*
Common Stock	~~All~~5% ~~directors~~ and ~~named~~greater ~~executive~~beneficial ~~officers as a group (3 persons)~~owners.	~~649,219 shares~~None	46.2%**None
Common Stock	5% and Greater Beneficial Owners	None	None

* Resigned February 5, 2016 _________________

** Figures may vary due to rounding.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. In accordance with Securities and Exchange Commission rules, shares of our common stock which may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the table are deemed beneficially owned by the optionees. Subject to community property laws, where applicable, the persons or entities named in the table above have sole voting and investment power with respect to all shares of our common stock indicated as beneficially owned by them.

2625 Table Of Contents

Changes in Control.

The following transaction resulted in "“changes in control"” as that term is defined by the provisions of Item 403(c) of Regulation S-K.

On October 1, 2014, the Company entered into an agreement and issued 300,000 unregistered shares of the Company'’s common stock to corporation beneficially owned by the Company'’s CEO, Murray Fleming, to purchase the Glucose ~~HealthÒ~~Health® Daily Blood Sugar Maintenance product. Additionally, on October 1, 2014, the Company entered into a management consulting agreement and issued 300,000 unregistered shares of the Company'’s common stock to Murray Fleming. The 300,000 shares issued to Mr. Fleming directly and the 300,000 shares issued to the corporation over which Mr. Fleming exercises voting control of the 300,000 shares, constitute a change of the control of the Company. OnAs of October 1, 2014, Mr. Fleming beneficially owned 600,000 shares or 50.1% of the outstanding shares of the Company'’s common stock.

Related Party Transactions.

On May 131, ~~2015~~2016, athe ~~consulting~~Company ~~agreement~~issued ~~was~~a ~~signed~~$35,000 ~~with~~note ~~Mr.~~to ~~William J. Gallagher,~~ a ~~previous~~corporation ~~CEO~~owned ofby the Company’s CEO. The ~~Agreement~~loan ~~rendered~~bears ~~all~~interest ~~previous~~at ~~agreements~~24% ~~and~~per ~~monies~~annum ~~owing pursuant to those agreements null~~ and ~~void~~has ~~and~~a ~~provided~~maturity ~~for~~date ~~compensation~~ of ~~$750~~December on31, a2016. ~~monthly~~$35,000 ~~basis~~remains atoutstanding ~~the~~as ~~election~~ of ~~the~~December ~~Company.~~31, 2016.

On ~~March~~April 181, ~~2015~~2016, anthe ~~agreement~~Company ~~for consulting~~consolidated ~~services~~18 ~~was~~separate ~~signed~~convertible ~~with~~promissory ~~Mr.~~notes ~~James~~of ~~Hodge~~various principal amounts and fixed conversion prices, aall ~~previous~~bearing ~~CEO~~5% ~~and~~interest ~~CFO~~per ofannum, issued to a corporation owned by the Company.’s ~~The~~CEO ~~agreement~~during ~~provided~~the ~~for~~period ~~compensation~~from August 4, 2014 through April 1, 2016, into a single convertible promissory note of $~~500~~112,157, bearing 5% interest per ~~month~~annum with a pro-rata fixed conversion price of $0.011, ~~Subsequent~~plus $5,939 accrued interest not subject to additional interest. The consolidation was for the ~~period~~purposes ~~ending~~of ~~December~~administrative ~~31,~~simplification ~~2015,~~and onno ~~February~~inducement 4,nor ~~2016,~~benefit Mrwas given to the corporation owned by the Company’s CEO. ~~Hodge~~The ~~resigned~~current asnet ~~director~~note balance is $112,157.

On March 11, 2016, the Company issued a $35,000 note to a corporation owned by the Company's CEO. The loan bears interest at 24% per annum and has a maturity date of July 11, 2016. On July 29, 2016, the loan was repaid in full.

With regard to any future related party transaction, we plan to fully disclose any and all related party transactions, including, but not limited to, the following:

· disclose such transactions in prospectuses where required; · disclose in any and all filings with the Securities and Exchange Commission, where required; · obtain ~~disinterested~~ directors consent where required; and · obtain shareholder consent where required.

Director Independence.

Members of our board of directors are not independent as that term is defined by defined in Rule 4200(a) (15) of the Nasdaq Marketplace Rules.

~~Item~~26 ~~14.~~Table ~~Principal~~Of ~~Accountant Fees and Services.~~Contents

27Item 14. Principal Accountant Fees and Services.

Audit Fees.

	2016		2015
Audit Fees	$	11,050	$	10,900
Audit Related Fees	$	500	$	-
Tax Fees	$	-	$	-
All Other Fees	$	-	$	-
Total	$	11,550	$	10,900

~~Fees~~Audit of $10,900 and $16,480 in the fiscal year ended December 31, 2015 and 2014, respectively, were paid for professional services rendered by the principal accountant for the audit of our annual financial statements and quarterly review of the financial statements included in our Form 10-K.Fees

~~Audit-Related~~ Fees of $11,550 and $10,900 for the fiscal years ended December 31, 2016 and 2015, respectively, were paid for services rendered by our independent registered public accounting firm for the audit of our annual financial statements and quarterly review of our financial statements included in our Form 10-K.

For the fiscal year ended December 31, 2015 and 2014, there were no fees billed for services reasonably related to the performance of the audit or review of the financial statements outside of those fees disclosed above under "Audit-Related Fees."

~~Tax~~Fees of $500 and -0- for the fiscal years ended December 31, 2016 and 2015, respectively, were paid for services rendered by our independent registered public accounting firm related to the audit of our annual financial statements and quarterly review of our financial statements included in our Form 10-K, in addition to those fees disclosed above under “Audit Fees.”

~~For~~Tax ~~the fiscal year ended December 31, 2015 and 2014 respectively, our accountants did not render any service for tax compliance, tax advice, and tax planning work.~~ Fees

~~All~~For ~~Other~~the ~~Fees~~fiscal year ended December 31, 2016 and 2015 respectively, our independent registered public accounting firm did not render any services for tax compliance, tax advice, and tax planning work.

~~None.~~All Other Fees

~~Pre-Approval~~For ~~Policies~~the fiscal year ended December 31, 2016 and ~~Procedures~~2015 respectively, our independent registered public accounting firm did not render any other services.

~~Prior~~Pre-Approval toPolicies ~~engaging~~and our accountants to perform a particular service, our board of directors obtains an estimate for the service to be performed. The board of directors in accordance with its procedures approved all of the services described above. Procedures

28Prior to engaging our independent registered public accounting firm to perform any services, our board of directors obtains an estimate for the service to be performed. The board of directors in accordance with its procedures, approved all services described above.

~~PART~~27 IVTable Of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Financial Statements.

Included in Item 7

(b) Exhibits.

Exhibit No.		Description
23.1		Consent of Auditors at December 31, 2015
31.1		Certification of Principal Executive Officer/Chief Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 as of December 31, 2016
31.1		Certification of Principal Executive Officer/Chief Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 as of December 31, 2015
32.1		Certification of Principal Executive Officer/Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 as of December 31, 2016
32.1		Certification of Principal Executive Officer/Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 as of December 31, 2015

101.INS **		XBRL Instance Document

101.SCH **		XBRL Taxonomy Extension Schema Document

101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB **		XBRL Taxonomy Extension Label Linkbase Document

101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

~~____________~~__________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

2928 Table Of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

April 14, 2016	By:	/s/ Murray Fleming
Date: March 28, 2017	By:	/s/ Murray Fleming
		Murray Fleming
	Its:	Chief Executive Officer, Chief Financial Officer
		(Principal Executive Officer/Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

April 14, 2016	By:	/s/ Murray Fleming
Date: March 28, 2017	By:	/s/ Murray Fleming
		Murray Fleming
	Its:	Chief Executive Officer, Chief Financial Officer
		(Principal Executive Officer/Financial Officer)

30 29

Filing Compare · Glucose Health, Inc.